Drug, bio-affecting and body treating compositions patents - Monitor Patents
FreshPatents.com Logo    FreshPatents.com icons
Monitor Keywords Patent Organizer File a Provisional Patent Browse Inventors Browse Industry Browse Agents



USPTO Class 514  |  Browse by Industry: Previous - Next | All     monitor keywords
08/2012 | Recent  |  14: Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 13: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 12: Dec | Nov | Oct | Sep | Aug | July | June | May | April | Mar | Feb | Jan | 11: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 10: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan |  | 09: Dec | Nov | Oct | Sep | Aug | Jl | Jn | May | Apr | Mar | Fb | Jn |  | 2008 | 2007 |

Drug, bio-affecting and body treating compositions August inventions list 08/12

Below are recently published patent applications awaiting approval from the USPTO. Recent week's RSS XML file available below.
Listing for abstract view: USPTO application #, Title, Abstract excerpt,Patent Agent. Listing format for list view: USPTO National Class full category number, title of the patent application.
  
08/30/2012 > 156 patent applications in 118 patent subcategories. inventions list

20120220517 - Glycopegylation methods and proteins/peptides produced by the methods: The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying group to a peptide.... Agent: Novo Nordisk A/s

20120220518 - Therapeutic agent delivery system and method: A therapeutic agent delivery system includes a therapeutic agent delivery platform and a therapeutic guest agent. The therapeutic agent delivery platform is capable of being implanted in a tissue being treated. The platform includes a substrate and at least one host molecule coupled to the substrate. The therapeutic guest agent... Agent: Case Western Reserve University

20120220519 - Peptide aptamers that bind to the rep proteins of ssdna viruses: Polypeptides and fusion proteins that bind to eukaryotic viruses, in particular, eukaryotic single-stranded DNA (ssDNA) viruses are provided. The polypeptides and fusion proteins bind to the replication initiation proteins (Rep) of ssDNA viruses and optionally inhibit viral replication and/or viral infection. The virus can be a plant pathogen or animal... Agent: North Carolina State University

20120220520 - Bioavailable combinations for hcv treatment: The present invention relates to the combination comprising an HCV NS3/4a protease inhibitor and a compound of formula (II). The combination is useful to improve the bioavailability of the HCV NS3/4a protease inhibitor. As such, the combination is useful for treating conditions associated with the Hepatitis C virus in patients.... Agent:

20120220521 - Modified peptides having toxin-enhancing effects: This invention relates in part to modifying BtBooster (BtB) peptides, in part to increase their stability in insect midgut digestive juices. Some preferred embodiments of BtB have removed proteinase cleavage sites resulting in increased stability of the modified BtB in the insect gut, while retaining the ability to enhance B.t.... Agent:

20120220522 - Ester insulin: Compositions and methods related to ester insulin or derivatives thereof are provided. The compositions include GluA4-ThrB30 ester insulin, in which side chains of GluA4 and ThrB30 of native human insulin or an insulin analogue such as insulin lispro are covalently linked via a single ester bond. The ester insulin is... Agent:

20120220523 - Use of a corn peptidi hydrolyzate as an active agent stimulating hair growth: The invention relates to the use of a composition comprising at least one corn (Zea mays L.) peptidic hydrolyzate, as an active agent to stimulate and/or restore hair growth, or prevent hair loss. The invention is also relative to the use of this novel active agent to produce a dermato-pharmaceutical... Agent: Isp Investments

20120220524 - Assays for cancer patient monitoring based on levels of analyte components of the plasminogen activator system in body fluid samples: The present invention describes methods of examining, screening over time, and monitoring the outcome of a cancer patient who is undergoing treatment or therapy. More specifically, the invention provides a method of monitoring the progression of disease, or the effectiveness of cancer treatment, in a cancer patient by measuring the... Agent: Siemens Healthcare Diagnostics Inc.

20120220525 - Stablized melanocortin ligands: Compositions and methods are disclosed for a non-naturally occurring melanocortin ligand comprised of a melanocortin analog coupled to a degradation-resistant C-terminal extension and, optionally, an N-terminal extension, to produce a stable melanocortin ligand having diminished or abolished cardiovascular activity while retaining desired melanocortin regulatory activity.... Agent: Tensive Controls, Inc.

20120220526 - Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders: The invention provides novel guanylate cyclase-C agonist peptides and their use in the treatment of human diseases including gastrointestinal disorders, inflammation or cancer (e.g., a gastrointestinal cancer). The peptides can be administered either alone or in combination with an inhibitor of cGMP-dependent phosphodiesterase. The gastrointestinal disorder may be classified as... Agent: Synergy Pharmaceuticals, Inc.

20120220527 - Methods and materials for reducing platelet counts and/or platelet adhesion: This document relates to methods and materials for treating diseases or disorders associated with elevated platelet counts (e.g., essential thrombocythemia, secondary thrombocytosis, congenital amegakaryocytic thrombocytopenia, sepsis, or asplenism) as well as methods and materials for treating diseases or disorders associated with elevated platelet adhesion to collagen (e.g., acute coronary syndromes,... Agent:

20120220528 - Systems and methods for therapy of kidney disease and/or heart failure using chimeric natriuretic peptides: Medical systems and methods for treating kidney disease alone, heart failure alone, kidney disease with concomitant heart failure, or cardiorenal syndrome are described. The systems and methods are based on delivery of a chimeric natriuretic peptide to a patient. Methods for increasing peptide levels include direct peptide delivery via either... Agent: Medtronic, Inc.

20120220529 - Nitric oxide-blocked cross-linked tetrameric hemoglobin: The present invention includes compositions containing carboxamidomethylated cross-linked hemoglobin where the cysteine moiety of the hemoglobin includes a thiol protecting group and where the hemoglobin has a reduced ability to bind with nitric oxide. Preferably, the hemoglobin is deoxygenated, endotoxin free, and stroma free. The present invention also includes method... Agent: Ikor, Inc.

20120220530 - Albumin variants: The present invention relates to variants of a parent albumin having altered plasma half-life compared with the parent albumin. The present invention also relates to fusion polypeptides and conjugates comprising said variant albumin.... Agent: Novozymes Biopharma Dk A/s

20120220531 - Surfactant protein d for the treatment of disorders associated with lung injury: Surfactant protein D (SP-D) is a member of the collectin family of collagenous lectin domain-containing proteins that is expressed in epithelial cells of the lung. Described herein are methods and compositions for the treatment of disorders associated with lung injury, including methods and compositions for the treatment of bronchopulmonary disorder... Agent: Cincinnati Children's Hospital Medical Center

20120220532 - Method for identifying a subject at risk of developing heart failure by determining the level of galectin-3 or thrombospondin-2: The present invention relates to a method for identifying a subject at risk of developing hypertensive end organ damage, such as and in particular heart failure, comprising: a) obtaining a biological sample of said subject; b) determining the level of at least one non-myocytal marker in said sample; c) comparing... Agent: Universiteit Maastricht

20120220533 - Modulating neuromuscular junction density changes in botulinum-toxin treated tissue: A method may include administering botulinum toxin to a tissue of a patient and administering a neuropeptide of the CRF family to the tissue of the patient. In some examples, the botulinum toxin is periodically administered to the tissue of the patient and/or the neuropeptide of the CRF family is... Agent:

20120220534 - Biomarker for neurodegeneration in neurological disease: The present invention provides a method of detecting or diagnosing a neurodegenerative disease or condition in a subject. Further aspects of the invention provide a method of monitoring a subject over a period of time to detect the development or progress of a neurodegenerative disease or condition. Methods of treating,... Agent: University Of Tennessee Research Foundation

20120220535 - Cyclic-glur6 analogs, methods of treatment and use: e

20120220536 - Use of endostatin peptides for the treatment of fibrosis: C-terminal endostatin polypeptides are disclosed herein. In some embodiments, these polypeptides include or consist of (1) at least at least 40 consecutive amino acids of the amino acid sequence set forth as amino acids 133-180 of SEQ ID NO: 2, SEQ ID NO: 13 or SEQ ID NO: 4; (2)... Agent:

20120220537 - 9-aminoacridine derivatives, their preparation and uses: N-substituted 9-aminoacridine and bis-acridino derivatives containing electron-withdrawing groups (EWG) or electron-donating groups (EDG), including amino acid residues, and one-pot methods for their synthesis are disclosed. The derivatives are potential candidates for cancer treatment.... Agent: Ariel-university Research And Development Company Ltd.

20120220538 - Lunasin-containing complex and purification of lunasin from plants: A method of purifying lunasin or a lunasin-containing complex produced in a plant includes providing a plant material from the plant, and isolating the lunasin-containing complex from the plant material, and/or releasing lunasin from the lunasin-containing complex. A composition for treating a cancer or an inflammation-related disease in a subject... Agent: University Of Louisville Research Foundation, Inc.

20120220539 - Conotoxin peptides: The present invention relates conotoxin peptides that are analogs of the α-contoxin peptide RgIA. These conotoxin peptides block the α9α10 subtype of the nicotinic acetylcholine receptor (nAChR) and can be used for treating pain, such as neuropathic pain and inflammatory pain, inflammatory disorders, such as rheumatic diseases, and in the... Agent: University Of Utah Research Foundation

20120220540 - Synbodies to akt1: The present application provides synbodies against AKT1 differing in amino acid sequence, conjugation chemistry, linker/scaffold, or adjunct moiety. The synbodies are useful for diagnosis and treatment of cancer and as research reagents.... Agent: Arizona Board Of Regents For And On Behalf Of Arizona State University

20120220541 - Use of yeast peptide hydrolysate as an active agent for strengthening hair: The invention concerns the use of a composition comprising at least one yeast (Saccharomyces cerevisiae) peptide hydrolysate as an active agent for strengthening hair and improving hair health. The invention also concerns the use of this novel active agent for making a dermo-pharmaceutical composition intended to stimulate hair growth or... Agent: Isp Investments Inc.

20120220542 - Pegylated c-peptide: The present invention relates to modified forms of C-peptide, and methods for their use. In one aspect, the modified forms of C-peptide comprise PEGylated C-peptide derivatives comprising at least one PEG group attached to the N-terminus, which exhibit superior pharmacokinetic and biological activity in vivo.... Agent: Cebix, Inc.

20120220544 - Ganglioside transmucosal formulations: A transmucosal formulation comprising a ganglioside and a mucosal absorption enhancer, as well as a method of treating or preventing Parkinson's disease in a human patient in need thereof comprising parenterally administering such a transmucosal formulation to said patient.... Agent:

20120220543 - Treatment of glaucoma and other retinopathies with gangliosides: A method of treating or preventing a retinopathy such as glaucoma in a human patient in need thereof comprising administering one or more gangliosides to the patient.... Agent:

20120220545 - Coumarin compounds as melanogenesis modifiers and uses thereof: wherein R3, R4, R5, R6, R7 and R8 are described herein. Also provided are plant extracts containing a compound of formula I, and the use of such a plant extract to modulate (e.g., inhibit) melanogenesis and pigmentation. The compound or plant extract may be prepared as pharmaceutical and cosmetic compositions,... Agent:

20120220645 - Genetic changes in atm and atr/chek1 as prognostic indicators in cancer: The present invention relates to the discovery that, in human cancer, an 11q deletion of ATM together with an increase in ATR and CHEK1 expression correlates with resistance to ionizing radiation which could be overcome by inhibition of the ATR/CHEK1 pathway. It provides for methods of identifying patients unlikely to... Agent:

20120220647 - Nano-hybrid of targetable sirna-layered inorganic hydroxide, manufacturing method thereof, and pharmaceutical composition for treating tumor comprising the nano-hybrid: A nanohybrid of the potent gene therapeutic agent siRNA (small interfering RNA) and a target-specific layered inorganic hydroxide, a preparation method thereof, and a pharmaceutical composition for tumor treatment containing the target-specific, siRNA/layered inorganic hydroxide nanohybrid. The nanohybrid increases the in vivo stability of the siRNA, and a target-specific multifunctional... Agent:

20120220646 - Treatment of cancer by inhibition of igfbps and clusterin: Agents that reduce the amount of IGFBP-2 and/or IGFBP-5 and that are known to be useful in the treatment of cancer result in increased expression of the protein clusterin. Since clusterin can provide protection against apoptosis, this secondary effect detracts from the efficacy of the therapeutic agent. In overcoming this,... Agent: The University Of British Columbia

20120220644 - Use of two microrna moleculars in lung cancer prognosis and medicine preparation: The present invention relates to use of two microRNAs in detection of lung cancer prognosis and in medicine preparation. Particularly, the invention relates to a composition comprising two small RNA molecules microRNA-150 and microRNA-886-3p, a device comprising the composition used in detection of lung cancer prognosis and in preparation of... Agent: Cancer Institute, Chinese Academy Of Medical Sciences

20120220648 - Method of treating aromatic l-amino acid decarboxylase (aadc) deficiency using adeno-associated virus (aav)-aadc vector: An adeno-associated virus (AAV) vector is used for treating aromatic L-amino acid decarboxylase (AADC) deficiency. The AAV vector is directly injected into human brain through a stereotactic technique. Activity of AADV is thus recovered for solving the problem of movement disorder.... Agent: National Taiwan University Hospital

20120220649 - Modified double-stranded polynucleotide: The present invention provides a double-stranded polynucleotide having a sense strand polynucleotide consisting of a nucleotide sequence complementary to a target sequence in a target gene, and an antisense strand polynucleotide having a nucleotide sequence complementary to the sense strand polynucleotide, wherein an aryl or heteroaryl compound is bound to... Agent: Daiichi Sankyo Company, Limited

20120220546 - Compostions designed for the inhibition and/or blocking of the epithelial/mesenchymal transition: The periodical intake of MTA [every 24 h for 21 days] significantly improves fibrosis and the markers for hepatic cellular damage in KO-Mdr2 mice with MTA (28 mg/kg). Following the daily oral administration of MTA, both the expression of EMT markers in the total liver and appreciable signs of fibrosis... Agent:

20120220547 - Food formulation comprising glycogen: The present invention relates to a food formulation for the controlled release of glucose comprising glycogen and at least one other edible component, as well the use of glycogen for its preparation.... Agent: Aziende Chim. Riun. Ang. Franc. A.c.r.a.f. S.p.a.

20120220548 - Compositions and methods for treatment of virus-associated cancer cells: Compositions, methods and kits are provided for treating a cancer, tumor or pre-cancerous tissue condition resistant to a chemotherapeutic agent, the tissue condition having one or more proteins or tumorigenesis markers induced by, upregulated by or otherwise associated with virus exposure. A marker may be a receptor for, or may... Agent: Medical University Of South Carolina

20120220549 - Pituitous silicone fluids: Fluid compositions are disclosed containing a branched organopolysiloxane and a carrier fluid. The branched organopolysiloxane is obtainable by reacting an organohydrogencyclosiloxane and an alkenyl terminated polydiorganosiloxane. The disclosed fluid compositions possess pituitous rheological properties.... Agent:

20120220550 - Pyrazole derivatives, preparation method thereof, and composition for prevention and treatment of osteoporosis containing same: The present invention provides pyrazole derivative compounds and pharmaceutically acceptable salts thereof. The compounds of the present invention have an excellent effect of preventing and treating osteoporosis.... Agent: Ewha University- Industry Collaboration Foundation

20120220551 - Phosphorus containing compounds as protein kinase inhibitors: The present invention relates to compounds represented by formula (I), which can modulate the activity of protein kinases. The invention also relates to a composition containing a compound of formula (I), and a method for synthesizing and using such compound for preventing or treating ALK or cMet mediated disorders or... Agent: Eternity Bioscience Inc.

20120220552 - (thio)morpholine derivatives as s1p modulators: e

20120220553 - The use of lpa for encouraging pregnancy, and fertility agent: The objective is to find compounds which have an activity to improve the success rate of pregnancy and implantation in blastocyst transfer in mammals, to provide a method of producing and using the compounds, and to provide a pregnancy-promoting agent. Disclosed is a pregnancy-promoting agent containing one or more lysophosphatidic... Agent: Jcr Pharmaceuticals Co., Ltd.

20120220554 - Combretastatins for prevention of posterior capsule opacification: Methods and compositions for the treatment and prevention of posterior capsular opacification are provided. The method comprises administering a therapeutically effective amount of a combretastatin to a subject suffering from or at risk of developing posterior capsule opacification.... Agent: Oxigene, Inc.

20120220555 - Methods of simultaneously treating ocular rosacea and acne rosacea: A method for simultaneously treating ocular rosacea and acne rosacea in a human in need thereof comprising administering systemically to said human a tetracycline compound in an amount that is effective to treat ocular rosacea and acne rosacea but has substantially no antibiotic activity.... Agent: Galderma Laboratories, Inc.

20120220556 - Drospirenone for hormone replacement therapy: A pharmaceutical composition comprising as a first active ingredient an estrogen, such as estradiol or estradiol valerate, in sufficient amounts to treat disorders and symptoms associated with deficient endogenous levels of estrogen in women, and as a second active ingredient 6β,7β;15β;16β-dimethylene-3-oxo-17α-preg-4-ene-21,17-carbolactone (drospirenone, DRSP) in sufficient amounts to protect the endometrium... Agent:

20120220557 - Liquid propellant-free formulation comprising an antimuscarinic drug: Liquid, propellant-free pharmaceutical formulation for administration by nebulization which comprising an antimuscarinic drug as active ingredient are useful for the prevention and/or treatment of a wide range of conditions including respiratory disorders.... Agent: Chiesi Farmaceutici S.p.a.

20120220558 - Methods of treating hormone-related conditions using thio-oxindole derivatives: q

20120220559 - Controlled release and taste masking oral pharmaceutical composition: Controlled release and taste masking compositions containing one or more active principles inglobated in a three-component matrix structure, i.e. a structure formed by successive amphiphilic, lipophilic or inert matrices and finally inglobated or dispersed in hydrophilic matrices. The use of a plurality of systems for the control of the dissolution... Agent: Cosmo Technologies Limited

20120220560 - Steroid tetrol solid state forms: The invention relates to solid state forms of androst-5-ene-3β,7β,16α,17β-tetrol, formulations containing or prepared from such solid state forms and use of these materials for modulating unwanted inflammation including acute and chronic non-productive inflammation. The formulations can be used to prevent, treat or slow the progression of conditions related to autoimmunity... Agent:

20120220564 - Selective calcium channel modulators: Methods and compounds effective in ameliorating conditions characterized by unwanted calcium channel activity, particularly unwanted T-type calcium channel activity are disclosed using a series of compounds containing N-acylated cyclic amines linked to an aπl ring as shown in formula (I).... Agent: Zalicus Pharmaceuticals Ltd.

20120220563 - Substituted piperidines: The invention relates to novel substituted piperidines, to processes for preparation thereof, to the use thereof for treatment and/or prophylaxis of diseases and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially of cardiovascular disorders and tumour disorders.... Agent: Bayer Pharma Aktiengesellschaft

20120220562 - Anti-viral compounds: Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.... Agent: Abbott Labaoratories

20120220561 - Oxadiazole inhibitors of leukotriene production: m

20120220566 - Antimicrobial compounds and methods of making and using the same: The present invention relates generally to the field of antimicrobial compounds and to methods of making and using them. These compounds are useful for treating, preventing, and reducing the risk of microbial infections in humans and animals.... Agent: Rib-x Pharmaceuticals, Inc.

20120220565 - Pyridyl-amine fused azadecalin modulators: The present invention provides a novel class of pyridyl-amine fused azadecalin compounds and methods of using the compounds as glucocorticoid receptor modulators.... Agent: Corcept Therapeutics, Inc.

20120220567 - Benzo-fused oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors: The present invention relates to certain 4,5-dihydro-3H-spiro[benzo[b]-[1,4]oxazepine compounds of the Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, m, n, o, and p are as herein described. In addition, the invention relates to compositions comprising at least one such compound, and methods of using... Agent:

20120220568 - Histamine-3 receptor antagonists: wherein R1, R2, R4, R5, R6, R7, R8 and n are as defined herein, or a pharmaceutically acceptable salt thereof; a pharmaceutical composition containing a compound of formula I, a process of preparation of a compound of formula I, a method of treatment of a disorder or condition such as... Agent: Pfizer Inc.

20120220569 - Fused heterocyclic ring derivative and use thereof: e

20120220570 - Fused heterocyclic ring derivative and use thereof:

20120220571 - Hiv integrase inhibitors: Compounds of Formula I are inhibitors of HIV integrase and inhibitors of HIV replication: (I), wherein X is O or N(R3); and R1, R2, R3 and Y are defined herein. The compounds are useful for the prophylaxis or treatment of infection by HIV and the prophylaxis, treatment, or delay in... Agent:

20120220572 - Tricyclic inhibitors of kinases: m

20120220573 - Benzodiazepine bromodomain inhibitor: The present invention relates to a benzodiazepine compound of formula (I), processes for its preparation, pharmaceutical compositions containing such a compound and to its use in therapy.... Agent:

20120220574 - Methods of utilizing arylpiperazine derivatives: The present invention provides arylpiperazine derivatives which can be advantageously used for treating schizophrenia and related psychoses such as acute manic, bipolar disorder, autistic disorder, and depression.... Agent:

20120220575 - N-substituted oxazinopteridines and oxazinopteridinones: and pharmaceutically acceptable salts thereof, wherein Ar, R1, R2, R3, G1, G2, and m are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating inflammatory disorders, cardiovascular disease, cancer,... Agent: Takeda Pharmaceutical Company Limited

20120220577 - Glycine b antagonists: The invention relates to naphthalene derivatives as well as their pharmaceutically acceptable salts. The invention further relates to a process for the preparation of such compounds. The compounds of the invention are glycine B antagonists and are therefore useful for the control and prevention of various disorders, including neurological disorders.... Agent: Merz Pharma Gmbh & Co Kgaa

20120220578 - Gum resin as a carrier for topical application of pharmacologically active agents: Described are pharmacological compositions comprising a gum resin; a pharmacologically active agent and a topically acceptable volatile solvent for the gum resin and active agent. Also described are methods for the transdermal or transmucosal delivery of a pharmacologically active agent using such compositions.... Agent: Jaleva, LLC

20120220579 - Methods of utilizing arylpiperazine derivatives: The present invention provides arylpiperazine derivatives which can be advantageously used for treating schizophrenia and related psychoses such as acute manic, bipolar disorder, autistic disorder, and depression.... Agent:

20120220576 - Novel heterocyclic derivatives: e

20120220581 - Imidazo[1,2-b]pyridazine derivatives and their use as pde10 inhibitors: The present invention relates to novel imidazo[1,2-b]pyridazine derivatives which are inhibitors of the phosphodiesterase 10 enzyme (PDE10) and which are useful for the treatment or prevention of neurological, psychiatric and metabolic disorders in which the PDE10 enzyme is involved. The invention is also directed to pharmaceutical compositions comprising such compounds,... Agent: Janssen-cilag, S.a.

20120220580 - Preparation of carotenoid derivatives and their applications: Compounds having the structure of general formula I or pharmaceutically acceptable salts thereof which are derivatives of fucoxanthin and fucoxanthol are disclosed. A preparation method of the compound and its use in weight reducing are also disclosed.... Agent: Beijing Gingko Group Biological Technology Co., Ltd.

20120220582 - Imidazopyrazine syk inhibitors: Certain imidazopyrazines and pharmaceutical compositions thereof are provided herein. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of Syk activity, which comprises administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or... Agent: Gilead Connecticut, Inc.

20120220583 - Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use: wherein R1a-1c, B, R3-5 and W of Formula I, and R1a-1c, R2-5, A1-4, W, X, Z, m and n of Formula II are defined herein. The invention further provides compounds of Formula III and IV and sub-Formulas II-A-II-D and III-A-III-D. The compounds may be used in pharmaceutical compositions for treating,... Agent: Amgen Inc.

20120220584 - Heterocyclic compounds and methods of use: Heterocyclic compounds derived from benzotriazine, triazines, triazoles and oxadiazoles are disclosed. The methods of synthesis and of use of such heterocyclic compounds are also provided.... Agent: Targegen, Inc.

20120220585 - Heterocyclic compounds and their uses: Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE),... Agent: Amgen Inc.

20120220586 - Heterocyclic compounds and their uses: Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE),... Agent: Amgen Inc.

20120220587 - Pyridinylimidazolone derivatives for the inhibition of pi3 kinases: Compounds of the formula (I), in which X1, X2, L, Y, R2, R3, R4, R5, R6, R7, R8, R9, R10 have the meanings indicated in claim 1, are PI3K inhibitors and can be employed, inter alia, for the treatment of autoimmune diseases, inflammation, cardiovascular diseases, neurodegenerative diseases and tumours.... Agent: Merck Patent Gesellschaft Mit Beschrankter Haftung

20120220588 - Quinazoline compounds: Disclosed are compounds having the formula: wherein R1, R2, R3, R4, R5, R6 and R7 are as defined herein, and methods of making and using the same.... Agent:

20120220589 - Heterocyclic compounds for the inhibition of pask: Disclosed herein are new heterocyclic compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibiting PAS Kinase (PASK) activity in a human or animal subject are also provided for the treatment of diseases such as diabetes mellitus.... Agent: Bioenergenix

20120220590 - Novel compounds as modulators of glucocorticoid receptors: Compounds of formula (I) and pharmaceutical compositions containing them are described. The use of the compounds and compositions are also described.... Agent:

20120220591 - Pyrimidone compounds: wherein X represents hydrogen atom and Y represents hydroxyl group, or X represents fluorine atom and Y represents hydrogen atom; R1 represents a C1-6 alkyl group; R2 represents a morpholin-4-yl group which may be substituted, or the like, which is used for preventive and/or therapeutic treatment of a disease caused... Agent: Mitsubishi Tanabe Pharma Corporation

20120220592 - 2-phenylethylamino derivatives as calcium and/or sodium channel modulators: 2-Phenylethylamino substituted carboxamide derivatives and their use as sodium and/or calcium channel modulators useful in preventing, alleviating and curing a wide range of pathologies are presented.... Agent: Newron Pharmaceuticals S.p.a.

20120220593 - Substituted acrylamide derivative and pharmaceutical composition comprising the same: R1 is, for example, a C6-C10 aryl group which may be substituted with one group or more than one group selected from substituent group α; R2 is, for example, a C6-C10 aryl group which may be substituted with one group or more than one group selected from substituent group α;... Agent: Daiichi Sankyo Company, Limited

20120220595 - Deuterated tyrosine kinase inhibitors: Compounds of Formula I, as shown below and defined herein: enriched in deuterium, and pharmaceutically acceptable salts thereof, synthesis, intermediates, formulations, and methods of disease treatment therewith, including cancers mediated at least in part by IGF-1R and/or IR.... Agent: Osi Pharmaceuticals, LLC

20120220594 - Methods for treating cancer in patients having igf-1r inhibitor resistance: A method for treating cancer comprising identifying a mammal that overexpresses breast cancer resistance protein; and administering to said mammal a pharmaceutical composition comprising a therapeutically effective amount of ixabepilone. In one aspect, the mammal is not administered an agent that is susceptible to breast cancer resistance protein overexpression resistance.... Agent: Bristol-meyers Squibb Company

20120220598 - Besylate salts of 6-(5-chloro-2-pyridyl)-5-[(4 methyl-1-piperazinyl)carbonyloxy]-7-oxo-6, 7-dihydro-5h-pyrrolo[3,4-b]pyrazine: A novel besylate salt of (6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine) is provided.... Agent: Sunovion Pharmaceuticals Inc.

20120220596 - Cysteine and cystine prodrugs to treat schizophrenia and reduce drug cravings: The present invention provides cysteine and cystine prodrugs for the treatment of schizophrenia and drug addiction. The invention further encompasses pharmaceutical compositions containing prodrugs and methods of using the prodrugs and compositions for treatment of schizophrenia and drug addiction.... Agent: Marquette University

20120220597 - L-malate salts of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5h-pyrrolo[3,4-b]pyrazine: A novel L-malate salt of (6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine) is provided.... Agent: Sunovion Pharmaceuticals Inc.

20120220599 - Aza-bicycloalkyl ethers and their use as alpha7-nachr agonists: n

20120220600 - N-oxide of 3-(2,6-dichloro-3,5-dimethoxy-phenyl) -1--1-methyl-urea: An N-oxide of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea, pharmaceutically acceptable salts thereof, compositions including the compound and its pharmaceutically acceptable salts, and methods of preparing the compound and the compositions (such as, for example, by oxidizing 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea with an oxidizing agent) are described. Further described herein are methods of using the compound and compositions... Agent:

20120220601 - Delta opioid receptor agonist compounds: Compositions and methods for treatment of sexual dysfunctions by administering to a subject a pharmaceutical composition comprising a delta opioid receptor agonist in an amount effective to delay the onset of ejaculation in the subject during sexual stimulation.... Agent:

20120220602 - Cysteine protease inhibitors: m

20120220603 - Substituted heterocyclic derivatives for the treatment of pain and epilepsy: Compounds of formula (I) which are useful in ameliorating conditions characterized by unwanted sodium and/or calcium channel activity, particularly unwanted NaV 1.7, NaV 1.8, or CaV 3.2 channel activity are disclosed. Specifically, a series of compounds containing piperidine or piperazine linked through an amide, isoxazole or similar linker to an... Agent: Zalicus Pharmaceuticals Ltd.

20120220604 - Piperazinyl-alkyl-benzoimidazol-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors: The present application discloses novel piperazinyl-alkyl-benzoimidazol-2-one derivatives useful as monoamine neurotransmitter re-uptake inhibitors. In other aspects the invention discloses the use of these compounds in a method for therapy, and pharmaceutical compositions comprising the compounds of the invention.... Agent: Neurosearch A/s

20120220605 - Oxopiperazine derivatives for the treatment of pain and epilepsy: Compounds of formula (I) which are useful in ameliorating conditions characterized by unwanted sodium and/or calcium channel actrvrh, particularly Nav1.7, Nav 1.8, or Cav 3.2 channel activity are disclosed. More specifically, compounds for use in the treatment of conditions such as epilepsy, cancer, pain, migraine, Parkinson's disease, depression, schizophrenia, psychosis,... Agent: Zalicus Pharmaceuticals Ltd.

20120220606 - New capped pyrazinoylguanidine sodium channel blockers: The present invention relates to sodium channel blockers. The present invention also includes a variety of methods of treatment using these inventive sodium channel blockers.... Agent: Parion Sciences, Inc.

20120220607 - Compositions and methods for treatment and prevention of hyperuricemia related health consequences: Disclosed herein are methods of delaying the onset or treating diabetes that comprises administering a uric acid lowering agent. The inventors have made the remarkable discovery that elevated uric acid levels are not a corollary to insulin resistance, but rather a primary mediator of insulin resistance. Specifically exemplified are methods... Agent:

20120220608 - Method of preventing and treating hepatic disease using a2b adenosine receptor antagonists: The invention is related to methods of preventing and treating hepatic fibrosis using A2B adenosine receptor antagonists and utility in the treatment and prevention of liver damage caused by alcohol abuse, surgical intervention, viral hepatitis, the ingestion of hepatotoxic drugs, or other hepatic diseases. The invention also relates to pharmaceutical... Agent: Gilead Sciences, Inc.

20120220609 - 5-hydroxypyrimidine-4-carboxamide derivative: [wherein, R4 and R5: H, halogen, or alkyl; R6: H, halogen, alkyl, or the like; R7: substitutable hydroxyalkyl, substitutable hydroxyhalo alkyl, substitutable alkoxyalkyl, or the like; substituent group α: oxo, hydroxy, amino, or the like; ring Q1: a monocyclic heterocyclic group; ring Q2: a monocyclic hydrocarbon ring group, or a... Agent: Daiichi Sankyo Company, Limited

20120220610 - Inhibitions of glutaminase c: The present invention relates to a method of reducing the production of glutamate from glutamine by glutaminase C in a cell or tissue. The method involves inhibiting glutaminase C activity in the cell or tissue under conditions effective to reduce production of glutamate from glutamine. Compounds for carrying out this... Agent: Cornell University

20120220611 - 1,3-benzoxazolyl derivatives as kinase inhibitors: Compounds of the formula I, the preparation and use thereof for the preparation of a medicament for the treatment of diseases, in particular tumours and/or diseases that are caused, mediated and/or propagated by angiogenesis. Compounds of the formula I are effective inhibitors of tyrosine kinases, in particular TIE-2 and VEGFR,... Agent: Merck Patent Gmbh

20120220613 - Method for determining sensitivity to an anticancer agent: The marker for determining sensitivity to an anti-cancer agent is formed of a protein selected from the group consisting of a protein or a fragment thereof which is detected as a peak at m/z of 16,450 to 16,620, a protein or a fragment thereof which is detected as a peak... Agent: Keio University

20120220612 - Pharmaceutical comprising ppar agonist: There are provided an agent for promoting proliferation of a meibomian gland epithelial cell or a corneal epithelial cell, containing a PPARα or δ agonist as an active ingredient, as well as an agent for treating an ocular disease such as meibomian gland dysfunction or evaporative dry eye, containing a... Agent:

20120220614 - Substituted biaryl derivatives and methods of use thereof: The present invention relates to Substituted Biaryl Derivatives, compositions comprising a Substituted Biaryl Derivative, and methods of using the Substituted Biaryl Derivatives for treating or preventing obesity, diabetes, a metabolic disorder, a cardiovascular disease or a disorder related to the activity of GPR119 in a patient.... Agent:

20120220615 - Substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase: e

20120220616 - Novel spiropiperidine compounds: A compound of the formula: or a pharmaceutically acceptable salt thereof as well as a pharmaceutical composition, and a method for treating diabetes.... Agent: Eli Lilly And Company

20120220617 - Fluorescent perylene derivatives for direct detection of heparin: The invention relates to a perylene diimide derivative and to an in vitro method for preparing the same. In addition, the invention relates to a method for detecting heparin in a sample using perylene diimide derivatives, wherein the interaction of the perylene diimide derivative with heparin modulates the intensity of... Agent:

20120220618 - Anticancer agent sensitivity-determining marker: The marker for determining sensitivity to an anti-cancer agent is formed of one or more substances selected from the group consisting of a substance or a fragment thereof detected as an anion at m/z of 149.05 to 149.06, a substance or a fragment thereof detected as an anion at m/z... Agent: Keio University

20120220619 - Rapamycin derivative or an impdh inhibitor for treating polycystic kidney disease: A method for treating polycystic kidney disease, comprising administering to a subject in need thereof a therapeutical effective amount of an inosine-5′-monophosphate dehydrogenase inhibitor or a rapamycin derivative.... Agent:

20120220621 - Anti-cancer compound and pharmaceutical composition containing the same: The invention relates to a compound of formula (I), more specifically in the levorotatory form (1a) thereof, in particular the form having a rotatory power [α]D=−38.6+0.7 at a concentration of 0.698 mg/ml in methanol. The compound may be in the form of a base or an acid addition salt, in... Agent: Sanofi

20120220620 - Antitubercular alkaloid: A derivative of β-carboline alkaloid harmine, 10,12-diheptanoyl-11-hydroxy-3-methyl-β-carboline, prepared by a Friedel-Crafts acylation of harmine is reported as a novel potent antitubercular drug.... Agent:

20120220622 - Heterocyclic derivatives: The present invention relates to a heterocyclic derivative of formula (I) wherein the variables are as defined in the specification, or to a pharmaceutically acceptable salt or solvate thereof. The present invention further relates to pharmaceutical compositions comprising said heterocyclic derivatives and to their use in therapy, for instance in... Agent:

20120220624 - Pyrazolo [3,4-b] pyridin-4-one kinase inhibitors: The present invention is directed to novel kinase inhibitors of general formula (I) and pharmaceutically acceptable salts thereof, and to the use of the kinase inhibitors of general formula (I) for treating diseases or disorders in which tau phosphorylation and cell cycle regulation is implicated, such as Alzheimer's Disease and... Agent:

20120220623 - The enantiomer of tenatoprazole and the use thereof in therapy: This invention relates to optically active substances of tenatoprazole, (+) and (−)-5-methoxy-2-{(4-methoxy-3,5-dimethyl-2-pyridyl)methyl]sulfinyl}-1H-imidazo[4,5-b]pyridine. The compound and pharmaceutical compositions thereof are useful for anti-ulcer agent.... Agent: Mitsubishi Tanabe Pharma Corporation

20120220626 - Novel quinoline compound, and composition containing centipede extract or compounds isolated therefrom for prevention and treatment of cardiovascular disease: The present invention relates to a composition for the prevention and treatment of cardiovascular diseases containing the novel quinoline compound, the centipede extracts or compounds isolated from the extracts. The novel quinoline compound, the centipede extracts or a quinoline compound and a phenol compound isolated from the extracts of the... Agent: Korea Research Institute Of Bioscience And Biotechnology

20120220625 - Pharmaceutical composition and administrations thereof: The present invention relates to pharmaceutical compositions comprising a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide, methods of manufacturing pharmaceutical compositions of the present invention, and methods of administering pharmaceutical compositions of the present invention.... Agent: Vertex Pharmaceuticals Incorporated

20120220627 - Substituted 2-amino-quinoline-3-carboxamides as kcnq2/3 modulators: The invention relates to substituted 2-amino-quinoline-3-carboxamides, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.... Agent: Grunenthal Gmbh

20120220629 - Asymmetric ureas and medical uses thereof: Disclosed are compounds, compositions and methods for the prevention and/or treatment of diseases which are pathophysiologically mediated by the ghrelin receptor. The compounds have the general formula (I):... Agent:

20120220628 - Tablets comprising a taste masking agent: The present invention is directed to a tablet comprising at least one bitter tasting and/or mucosa numbness causing pharmaceutically active compound; and at least one zinc salt. In addition, the present invention relates to the use of a zinc salt to reduce or mask the bitter taste of or the... Agent: Hexal Ag

20120220630 - Prucalopride oral solution: The present invention is concerned with an oral aqueous solution comprising prucalopride or pharmaceutically acceptable acid addition salts thereof having good organoleptic properties.... Agent: Shire-movetis Nv

20120220631 - Use of 5h-thioeno(3,4-c)pyrrole-4,6-dione derivatives as tumor necrosis factor inhibitor: A method of treating or curing a disease caused by or associated with elevated levels of TNF in a patient including administering to the patient 5H-thioeno(3,4-c)pyrrole-4,6-dione derivatives.... Agent: Tianjin Hemay Bio-tech Co., Ltd.

20120220632 - Methods for treatment of fabry disease: Provided are in vitro and in vivo methods for determining whether a patient with Fabry disease will respond to treatment with a specific pharmacological chaperone.... Agent: Amicus Therapeutics, Inc.

20120220633 - Piperidine derivatives as human papilloma virus inhibitors: HPV inhibitors with formula (I) where G1 represents a hydrocarbonated bond or chain possibly substituted by one or two alkyl groups, G2 represents a group (see formula Ia+Ib) or R represents a hydrogen, an alkyl, halogenoalkyl, or a prodrug radical such as carbamate, acetyl or dialkylaminomethy, G represents a bond... Agent: Anaconda Pharma

20120220634 - Taxane compounds, compositions and methods: The present invention provides a method for the preparation of orally available pentacyclic taxane compounds, as well as intermediates useful in their preparation.... Agent: Genta Incorporated

20120220635 - Aminoethylaromatic compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor: The present invention relates to aromatic compounds of the formula (I) and the physiologically tolerated acid addition salts thereof. The invention also relates to the use of a compound of the formula (I) or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical composition for the treatment of a medical... Agent:

20120220636 - Pharmaceutical composition for the treatment of mcp-1 mediated inflammatory diseases: The present invention relates to a pharmaceutical composition comprising a combination of 1-benzyl-3-hydroxymethyl-indazole derivative, a pressure lowering agent selected from ACE-inhibitors, renin inhibitors, ARBs and CCBs, and/or a cholesterol lowering agent selected from statin derivatives. The combination showed an additive and synergistic activity in reducing MCP-1 levels, thus significantly improving... Agent: Aziende Chimiche Riunite Angelini Francesco A.c.r.a.f.s.p.a.

20120220637 - Ophthalmologic compositions and use mode thereof: The invention concerns a pharmaceutical composition characterized in that it contains a combination of a parasympatholytic agent, a sympathomimetic agent and a local anaesthetic. Such a composition may be injected into the anterior chamber of the eye before a cataract operation or instilled on the eye before laser treatment.... Agent:

20120220638 - 5-iodotriazole derivatives: The present invention relates to novel 5-iodotriazole derivatives, to processes for preparing these compounds, to compositions comprising these compounds, and to the use thereof as biologically active compounds, especially for control of harmful microorganisms in crop protection and in the protection of materials and as plant growth regulators.... Agent: Bayer Cropscience Ag

20120220639 - Rhodacyanine derivative and pharmaceutical composition for treating leishmaniasis: A rhodacyanine derivative represented by the following General Formula (1), wherein, in General Formula (1), R1, R2, and R3 each independently represent an alkyl group which may be substituted; Y1 and Y2 each independently represent a hydrogen atom, a chlorine atom, or a fluorine atom provided that Y1 and Y2... Agent: Fujifilm Corporation

20120220640 - Methods of treating diseases: The present invention relates to computer-implemented methods and system for analysing a biomarker which cycles in a subject. In some other aspects, the present invention relates to analysing a biomarker which at least initially increases or decreases in amount in a subject following a treatment for a disease. In further... Agent: Immunaid Pty Ltd

20120220641 - Laser enhanced amino acid blend and use of same to regenerate active myocardial tissue: The invention provides a blend of amino acid powders that have been exposed to pulsed laser radiation. The pulsed laser radiation is obtained by passing laser radiation through a device, which has a first diffraction grating, a second diffraction grating, and a refractive element positioned between the first and second... Agent:

20120220642 - Amino acid compounds: Methods for increasing the bioabsorption of amino acids and for preventing the development of nitrate tolerances in a human or animal are disclosed. The methods include administering to the human or animal a pharmaceutically effective amount of an amino acid compound consisting essentially of a nitrate or nitrite of an... Agent: Thermolife International, LLC

20120220643 - Amino acid compounds: A method for increasing the vasodilative characteristics of amino acids in a human or animal is disclosed. The method includes administering to the human or animal a pharmaceutically effective amount of an amino acid compound consisting essentially of a nitrate or nitrite of an amino acid selected from the group... Agent: Thermolife International, LLC

20120220650 - Functional microbially fermented tea extract containing polyphenol derivative and method for producing the same: A functional microbially fermented tea extract containing a novel polyphenol derivative and a method for producing the same are provided. A functional microbially fermented tea extract containing various extracts and a novel polyphenol derivative is produced by subjecting, to an extraction treatment, a microbially fermented tea leaf obtained by culturing... Agent: Saga University

20120220651 - Desferrioxamine-metal complexes for the treatment of immune-related disorders: The present invention relates to methods kits and combined compositions using DFO-metal complexes, specifically, Zinc-desferrioxamine (Zn-DFO), gallium-desferrioxamine (Ga-DFO) complexes and any combinations thereof for preventing, treating, ameliorating or inhibiting an immune-related disorder, specifically, a skin-related inflammatory disorder such as psoriasis, an inflammatory respiratory condition such as asthma, and an autoimmune... Agent: Yissum Research Development Company Of The Hebrew

20120220652 - Synthetic triterpenoids and methods of use in the treatment of disease: The present invention concerns methods for treating and preventing renal/kidney disease, insulin resistance/diabetes, fatty liver disease, and/or endothelial dysfunction/cardiovascular disease using synthetic triterpenoids, optionally in combination with a second treatment or prophylaxis.... Agent:

20120220653 - Pest-control, compositions, and methods and products utilizing same: Pest-combating compositions containing modified volatility pest-control actives are formulated for sustained test-combating efficacy, utilizing oleochemicals subjected to transesterification, methanolysis or conversion of fatty acids to alkyl esters as modified volatility components. In a specific formulation, the pest-combating composition includes soy methyl ester and 2-undecanone. The composition may be constituted as... Agent: Smg Brands, Inc.

20120220654 - Therapeutic solution concentrate: A concentrated poly(ethylene glycol) solution that has good stability for extended storage is provided for use as a laxative. The concentrated solution comprises water, sodium benzoate, poly(ethylene glycol), and enough acid to yield a solution having a pH at 25° C. in the range 3.0-5.0. It is prepared and packaged... Agent:

20120220655 - Crystalline forms of fesoterodine fumarate and fesoterodine base: Polymorphically pure crystalline forms of fesoterodine fumarate and fesoterodine base are described and characterized.... Agent: Teva Gyogyszergyar Zartkoruen Mukodo Reszvenytarsasag

20120220656 - Use of 4-[ethyl(dimethyl)ammonio]butanoate in the treatment of cardiovascular disease: New compound 4-[ethyl(dimethyl)ammonio]butanoate, method of preparation thereof and use in the treatment of cardiovascular disease.... Agent: Jsc Grindeks

20120220658 - Method for treating sepsis or septic shock: The present invention is a method for treating sepsis or septic shock using Lipoxin A4.... Agent: University Of Medicine And Dentistry Of New Jersey

20120220657 - Synergistic anti-inflammatory and antioxidant dietary supplement compositions: Disclosed herein are novel dietary supplement compositions comprising enriched 3-O-acetyl-11-keto-β-boswellic acid and enriched demethylated curcuminoids, wherein the composition exhibits anti-inflammatory, antiulcerogenic and anti-oxidant activities. Also disclosed are novel compositions comprising enriched 3-O-acetyl-11-keto-β-boswellic acid, enriched demethylated curcuminoids that have a synergistic effect on specific inhibition of—COX-2 and 5-LOX activity and optionally... Agent: Laila Impex

20120220660 - Composition with preventive or improvement effect on symptoms or diseases associated with stress-induced behavior disorders: A composition with a preventive or improvement effect on symptoms or diseases associated with stress-induced behavior disorders, comprising arachidonic acid and/or a compound comprising arachidonic acid as a constituent fatty acid.... Agent: Suntory Holdings Limited

20120220659 - Medicament having promoting action on hepatocyte proliferation: A medicament for promoting proliferation of hepatocytes and liver regeneration, which comprises a polyprenyl compound such as 3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid as an active ingredient.... Agent: Josai University Educational Corporation

20120220661 - Methods of modulation of branched chain acids and uses thereof: A method of modulating plasma levels of branched chain amino acids and branched chain alpha-keto acids is disclosed, wherein an ammonia scavenger compound or a salt thereof, for example phenylbutyrate or an even numbered congener thereof or a salt thereof, is administered to an individual in need thereof. In various... Agent: Baylor College Of Medicine

20120220662 - Phytoceutical compositions for pets: This invention comprises applying phytoceutical compositions to pets, which given their sedentary life and nutrition, are susceptible to a higher prevalence of cancer and degenerative diseases. The compounds contained in said compositions frequently have anti-oxidizing properties acting to inhibit harmful reactions of free radicals; free radicals are often a cause... Agent: Biokab, S.a. De C.v.

20120220663 - Solid forms of aliskiren hemifumarate and processes for preparation thereof: The present invention provides polymorphic forms of aliskiren hemifumarate, and processes for preparation thereof and for the preparation of the amorphous form of aliskiren hemifumarate. The present invention also provides pharmaceutical compositions comprising the aliskiren hemifumarate crystalline forms T1, T3 or T4, T5, T6, T7, T8 and at least one... Agent: Teva Pharmaceutical Industries Ltd.

20120220664 - Use of metformin in cancer treatment and prevention: Disclosed herein is a method for treating a tumor in a subject in need thereof comprising administering an enhancing amount of metformin and a reduced amount of one or more chemotherapeutic agents. One example of an enhancing amount of metformin is about 250 mg/day. Also disclosed is a Untreated method... Agent: President And Fellows Of Harvard College

20120220665 - Inhibiting neurotransmitter reuptake: This document relates to compounds as well as methods and materials involved in modulating neurotransmitter reuptake. For example, compounds, methods for synthesizing compounds, and methods for inhibiting neurotransmitter reuptake are provided.... Agent: Mayo Foundation For Medical Education And Research

20120220666 - Composition to enhance the bioavailability of curcumin: A composition having a curcuminoid and an essential oil of turmeric. A composition having a curcuminoid and an essential oil of turmeric, wherein the essential oil is present in an amount sufficient to cause an enhancement of bioavailability of curcumin when the composition is administered to a human as compared... Agent:

20120220667 - Use of methylsulfonylmethane (msm) to inhibit microbial activity: Disclosed herein are methods of use of methylsulfonylmethane (MSM) to modulate microbial activity, such as to enhance or inhibit the activity of microorganisms. In one example, MSM (such as about 0.5% to 5% MSM) is used to enhance fermentation efficiency, such as to enhance fermentation efficiency associated with the production... Agent: Biogenic Innovations, LLC

20120220668 - Membrane stabilizing compositions and methods: A sugar-anchor polymer and methods of making and using the same to stabilize a lipid membrane. The sugar-anchor polymer includes a sugar covalently bound to a first anchor and a second anchor wherein the covalent bonds are selected from the group consisting essentially of an oxime bond, a hydrazone bond,... Agent:

20120220669 - Formulations for the treatment of deep tissue pain: Disclosed herein are vesicular formulations comprising one or more phospholipids and one or more nonionic surfactants that are effective in the treatment of pain or inflammation or osteoarthritis, more specifically in the treatment of deep tissue pain, for example osteoarthritis and other joint or muscle pain, as well as methods... Agent:

20120220670 - Water-in-oil type emulsion skin cosmetic: A skin cosmetic in which the emulsion stability can be ensured by adding a volatile hydrocarbon oil to a water-in-oil-type emulsion composition containing a non-volatile silicone oil, and which has an excellent non-oily sensation upon application. Specifically disclosed is a water-in-oil-type emulsion skin cosmetic which is characterized by comprising (A)... Agent:

20120220672 - Presence of erg gene rearrangements and protein over-expression in low grade pin (lg-pin) in prostate biopsies: The present disclosure relates to methods for the early detection of ERG over-expression, gene rearrangements, and diagnosis and/or prognosis of prostate cancer using a combined ERG IHC-FISH assay.... Agent: Ventana Medical Systems, Inc.

20120220671 - Use of galectin-3 for detecting and prognosing heart failure after acute coronary syndrome: The present invention relates to materials and methods for predicting the risk of heart failure in a subject with Acute Coronary Syndrome. The invention further relates to monitoring the efficacy of treatment for heart failure in a subject with Acute Coronary Syndrome.... Agent: Bg Medicine, Inc.

  
08/23/2012 > 153 patent applications in 105 patent subcategories. inventions list

20120214728 - Ex vivo and in vivo methods and related compositions for regenerating hematopoietic stem cell populations: Various embodiments provide methods and related compositions for increasing the population size of hematopoietic stem cells (HSCs) in patients that may benefit from reconstitution of stem cells and/or differentiated cells of the blood lineage. The present methods enable the production of HSCs ex vivo and in vivo by reducing latexin... Agent: University Of Kentucky Research Foundation

20120214729 - Composition for preventing or treating inflammation: The present invention relates to a composition containing Substance P for preventing or treating an inflammation. The composition containing Substance P according to the present invention exhibits the effect of decreasing leukocytes, neutrophils and hematopoietic stem cells in a blood, which are associated with the inflammation, and of increasing anti-inflammatory... Agent: University-industry Cooperation Group Of Kyung Hee

20120214730 - Method of using heparin binding motif for treating asthma: The present invention is for an isolated peptide consisting of the amino acid sequence of SEQ ID NO: 9 and using the peptide for treating asthma by reducing cytotoxicity of eosinophil derived toxins in bronchial epithelial cells of the subject suffers from asthma. The method comprises preparing a pharmaceutical composition... Agent: National Tsing Hua University

20120214731 - Compound ws 727713: The present invention relates to a new compound useful as a modulator of melanocortin receptors. In particular, the present invention relates to a compound WS727713, a process for production of the compound by culturing, in a culture medium, a WS727713-producing strain belonging to Pseudonocardia and recovering the compound from a... Agent: Astellas Pharma, Inc.

20120214732 - Inhibitors of the trypsin-like site of the proteasome and methods of use thereof: The present invention is an inhibitor of the trypsin-like β2/β2i sites of the proteasome. The inhibitor is characterized as being a peptide-based epoxyketone or vinyl sulfone that contains an arginine or 4-aminomethylene-L-phenylalanine at the C-terminus (i.e., at the P1 position). Methods for using the inhibitor to inhibit the activity of... Agent: Trustees Of Dartmouth College

20120214733 - Oxytocin receptor agonists: The present invention relates to oxytocin receptor agonist compounds, pharmaceutical compositions comprising the same, use of such compounds for the manufacture of a medicament for treatment of inter alia, abdominal pain, irritable bowel syndrome (IBS), autism, erectile dysfunction, female sexual dysfunction, labor induction and maintenance, lactation induction and maintenance, postpartum... Agent: Ferring International Center S.a.

20120214735 - Acetamide derivatives as glucokinase activators, their process and medicinal applications: e

20120214734 - Treatment of metabolic disorders: The present invention provides methods for treating, preventing, and/or delaying the onset of metabolic disorders including multi-factorial syndromes such as insulin-insensitivity and metabolic syndrome by administering an effective amount of an ACE inhibitor.... Agent:

20120214736 - Compositions and methods for the modulation of jnk proteins: The invention provides compositions and methods for the treatment and diagnosis of diseases or disorders amenable to treatment through modulation of expression of a gene encoding a Jun N-terminal kinase 1 (JNK1 protein.... Agent: Isis Pharmaceuticals, Inc.

20120214737 - Methods for protecting dopaminergic neurons from stress and promoting proliferation and differentiation of oligodendrocyte progenitors by nrg-2: The invention features methods of treatment and diagnosis using NRG-2 polypeptides, nucleic acid molecules, and antibodies. The invention also provides novel NRG-2 polypeptides and nucleic acid molecules.... Agent: Acorda Therapeutics, Inc.

20120214738 - Therapeutic agent and therapeutic method for periodontal diseases and pulpal diseases: e

20120214739 - Fgf variants and methods for use thereof: The present invention provides fibroblast growth factor variants demonstrating enhanced receptor subtype specificity and/or affinity. Preferred embodiments include both variants having enhanced activity that act as improved agonists and variants having reduced activity that act as antagonists. Methods of utilizing preferred FGF variants in preparation of medicaments for the treatment... Agent: Prochon Biotech, Ltd.

20120214740 - Medicinal compositions containing highly functionalized chimeric protein: There is provided an FGF2 substitute-containing medicinal composition which comprises, as an active ingredient, a chimeric protein comprising the amino acid sequence of an FGF1 protein in which a partial sequence including a sequence of at least positions 62-83 within a sequence of positions 41-83 is substituted with a partial... Agent: National Institute Of Advanced Industrial Science And Technology

20120214741 - Vdac1 compositions and methods of use thereof for regulating apoptosis: The present invention relates generally to the mitochondrial protein, voltage-dependent anion channel (VDAC), polynucleotides encoding same and variants thereof, as well as peptide fragments, peptide derivatives and analogs. In particular, the present invention is directed to VDAC1 and specific amino acid and polynucleotide sequences thereof useful in inducing or regulating... Agent: Ben Gurion University Of The Negev Research And Development Authority Ltd.

20120214742 - Gaba release-regulating agent in cerebellum: A GABA (gamma-aminobutyric acid) release-inhibiting agent in the cerebellum and a composition for treating pathological symptoms caused by over-release of GABA in the cerebellum, each comprising a Bestrophin 1(Best1) channel inhibitor as an active ingredient; a GABA release-promoting agent in the cerebellum and a composition for treating pathological symptoms caused... Agent:

20120214743 - Itch suppressant: G

20120214744 - Polypeptides and nucleic acids for treating erbb2-dependent cancers: The present invention relates to polypeptides, nucleic acids and pharmaceutical compositions suitable for use in the treatment of ErbB2 dependent-cancers, in particular of tumors overexpressing ErbB2 or expressing mutated forms of the ErbB2 gene.... Agent:

20120214745 - Deuterated cyclosporine analogs and methods of making the same: Cyclosporine derivatives are disclosed which possess enhanced efficacy and reduced toxicity over naturally occurring and other presently known cyclosporin and cyclosporine derivatives. The cyclosporine derivatives of the present invention are produced by chemical and isotopic substitution of the cyclosporine A (CsA) molecule by: (1) Chemical substitution and optionally deuterium substitution... Agent: Isotechnika Pharma Inc.

20120214746 - Use of a composition comprising a non-fermented rice peptide hydrolyzate for stimulating hair growth: The present invention relates to the use of a composition comprising at least one non-fermented rice peptidic hydrolyzate as an active agent for slowing down and limiting hair loss and/or stimulating hair growth. Said composition is also intended to protect the follicular adult stem cells as well as their specific... Agent: Isp Investments

20120214747 - Recombinant human alpha1- antitrypsin: The present invention relates recombinant human α1-antitrypsin (rhAAT) comprising N-linked glycans, wherein at least 10% of said N-linked glycans are tetra-antennary glycans; and the degree of capping with sialic acid on said N-linked glycans (Z/A) is at least 50%. The invention further relates to rhAAT for use as a medicament,... Agent: Crucell Holand B.v.

20120214750 - Crystalline form of linaclotide: The present invention relates to crystalline forms of linaclotide, as well as to various methods and processes for the preparation and use of the crystalline forms.... Agent: Forest Laboratories Holdings Ltd.

20120214749 - Microparticles comprising somatostatin analogues: Disclosed are microparticles comprising a somatostatin analogue embedded in a biocompatible pharmacologically acceptable polymer matrix for a long acting release and pharmaceutical compositions comprising such microparticles.... Agent: Novartis Ag

20120214748 - Novel peptides, process for preparation thereof, and use thereof: The invention relates to peptides of the general formula (I) GX1CSX2SX3PPX4CX5PD (SEQ ID NO: 20), where X1 is Y, M, W, I, V, or A; X2 is R or K; X3 is Y, F, I, M, L, E, D, or H; X4 is V, I, or H; and X5 is... Agent:

20120214751 - Glucosyl stevia composition: Glucosyl stevia compositions are prepared from steviol glycosides of Stevia rebaudiana Bertoni. The glucosylation was performed by cyclodextrin glucanotransferase using the starch as source of glucose residues. The short-chain glucosyl stevia compositions were purified to >95% content of total steviol glycosides. The compositions can be used as sweetness enhancers, flavor... Agent:

20120214752 - Glucosyl stevia composition: Glucosyl stevia compositions are prepared from steviol glycosides of Stevia rebaudiana Bertoni. The glucosylation was performed by cyclodextrin glucanotransferase using the starch as source of glucose residues. The short-chain glucosyl stevia compositions were purified to >95% content of total steviol glycosides. The compositions can be used as sweetness enhancers, flavor... Agent:

20120214753 - Pharmaceutical composition for oral administration: The present invention provides a solid pharmaceutical composition comprising a cocrystal of (1S)-1,5-anhydro-1-[3-(1-benzothien-2-ylmethyl)-4-fluorophenyl]-D-glucitol and L-proline, in combination with crystalline cellulose, and also provides a method for producing the composition.... Agent:

20120214754 - Fgf receptor-activating n-acyl octasaccharides, preparation thereof, and therapeutic use thereof: The invention relates to FGF receptor-activating N-acyl octasaccharides having Formula (I), wherein: R1 is an O-alkyl group optionally replaced by one or more aryl or cycloalkyl groups, R2 is an OSO3− or hydroxyl group, R3 is an alkyl, cycloalkyl, or alkyl-cycloalkyl group, R4 is a disaccharide having Formula (II), R6... Agent: Sanofi

20120214755 - Methods of producing and using nutritional and pharmaceutical compositions that include one or more active substances: Methods for producing a composition that includes an active agent, nutraceutical and pharmaceuticals compositions, and methods for ameliorating and/or treating a disease using the composition that includes an active substance are described herein. More particularly, methods for producing a composition that contains one or more active substances such as oleocanthal,... Agent:

20120214756 - Cooperative conveyance of basic active principles by amphiphilic acid molecules: The present invention relates to an intermolecular association complex of an amphiphilic carrier and an active principle G, having the following general formula (I), as well as to the compositions containing same, to the uses thereof, particularly as a drug, and to the method for preparing same.... Agent: Centre National De La Recherche Scientifique

20120214757 - Methods and compositions for treating cancer using proteasome inhibitors: The present invention relates to therapeutic compositions for treating cancer or preventing the growth of cancer cells, e.g., tumor growth, in a subject. The present invention also relates to methods for treating cancer, e.g., inhibiting tumor growth, in a subject who has become resistant to treatment, by administering to a... Agent: Dana-farber Cancer Institute, Inc.

20120214758 - Tyrosine kinase receptor antagonists and methods of treatment for pancreatic cancer: A method of treatment is disclosed whereby cancer cells are brought into contact with a formulation comprising an inhibitor of tyrosine kinase receptors. The formulation may be comprised of an injectable carrier and two or more tyrosine kinase receptor inhibitors which may be nordihydrogluaiaretic acid (NDGA) and doxyrubicine.... Agent: The Regents Of The University Of California

20120214759 - Treatment of klebsiella pneumoniae infections with antibacterial aminoglycoside compounds: A method for treating a Klebsiella pneumonia infection in a mammal in need thereof is disclosed, the method comprising administering to the mammal an effective amount of an antibacterial aminoglycoside compound.... Agent: Achaogen, Inc.

20120214760 - Treatment of urinary tract infections with antibacterial aminoglycoside compounds: A method for treating a urinary tract infection in a mammal in need thereof is disclosed, the method comprising administering to the mammal an effective amount of an antibacterial aminoglycoside compound.... Agent: Achaogen, Inc.

20120214863 - Anti-mir-1 therapy for wound healing: Methods for modulating gene expression in a skin cell by administering to the cell an amount of a therapeutic composition in an amount sufficient to modulate the expression of miR-1, and therapeutic compositions and uses thereof are disclosed.... Agent: The Ohio State University Research Foundation

20120214860 - Method of regulating the expression level of survival of motor neuron 1 (smn1) and detecting enzyme activity of ubiquitin carboxyl-terminal hydrolase l1 (uchl1): The present invention relates to a method of regulating the expression level of survival of motor neuron 1 (SMN1) comprising administering to a subject in need thereof a therapeutically effective amount of ubiquitin carboxyl-terminal hydrolase L1 (UCHL1) regulator and a pharmaceutically acceptable carrier. The present invention also relates to a... Agent: Kaohsiung Medical Universisty

20120214861 - Methods and compositions for treating neurological disease: This invention relates to methods and compositions for treating neurological disease, and more particularly to methods of delivering iRNA agents to neural cells for the treatment of neurological diseases.... Agent: University Of Massachusetts

20120214865 - Methods for slowing familial als disease progression: Methods for slowing disease progression in an individual suffering from familial ALS are provided. Also provided are methods of increasing the survival time of an individual suffering from familial ALS. These methods employ antisense oligonucleotides targeted to SOD1, for use in inhibiting the expression of SOD1 in the central nervous... Agent: Isis Pharmaceuticals, Inc.

20120214864 - Mirnas dysregulated in triple-negative breast cancer: The invention provides methods of diagnosing and treating cancer in a subject. The inventors have identified a series of dysregulated miRNAs that are indicative of triple-negative breast cancer. In some embodiments, the invention further provides for the administration of a cancer therapy to the subject.... Agent: The Regents Of The University Of Colorado A Body Corporate

20120214862 - Modulation of factor 7 expression: Disclosed herein are antisense compounds and methods for decreasing Factor 7 and treating or preventing thromboembolic complications in an individual in need thereof. Examples of disease conditions that can be ameliorated with the administration of antisense compounds targeted to Factor 7 include thrombosis, embolism, and thromboembolism, such as, deep vein... Agent: Isis Pharmaceuticals, Inc.

20120214867 - Bacteriophage t4 nanoparticles for eukaryotic delivery: A T4 nanoparticle is a non-infectious, tail-less variant of a T4 bacteriophage. In one embodiment, eukaryotic cells are labeled with dyed T4 nanoparticles, wherein each dyed T4 nanoparticle comprises at least 350 dye molecules covalently bound thereto. In another embodiment, T4 nanoparticles are used to deliver exogenous DNA to eukaryotic... Agent: The Government Of The United States Of America, As Represented By The Secretary Of The Navy

20120214868 - Modified l-nucleic acid: A modified L-nucleic acid, containing an L-nucleic acid part conjugated to a non-L-nucleic acid part is described. The conjugate has extended retention time in and demonstrates a delayed elimination from an organism.... Agent: Noxxon Pharma Ag

20120214866 - Treatment with cytokines: An inflammatory process is suggested to be involved in the pathogenesis of Alzheimer's disease (AD), a neurodegenerative disorder characterized by the presence of neuritic plaques within the cerebral cortex that are mainly composed of a small insoluble protein of 40-42 aminoacids (amyloid protein). Amyloid-specific Interleukin-10 (IL-10) generation is found to... Agent: Immunoclin Limited

20120214761 - Pre-mixed, ready-to-use iv bolus nicardipine compositions and methods of use: Provided herein are ready-to-use premixed bolus injection pharmaceutical compositions of nicardipine or a pharmaceutically acceptable salt and methods for use in treating cardiovascular and cerebrovascular conditions.... Agent: Ekr Therapeutics, Inc.

20120214762 - 6,5-heterocyclic propargylic alcohol compounds and uses therefor: wherein A, Y, R1, R2 and the subscript b each has the meaning as described herein and compounds of Formula I, and stereoisomers, geometric isomers, tautomers, solvates, metabolites, isotopes, pharmaceutically acceptable salts, or prodrugs thereof. Compounds of Formula I and pharmaceutical compositions thereof are useful in the treatment of disease... Agent: Genentech, Inc.

20120214763 - Memory fixation accelerator: A medicament for promoting memory consolidation, which comprises, as an active ingredient, a non-natural retinoid, preferably a retinoid having a basic skeleton comprising an aromatic ring bound with an aromatic carboxylic acid or tropolone by means of a bridging group, more preferably 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)carbamoyl]benzoic acid or 4-[(3,5-bis-trimethylsilylphenyl)-carboxamido]benzoic acid.... Agent: Research Foundation Itsuu Laboratory

20120214764 - Method and kit for gastro-intestinal cleansing: A method of cleansing a mammalian GI tract is described and includes ingestion of polyethylene glycol (PEG) and magnesium citrate in a split-dose regimen. The split-dose regimen provides effective cleansing of the GI tract while minimizing discomfort and side effects to the patient A kit packaged with a first and... Agent:

20120214765 - Boron-containing small molecules as anti-inflammatory agents: Compounds and methods of treating anti-inflammatory conditions are disclosed.... Agent: Anacor Pharmaceuticals, Inc.

20120214766 - Cannabinoid receptor modulators: The present invention relates to certain compounds of Formula Ia and pharmaceutical compositions thereof that modulate the activity of the cannabinoid CB2 receptor. The present invention further relates to certain compounds of Formula Ia and pharmaceutical compositions thereof that modulate the activities of both the CB1 receptor and the CB2... Agent:

20120214767 - Tricyclic heterocyclic compounds: or stereoisomers or salts thereof, wherein: X1, X2, X3, W, Q1, Q2, and G2 are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression... Agent:

20120214768 - Novel pyridopyrazine derivatives, process of manufacturing and uses thereof: The invention relates to pyrido[2,3-b]pyrazine compounds of general formulae (Ia) and (Ib), to their preparation and use, for example, for the treatment of malignant disorders and other disorders based on pathological cell proliferations.... Agent: Aeterna Zentaris Gmbh

20120214769 - Novel antagonists of the glucagon receptor: The present invention provides for novel compounds of Formula (I) and pharmaceutically acceptable salts and co-crystals thereof which have glucagon receptor antagonist or inverse agonist activity. The present invention further provides for pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or... Agent: Metabasis Therapeutics, Inc.

20120214770 - Substituted benzofurans, benzothiophenes, benzoselenophenes and indoles and their use as tubulin polymerisation inhibitors: The present invention relates generally to substituted benzofurans, benzothiophenes, and indoles and their use as tubulin polymerisation inhibitors.... Agent: Bionomics Limited

20120214771 - Compositions for treatment of cardiometabolic disorders: The present invention provides for methods of preventing or improving cardiometabolic disorders/metabolic disorders, compositions and pharmaceutical compositions comprising therapeutically effective amount of therapeutic phospholipid compositions and therapeutically effective amount of one or more lipid modifying agents, including statins.... Agent:

20120214772 - Compositions for treatment of inflammatory diseases: Inflammatory bowel diseases are represented by two idiopathic disorders, which include ulcerative colitis and Crohn's disease. Ulcerative colitis is restricted to the colon and involves uncertain and inflammation of the lining (mucosa) of the large intestine. Crohn's disease, on the other hand, can involve the mucosa of the small and/or... Agent: The Board Of Regents Of The University Of Oklahoma

20120214773 - Formulation for lipophilic agents: The invention relates to pharmaceutical formulations of lipophilic therapeutic agents in which such agents are solubilized in largely aqueous vehicles, and processes for preparing and using the same.... Agent:

20120214775 - Pharmaceutical salts of 3-o-(3',3'-dimethylsuccinyl) betulinic acid: Salts of 3-O-(3′,3′-dimethylsuccinyl)Betulinic acid (DSB) are disclosed. Particularly, the preparation, pharmaceutical evaluation, and in vivo bioavailability evaluation of N-methyl-D-glucamine and alkali metal salt forms of DSB are disclosed. Pharmaceutical compositions including these salt forms are used in methods of treating HIV and related diseases. Methods of making the salts of... Agent: Myrexis, Inc.

20120214774 - Treatment of solid tumors with rapamycin derivatives: Rapamycin derivatives have interesting effects in the treatment of solid tumours, optionally in combination with a chemotherapeutic agent.... Agent:

20120214776 - Topical formulations comprising a steroid: The application provides formulations for the topical administration of an active agent comprising at least one steroid, in the form of topical sprays that are propellant-free, and/or substantially non-foaming, and/or alcohol-free. The present application also provides processes for preparing such compositions and methods of using them in management of skin... Agent: Dr. Reddy's Laboratories Ltd.

20120214777 - Stabilized compositions containing alkaline labile drugs: A stabilized bioadhesive composition containing an alkaline labile drug and a method for its preparation are provided. In one aspect, the composition is a hot-melt extruded (HME) composition comprising a preformed excipient mixture comprising an acidic component and an alkaline thermoplastic matrix-forming material, e.g. polymer. The excipient mixture is formed... Agent: Auxilium U.s. Holdings, LLC

20120214779 - Application of 20(s)-protopanaxadiol in preparation of antidepressants: The invention provides the novel use of 20(S)-protopanaxadiol in the preparation of medicaments for the treatment of depressive psychiatric disorders. The pharmacological test results indicated that the compound could remarkably increase the level of NE, 5-HT and HAV in the brains of model rats having depressive disorders, remarkably enhance tremors... Agent:

20120214778 - Fulvestrant in a dosage of 500mg for the treatment of advanced breast cancer: The present disclosure is directed to fulvestrant at a dosage of 500 mg and its use in the treatment of a postmenopausal woman with advanced breast cancer.... Agent:

20120214780 - Substituted porphyrins: The present invention relates, in general, to a method of modulating physiological and pathological processes and, in particular, to a method of modulating cellular levels of oxidants and thereby processes in which such oxidants are a participant. The invention also relates to compounds and compositions suitable for use in such... Agent: National Jewish Health

20120214781 - Antibacterial food composition: The present invention relates to an antibacterial food composition comprising a Propolis extract and a Vaccinium macrocarpon cranberry extract.... Agent:

20120214785 - New compounds, pharmaceutical compositions and uses thereof: e

20120214788 - Heteroaryl-substituted piperidines: The invention relates to novel heteroaryl-substituted piperidines, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular of cardiovascular diseases and tumour diseases.... Agent: Bayer Pharma Aktiengesellschaft

20120214790 - N-acyl cyclic amine derivative or pharmaceutically acceptable salt thereof: The present invention provides compounds which show high effectiveness against positive symptoms, negative symptoms and cognitive dysfunction in schizophrenia and reduce conventional side-effect risks as well as have remarkable effects for central neurological diseases associated with cognitive dysfunction other than schizophrenia. N-Acyl cyclic amine derivatives of formula (1): wherein Ar1... Agent: Dainippon Sumitomo Pharma Co., Ltd.

20120214786 - New compounds: e

20120214787 - Oxadiazole inhibitors of leukotriene production:

20120214789 - Tetrazole-substituted arylamides as p2x3 and p2x2/3 antagonists: or a pharmaceutically acceptable salt thereof, wherein, R1 is optionally substituted tetrazolyl, R2 is optionally substituted phenyl, optionally substituted pyridinyl or optionally substituted thienyl, and R3, R4, R5 and R6 are as defined herein. Also provided are methods of using the compounds for treating diseases associated with the P2X3 and/or... Agent:

20120214782 - New compounds, pharmaceutical compositions and uses thereof:

20120214784 - Spiropiperidine compounds as orl-1 receptor antagonists: An ORL-1 receptor antagonist of the formula: its uses, and methods for its preparation are described. ORL-1 antagonists are deemed to be useful in the treatment of depression and/or the treatment of overweight, obesity, and/or weight maintenance post treatment for overweight or obesity. Certain compounds have also demonstrated through animal... Agent: Eli Lilly And Company

20120214783 - Viral polymerase inhibitors:

20120214791 - Imidazo[5,1-f][1,2,4]triazines for the treatment of neurological disorders: and pharmaceutically acceptable salts thereof, to processes for the preparation of, intermediates used in the preparation of, and compositions containing such compounds and the uses of such compounds as a method for the treatment of a disease or condition selected from the group consisting of central nervous system disorders, cognitive... Agent: Pfizer Inc.

20120214792 - Thieno- adn furo-pyrimidine modulators of the histamine h4 receptor: Thieno- and furo-pyrimidine compounds are described, which are useful as H4 receptor modulators. Such compounds may be used in pharmaceutical compositions and methods for the modulation of histamine H4 receptor activity and for the treatment of disease states, disorders, and conditions mediated by H4 receptor activity, such as inflammation.... Agent:

20120214793 - Sleep aid composition and method: A sleep composition including zolpidem and quetiapine in combination provides a healthy sleep pattern allowing the user to get seven or eight hours sleep. The amount of each ingredient in the combination is lower than the amount usually needed to provide this amount of sleep when the ingredients are being... Agent:

20120214794 - Heteroaryls and uses thereof: s

20120214795 - Fused heterocyclic ring derivative and use thereof:

20120214796 - Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.... Agent:

20120214797 - Use of 5h-dibenz/b,f/azepine-5-carboxamide derivatives for treating fibromyalgia: where R1 is hydrogen, alkyl, halogenalkyl, aralkyl, cycloalkyl, cycloalkylalkyl, alkoxy, aryl, or pyridyl; the term alkyl means a straight or branched hydrocarbon chain containing from 1 to 18 carbon atoms; the term halogen means fluorine, chlorine, bromine or iodine; the term cycloalkyl means an alicyclic saturated group with 3 to... Agent: Bial - Portela & Ca S.a.

20120214799 - Kinase inhibitors: The present invention relates to compounds useful as inhibitors of protein kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing compounds of the inventions.... Agent: Vertex Pharmaceuticals Incorporated

20120214798 - Novel ethanediamone hepcidine antagonists: The present invention relates to novel hepcidin antagonists of formula (I), pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for treatment of disorders in iron metabolism, such as, in particular, iron deficiency diseases and anaemias, in particular anaemias in connection with chronic inflammatory diseases (ACD: anaemia... Agent: Vifor (international) Ag

20120214800 - Organic compounds: e

20120214801 - Compositions and methods relating to novel compounds and targets thereof: The present invention relates to novel chemical compounds, methods for their discovery, and their therapeutic use. In particular, the present invention provides benzodiazepine derivatives and related compounds and methods of using benzodiazepine derivatives and related compounds as therapeutic agents to treat a number of conditions associated with the faulty regulation... Agent: The Regents Of The University Of Michigan

20120214802 - Pyrrolidine compounds which inhibit beta-secretase activity and methods of use thereof: Described herein are novel beta-secretase inhibitors and methods for their use, including methods of treating Alzheimer's disease.... Agent:

20120214803 - Novel sulfonaminoquinoline hepcidin antagonists: The present invention relates to novel hepcidin antagonists, pharmaceutical compositions comprising them and the use thereof as medicaments for the use in the treatment of iron metabolism disorders, such as, in particular, iron deficiency diseases and anemias, in particular anemias in connection with chronic inflammatory diseases.... Agent: Vifor (international) Ag

20120214804 - Pharmaceutical composition comprising indole compound: The present invention relates to a pharmaceutical composition comprising a compound of formula (1), (2) or (3) as defined in the specification for the prevention or treatment of diseases associated with oxidative stress, mitochondria dysfunction, hypoxic injury, necrosis and/or ischemic reperfusion injury, and a cosmetic composition comprising an indole compound... Agent:

20120214805 - Bridged bicyclic piperidine derivatives and methods of use thereof: The present invention relates to Bridged Bicyclic Piperidine Derivatives, compositions comprising a Bridged Bi-cyclic Piperidine Derivative, and methods of using the Bridged Bicyclic Piperidine Derivatives for treating or preventing obesity, diabetes, a metabolic disorder, a cardiovascular disease or a disorder related to the activity of GPR119 in a patient.... Agent:

20120214806 - 3-amino-5-phenyl-5,6-dihydro-2h-[1,4]oxazines: e

20120214809 - Aminoindane compounds and use thereof in treating pain: The present application provides novel aminoindane compounds and methods for preparing and using these compounds. These compounds are useful in treating pain and/or itch in patients by administering one or more of the compounds to a patient. The methods include administering a compound of formula (I) or (II) and a... Agent:

20120214808 - Aryl urea derivatives for treating obesity: A method of treating a condition associated with the CB-1 receptor, in particular obesity, by administering an effective amount of an aryl urea CB-1 receptor modulating compound to a subject in need of such treatment.... Agent: Prosidion Limited

20120214807 - Compounds useful as antagonists of ccr2: or a pharmaceutically acceptable salt thereof, wherein X, n, Y, and R1 are defined generally and in subsets herein. Compounds of the invention are inhibitors of CCR2 and accordingly are useful for the treatment of a variety of inflammatory, allergic, and autoimmune diseases, disorders, or conditions.... Agent: Millennium Pharmaceuticals, Inc.

20120214810 - Salts of n-[6-cis-2,6-dimethylmorpholin-4-yl)pyridine-3-yl]-2-methyl-4'-(trifluoromethoxy)[1,1'-biphenyl]-3-carboxamide: Salts of N-[6-(cis-2,6-dimethylmorpholin-4-yl)pyridine-3-yl]-2-methyl-4′-(trifluoromethoxy)[1,1′-biphenyl]-3-carboxamide are prepared and characterized.... Agent: Novartis Ag

20120214811 - Raf inhibitor compounds and methods of use thereof: Compounds of Formula I are useful for inhibition of Raf kinases. Methods of using compounds of Formula I and stereoisomers, tautomers, prodrugs and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are... Agent:

20120214812 - Compounds and compositions as lxr modulators: The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of liver X receptors (LXRs).... Agent: Irm LLC

20120214813 - Isoxazole compound for the treatment of cancer: The use of 5-(2,4-Dihydroxy-5-isopropyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylic acid ethylamide or a tautomer thereof or a pharmaceutically acceptable salt or a hydrate or a solvate for the treatment of cancer of the bladder, the colon, the liver, the lung, the breast, the vagina, the ovaries, the pancreas, the kidney, the stomach, the gastrointestinal tract,... Agent: Novartis Ag

20120214814 - Antioxidant inflammation modulators: oleanolic acid derivatives with amino acid and other modifications at c-17: e

20120214815 - 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses: The present invention concerns 2-oxo-1-pyrrolidine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals.... Agent: Ucb Pharma, S.a.

20120214816 - Methods and compositions for safe and effective treatment of erythema: Improved methods and compositions for safe and effective treatment of erythema or a symptom associated with erythema in a subject are described. The methods involve topically applying to an affected skin area a topical composition comprising about 0.4% to about 0.6% by weight of brimonidine and a pharmaceutically acceptable carrier.... Agent: Galdema R&d Inc.

20120214817 - Urotensin ii receptor antagonists: The invention is directed to Urotensin II antagonists. More specifically, the present invention relates to certain novel compounds, methods for preparing compounds, compositions, intermediates and derivatives thereof and methods for treating Urotensin-II mediated disorders. Pharmaceutical and veterinary compositions and methods of treating cardiovascular disorders and various other disease states or... Agent:

20120214818 - Methods of treating diastolic dysfunction and related conditions: The invention provides a method of treating diastolic dysfunction, e.g., diastolic dysfunction with preserved ejection fraction, in a subject. The method comprises administering to the subject in an amount effective to treat the diastolic dysfunction a cardiac metabolic modifier, as described herein. In some embodiments, the diastolic dysfunction is characterized... Agent: The Board Of Trustees Of The University Of Illinois

20120214819 - Use of n--4-(3-pyridyl)-2-pyridine-amine for the treatment of pulmonary hypertension: e

20120214820 - Orally disintegrating pharmaceutical dosage form containing aripiprazole: The present invention relates to an orally disintegrating dosage form containing aripiprazole. The formulation of the invention shows a fast disintegration.... Agent: Ratiopharm Gmbh

20120214821 - Lipidomic biomarkers of diabetes: The invention, in some aspects, relates to methods for predicting a subject's risk of developing a glucose-related metabolic disorder, e.g., diabetes. In some aspects, the invention relates to methods for selecting and monitoring a treatment for a glucose-related metabolic disorder, e.g., diabetes.... Agent: The General Hospital Corporation

20120214822 - N-cyclopropyl-3-fluoro-5-[3-[[1-[2-[2- [(2-hydroxethyl)amino] ethoxy]phenyl] cyclopropyl] amino]-2-oxo- 1 (2h)-pyrazinyl]-4-methyl-benzamide, or pharmaceutically acceptable salts thereof and their uses: e

20120214823 - Novel compounds that are erk inhibitors: Disclosed are the ERK inhibitors of formula 1.0: (Formula (A1)), and the pharmaceutically acceptable salts, esters and solvates thereof. Q is a piperidine ring that can have a bridge or a fused ring. All other substitutents are as defined herein. Also disclosed are methods of treating cancer using the compounds... Agent:

20120214824 - Proteostasis regulators: The present invention is directed to compounds of Formulae (I), (II), (III), (IV), (V), (VI), (VII), and (VIII), pharmaceutical compositions thereof and methods of use thereof in the treatment of conditions associated with a dysfunction in proteostasis.... Agent:

20120214827 - Anhydrous crystalline forms of n-[1-(2-ethoxyethyl)-5-(n-ethyl-n-methylamino)-7-(4-methylpyridin-2-yl-amino)-1h-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide: The invention comprises (1) anhydrous crystalline forms of N-[1-(2-ethoxyethyl)-5-(N-ethyl-N-methylamino)-7-(4-methylpyridin-2-yl-amino)-1H-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide, (2) pharmaceutical compositions comprising at least one such form, (3) methods for the treatment of a phosphodiesterase-5-mediated condition using at least one such form, and (4) methods for preparing such forms. The compound N-[1-(2-ethoxyethyl)-5-(N-ethyl-N-methylamino)-7-(4-methylpyridin-2-yl-amino)-1H-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide has the following structure (I).... Agent: Pfizer Inc.

20120214826 - Inhibitors of bruton's tyrosine kinase: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination... Agent: Pharmacyclics, Inc.

20120214825 - Mtor/jak inhibitor combination therapy: Provided herein is a combination therapy comprising an mTOR inhibitor and a JAK inhibitor. The combination therapy is useful for the treatment of a variety of cancers, including MPNs. The combination therapy is also useful for the treatment of any number of JAK-associated diseases.... Agent:

20120214830 - Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma: The present invention provides diagnostic methods for predicting the effectiveness of treatment of an hepatocellular carcinoma (HCC) patient with an IGF-1R kinase inhibitor by assessing whether the HCC tumor cells express a high level of AFP, or whether serum levels of AFP protein are high. The present invention also provides... Agent: Osi Pharmaceuticals, LLC

20120214828 - Determining sensitivity of cells to b-raf inhibitor treatment by detecting kras mutation and rtk expression levels: The present invention relates to prognostic methods for identifying tumors that are not susceptible to B-Raf inhibitor treatment by detecting mutations in a K-ras gene or protein or by detecting overexpression of RTKs and/or their ligands. Kits are also disclosed for carrying out the methods.... Agent:

20120214829 - Molecular predictors of therapeutic response to specific anti-cancer agents: Herein is described the use of a collection of 50 breast cancer cell lines to match responses to 77 conventional and experimental therapeutic agents with transcriptional, proteomic and genomic subtypes found in primary tumors. Almost all compounds produced strong differential responses across the cell lines produced responses that were associated... Agent: The Regents Of The University Of California

20120214831 - Method for determination of sensitivity to anti-cancer agent: The marker for determining sensitivity to an anti-cancer agent is formed of a protein selected from the group consisting of a protein or a fragment thereof which is detected as a peak at m/z of 5,300 to 5,400, a protein or a fragment thereof which is detected as a peak... Agent: Keio University

20120214832 - Isoform selective phospholipase d inhibitors: Disclosed are isoform selective Phospholipase D inhibitors. In one aspect, the disclosed compounds can have a structure represented by a formula (I): Also disclosed are methods of making and using the compounds. Also disclosed are pharmaceutical compositions and kits comprising the compounds. This abstract is intended as a scanning tool... Agent:

20120214833 - Solid dispersion of rifaximin: A solid dispersion of rifaximin comprising rifaximin and pharmaceutically acceptable carrier. A pharmaceutical composition comprising the solid dispersion of rifaximin.... Agent: Lupin Limited

20120214834 - Immune enhancement composition and kit and use thereof: An immune enhancement composition is disclosed. The immune enhancement composition includes rapamycin, substituted quinoline and a pharmaceutically acceptable carrier, diluent, excipient or a combination thereof. An immune enhancement kit containing the two aforementioned compounds and a use of a combination containing the two aforementioned compounds as an immune enhancement composition... Agent:

20120214835 - Sensitizer, kit and use for cancer therapy: A cancer therapy sensitizer is disclosed. The cancer therapy sensitizer includes rapamycin and substituted quinoline. The present invention discloses a cancer therapy sensitization kit containing the two aforementioned compounds and a use of a combination of the two aforementioned compounds as a cancer therapy sensitizer as well. The application of... Agent:

20120214836 - Sensitizer, pharmaceutical composition, kit and use for target therapy: A target therapy sensitizer including rapamycin and substituted quinoline is disclosed. In addition, a pharmaceutical composition containing the sensitizer, a target therapy sensitization kit containing the two aforementioned compounds, and a use of a combination of the two aforementioned compounds as a target therapy sensitizer are also disclosed. The application... Agent:

20120214837 - Substituted 6,7-dialkoxy-3-isoquinolinol derivatives as inhibitors of phosphodiesterase 10 (pde10a): wherein R′, R1, through R7 and Ar are as defined herein. These compounds are useful as inhibitors of phosphodiesterase 10 (PDE10A) which are useful in treating central nervous system diseases such as psychosis and also in treating, for example, obesity, type II diabetes, metabolic syndrome, glucose intolerance, pain and ophthalmic... Agent: Allergan, Inc.

20120214838 - Therapeutically useful substituted hydropyrido [3,2,1-ij] quinoline compounds: e

20120214840 - Indolizine inhibitors of 5-lipoxygenase: Described herein are compounds and pharmaceutical compositions containing such compounds, which inhibit the activity of 5-lipoxygenase (5-LO). Also described herein are methods of using such 5-LO inhibitors, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other leukotriene-dependent or leukotriene mediated conditions, diseases, or disorders.... Agent: Panmira Pharmaceuticals, LLC

20120214839 - Treatment of progressive neurodegenerative disease with ibudilast: Compositions and methods for treating progressive neurodegenerative diseases, and their associated symptoms by administration of ibudilast (3-isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine).... Agent: Medicinova, Inc.

20120214841 - Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide: The present invention relates to solid state forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (Compound 1), pharmaceutical compositions thereof and methods therewith.... Agent: Vertex Pharmaceuticals Incorporated

20120214842 - Methods for treating diseases of the retina: e

20120214843 - Combination treatment of hydroxpyridonate actinide/lanthanide decorporation agents: The invention provides for a method for treating a subject in need of such treatment comprising administering a therapeutically effective amount of one or more pharmaceutical compositions comprising a 1,2-HOPO chelating agent and a 3,2-HOPO chelating agent to a subject in need of such treatment. The use of both 1,2-HOPO... Agent: The Regents Of The University Of California

20120214845 - Active metabolite of a thrombin receptor antagonist: Disclosed herein is an active metabolite (“M20”) of a molecule that is useful as a thrombin receptor antagonist: Also disclosed are formulations of this compound, synthetic routes to this compound, and methods of treating a variety of cardiovascular conditions, including acute coronary syndrome and peripheral arterial disease, and of effecting... Agent:

20120214844 - Liquid pest control formulation: The present invention relates to a liquid pest control system that includes a synthetic pyrethroid as a pest control active ingredient and an agent selected from the group consisting of purified diethylene glycol monoethyl ether, tocopherol nicotinate and tocopherol succinate, and combinations thereof, to reduce or eliminate paresthesia of the... Agent: Redline Products, Inc.

20120214847 - 2-[1-phenyl-5-hydroxy-4a-substituted-hexahydrocyclopenta[f]indazol-5-yl]ethyl phenyl derivatives as glucocorticoid receptor ligands: The present invention encompasses compounds of Formula I: or pharmaceutically acceptable salts or hydrates thereof, which are useful as selective glucocorticoid receptor ligands for treating a variety of autoimmune and inflammatory diseases or conditions. Pharmaceutical compositions and methods of use are also included.... Agent: Merck Sharp & Dohme Corp.

20120214846 - Hexahydrocyclopentyl[f]indazole pyridyl ethanols and derivatives thereof as selective glucocorticoid receptor modulators: The present invention encompasses compounds of Formula (I): or pharmaceutically acceptable salts or hydrates thereof, which are useful as selective glucocorticoid receptor ligands for treating a variety of autoimmune and inflammatory diseases or conditions. Pharmaceutical compositions and methods of use are also included.... Agent: Merck Sharp & Dohme Corp

20120214848 - [1,2,4]oxadiazol-3-yl acid salts and crystalline forms and their preparation: The present invention relates to salts and crystalline forms of [1,2,4]oxadiazol-3-yl]-phenoxy}-cycloalkyl carboxylic acids, processes for their preparation, pharmaceutical compositions comprising such compounds, and methods of using them.... Agent: Abbott Laboratories

20120214849 - Dual-acting antihypertensive agents: wherein: Ar, r, Z, X, R3, and R5-7 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have AT1 receptor antagonist activity and neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process... Agent: Theravance, Inc.

20120214850 - Compounds for treatment of cell proliferative diseases: The present invention concerns compounds and their use to treat cell proliferative diseases such as cancer. Compounds of the present invention display significant potency as kinase inhibitors, cause the downregulation of c-myc, and inhibit the growth and survival of cancerous cell lines.... Agent:

20120214851 - Aminobenzamide derivatives as useful agents for controlling animal parasites: The invention relates to a composition comprising at least one aminobenzamide compound or a salt thereof for controlling animal parasites, veterinary pharmaceutical compositions comprising at least one aminobenzamide of formula (I) for preventing infection with diseases transmitted through parasites, its use for the preparation of a veterinary pharmaceutical for controlling... Agent: Bayer Cropscience Ag

20120214852 - Alkoxy compounds for disease treatment: The present invention relates generally to compositions and methods for treating neurodegenerative diseases and disorders, particularly ophthalmic diseases and disorders. Provided herein are alkoxyl derivative compounds and pharmaceutical compositions comprising these compounds. The subject compositions are useful for treating and preventing ophthalmic diseases and disorders, including age-related macular degeneration (AMD)... Agent: Acucela Inc.

20120214854 - Carboxy oxazole or thiazole compounds as dgat- 1 inhibitors useful for the treatment of obesity: Heteroaryl compounds, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of diseases or disorders mediated by Diacylglycerol acyltransferase (DGAT) enzyme, particularly DGAT-1 is described.... Agent:

20120214853 - Ite for cancer intervention and eradication: A method of cancer intervention or eradication by administering an effective amount of an endogenous ligand for the aryl hydrocarbon (Ah) receptor (AhR) named ITE or one of its analogs (the active ingredient) to a subject with cancer is disclosed. An effective dose and dosing frequency of the active ingredient... Agent:

20120214855 - Heterocyclic compound and use thereof: m

20120214856 - Treatment for cancer: The present invention provides methods for the treatment of tumors, comprising administration of an effective amount of at least one taxoid and an effective amount of at least one benzimidazol carbamate compound of formula (I). The invention also provides a method for the treatment of tumors insensitive to one or... Agent: Newsouth Innovations Pty Limited

20120214857 - Use of polymer particles containing insecticide in order to improve the soil mobility of insecticides, insecticide formulas, polymer particles containing insecticide, and method for pest control: e

20120214858 - Imidamide sphingosine kinase inhibitors: Imidamide (amidine) analogs that can inhibit the activity of sphingosine kinase 1 and sphingosine kinase 2 (SphK1 & SphK2) are provided. The compounds can prevent angiogenesis in tumors.... Agent: University Of Virginia Patent Foundation

20120214859 - Methods and compositions for improving cognitive function: This invention relates to methods and compositions for treating central nervous system (CNS) disorders with cognitive impairment. In particular, it relates to the use of inhibitors of synaptic vesicle glycoprotein 2A (SV2A), alone or in combination with valproate, in treating central nervous system (CNS) disorders with cognitive impairment in a... Agent:

20120214869 - Novel ligand activators of the rar receptors and pharmaceutical/cosmetic applications thereof: i

20120214870 - Methods for diagnosis and treatment of chronic fatigue syndrome: Methods for the diagnosis and treatment of chronic fatigue syndrome (CFS) are disclosed based upon the finding that particular individual acylcarnitines are present in modified concentrations (ie decreased or increased concentrations) in CFS patients compared to healthy control subjects. In one form of the invention, a diagnostic method comprises determining... Agent: University Of South Australia

20120214872 - Bile acid or bile salt fatty acid conjugates: in which G is a bile acid or bile salt radical, which is optionally conjugated in position 24 with a suitable amino acid, W stands for one or two fatty acid radicals, each having from 14-22 carbon atoms, and X is a suitable bonding member or a direct C═C bond... Agent:

20120214871 - Leave-on nonsolid oil-continuous skin conditioning compositions containing 12-hydroxystearic acid: Leave-on non-solid oil-continuous skin conditioning compositions comprising 12-hydroxy stearic acid. Compositions contain 12HSA, yet have a relatively low viscosity, so are suitable for spreading on the skin, and are stable on storage and structurally reversible through temperature cycling.... Agent: Conopco, Inc., D/b/a Unilever

20120214873 - Cysteine for physiological injection: This application describes methods of making and using physiological cysteine solutions useful for reversing a neuromuscular blockade caused by a cysteine-reversible neuromuscular blockade agent, that overcomes problems of cysteine precipitation and dimerization.... Agent: Cornell University

20120214874 - Pharmaceutical formulations and methods of use: In one embodiment, the present invention provides a topical composition including a topically acting anesthetic active ingredient; an ester; a non-ionic surfactant; a polar solvent; water, and optionally a buffer, a pH adjusting agent or an anti-oxidant. The compositions are useful for alleviating pain especially associated with acute herpes zoster.... Agent: Nuvo Research Inc.

20120214875 - Phenoxybenzamine assay: The invention provides methods for measuring concentrations of basic or neutral compounds, such as phenoxybenzamine, in biological samples, and methods for treating patients based on the compound concentrations in the biological samples from the patients.... Agent:

20120214876 - Seizure and migraine treatments using the bone homeostasis drug cinacalcet: e

20120214877 - Stable rasagiline composition: The present invention provides a stable composition of rasagiline comprising an effective dosage of rasagiline or its pharmaceutically acceptable salts and an antioxidant used as a stabilizer. The dosage forms of the composition are pharmaceutically common transdermal-drug delivery dosage form and mucoadhesive delivery dosage form, such as patch, gel, ointment,... Agent: Chongqing Pharmaceutical Research Institute Co., Ltd.

20120214879 - Chemical system with self-timing indicator: A pH-modified luminescent composition and methods. In composition, a marker exhibiting luminescence change over a indicatory period. pH-based luminesce change may be in intensity or in wavelength. One embodiment provides a luminescent composition, including a selected luminescent marker having a first phase; and a selected ionizing agent comprising a second... Agent: Infection Prevention Systems, Inc.

20120214878 - High alcohol content sanitizer: This invention relates to an antimicrobial sanitizing composition in the form of a gel or cream that contains an alcohol in an amount of at least 55% by weight. The sanitizer is capable of disinfecting and providing prolonged antimicrobial property to a variety of surfaces, including the skin, without causing,... Agent: Donald R. Korb

20120214880 - Cancer screening by detection of ultrastructural and molecular markers: The present invention relates to detection of cancer, or assessment of risk of development thereof. In particular, the present invention provides compositions and methods detection of field carcinogenesis by identification of ultrastructural and molecular markers in a subject.... Agent: Northwestern University

  
08/16/2012 > 159 patent applications in 131 patent subcategories. inventions list

20120208742 - Compositions of a peptide targeting system for treating cancer: This invention describes a protein nanoparticle system for targeting siRNA or other drugs into tumors. The basis of the protein system is elastin-like peptides that self-assemble once exposed to the nucleic acid of the siRNA. Specific targeting peptides are fused to the core ELP structure by standard genetic engineering techniques.... Agent: Nanooncology

20120208743 - Use of gelsolin to diagnose and treat inflammatory diseases: The invention relates to the use of gelsolin to treat inflammatory diseases (e.g., rheumatoid arthritis) and to the use of gelsolin to diagnose, monitor, and evaluate therapies of inflammatory diseases (e.g., rheumatoid arthritis).... Agent:

20120208744 - Anti-microbial agents and compositions and methods of production and use thereof: Anti-microbial compositions for inhibiting gram-negative bacterial growth include inhibitors of one or more interactions between the bacterial proteins TonB and ExbD and/or between the bacterial proteins TolR and TolA. Methods of producing and using the anti-microbial compositions (e.g., treating gram-negative bacterial infections in a mammalian subject) are described. Novel antibiotics... Agent: The Penn State Research Foundation

20120208745 - Treatment of hiv: We describe methods of treatment of HIV using proopiomelanocortin (POMC) and corticotropin releasing factor (CRF) peptides and their products, as well as uses of such peptides in the preparation of medicaments.... Agent:

20120208746 - Genetic markers associated with response to cyclophilin-binding compounds: Methods of predicting the response in a patient infected with hepatitis C virus (HCV) to a treatment regime involving the use of a cyclophilin-binding compound are described which provide for improvements in treatments, pharmaceutical compositions, dosing regimen, assays, kits, and other aspects of the art.... Agent: Scynexis Inc.

20120208747 - Novel peptide for augmenting and expression of bdnf and pharmaceutical composition for prevention and treatment of neurodegenerative diseases including alzheimer's disease or parkinson's disease, comprising the same: Disclosed are peptides for augmenting the expression of BDNF (brain-derived neurotrophic factor) and a pharmaceutical composition for the prevention and treatment of Alzheimer's disease or Parkinson's disease, comprising the same. The peptides can induce the expression of BDNF in dopamine-reactive human cells, pass easily through the blood-brain barrier thanks to... Agent: Sungyunkwan University Foundation For Corporate Collaboration

20120208748 - Peptide compositions and methods for treating patients: The present invention is directed to peptide compositions and methods of using the peptide compositions to treat prediabetes, diabetes, obesity, high blood pressure and metabolic syndrome.... Agent: The Regents Of The University Of Michigan

20120208749 - Insulin derivatives: The present invention is related to insulin derivatives having a side chain attached either to the α-amino group of the N-terminal amino acid residue of B chain or to an ε-amino group of a Lys residue present in the B chain of the parent insulin molecule via an amide bond... Agent: Novo Nordisk A/s

20120208750 - Use of protein kinase c delta (pkcd) inhibitors to treat diabetes, obesity, and hepatic steatosis: Described are methods of improving insulin sensitivity, and treating fatty liver disease (including non-alcoholic steatohepatitis (NASH)), by administering specific inhibitors of PKC delta.... Agent: Joslin Diabetes Center, Inc.

20120208751 - Methods for regulating neurotransmitter systems by inducing counteradaptations: The present invention relates to methods for regulating neurotransmitter systems by inducing a counteradaptation response. According to one embodiment of the invention, a method for regulating a neurotransmitter includes the step of repeatedly administering a ligand for a receptor in the neurotransmitter system, with a ratio of administration half-life to... Agent:

20120208752 - Cell proliferation-promoting peptide and use thereof: A cell proliferation promoter includes, as an active ingredient, an artificially synthesized peptide that includes (A) an amino acid sequence constituting a membrane-permeable peptide and (B) an amino acid sequence selected from SEQ ID NOs: 19 to 103 or an amino acid sequence formed by substituting, deleting and/or adding one... Agent: Toagosei Co. Ltd.

20120208753 - Composition and method for the treatment or prevention of spinal disorders iii: The present invention relates to compositions comprising a modulator of GDF-6 signaling for the prevention of and/or treatment of a spinal disorder and/or spinal pain, eg., caused by and/or associated with intervertebral disc degeneration and methods of treatment of a spinal disorder and/or spinal pain comprising administering a modulator of... Agent:

20120208754 - Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles: This invention relates to stable non-aqueous single phase viscous vehicles and to formulations utilizing such vehicles. The formulations comprise at least one beneficial agent uniformly suspended in the vehicle. The formulation is capable of being stored at temperatures ranging from cold to body temperature for long periods of time. The... Agent: Intarcia Therapeutics, Inc.

20120208755 - Compositions, devices and methods of use thereof for the treatment of cancers: The use of GLP-1 receptor agonists, such as glucagon-like peptide-1 (GLP-1) or exenatide, for the treatment of cancer is described. The GLP-1 receptor agonists are typically delivered using an implanted osmotic delivery device that provides for continuous delivery of the GLP-1 receptor agonist for at least one month. Additional beneficial... Agent: Intarcia Therapeutics, Inc.

20120208756 - Composition for external preparation for skin: e

20120208757 - Use of hyaluronan for promoting angiogenesis: Use of hyaluronan, either alone or in combination with collagen, for promoting angiogenesis.... Agent: National Cheng Kung University

20120208758 - Composition for the attachment of implants to collagen or other components of biological tissue: The present invention relates to a novel composition comprising an implant, scaffold or construct bound to a biological or chemical moiety. The bound moiety has the ability to bind to a component of the extracellular matrix of biological tissue, allowing the implant to be bound to the biological tissue in... Agent: New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery

20120208759 - Long-acting coagulation factors and methods of producing same: Polypeptides comprising at least one carboxy-terminal peptide (CTP) of chorionic gonadotrophin attached to the carboxy terminus but not to the amino terminus of a coagulation factor and polynucleotides encoding the same are disclosed. Pharmaceutical compositions comprising the polypeptides and polynucleotides of the invention and methods of using and producing same... Agent:

20120208760 - Thrombopoietic compounds: The invention relates to the field of compounds, especially peptides or polypeptides, that have thrombopoietic activity. The peptides and polypeptides of the invention may be used to increase platelets or platelet precursors (e.g., megakaryocytes) in a mammal.... Agent: Amgen Inc.

20120208761 - Type i-type iv collagen hybrid gel: It is an object of the present invention to provide a Type I-Type IV collagen hybrid gel, which maintains characteristics of a Type IV collagen and is superior in gel strength. It is the Type I-Type IV collagen hybrid gel obtained by mixing 100 to 500 parts by mass of... Agent:

20120208762 - Methods of diagnosing diastolic dysfunction: Diagnostic methods relating to a cardiac ventricular dysfunction are provided. In some embodiments, the diagnostic method is a method of diagnosing diastolic dysfunction in the absence of systolic dysfunction in a subject. The method comprises assaying a sample obtained from the subject for evidence of activation of renin-angiontensin system (RAS),... Agent: The Board Of Trustees Of The University Of Illinois

20120208763 - Nap alpha-aminoisobutyric acid analog with neuroprotective activity: The invention relates to compositions and methods to confer protection on neurons. Peptides derived from the NAPVSIPQ (SEQ ID NO:4) peptide and including branched amino acids, such as alpha-aminoisobutyric acid, are included. Also included are methods of preventing and treating neurodegenerative disorders and damage caused by neurotoxic substances.... Agent: Ramot At Tel-aviv University, Ltd.

20120208764 - Method and compositions for treating stroke with fever: The invention provides methods of treating stroke and related conditions exacerbated by fever and/or hyperglycemia by administering peptides or peptidomimetics that inhibit binding of NMDAR 2B to PSD-95 to a patient.... Agent: Arbor Vita Corporation

20120208765 - Modified agrin-fragment capable of restoring muscle strength for use as a medicament: Modified agrin fragment having in vivo activity, comprising at least the domains LG2 and LG3 of human agrin in covalently interlinked form and modified in such a way that the fragment cannot be cleaved by neurotrypsin for use as medicament.... Agent: Neurotune Ag

20120208766 - Topical corneal analgesia using neurotensin receptor agonists and synergistic neurotensin combinations without delaying wound healing: A method for administering an ocular analgesic is described. The method includes the steps of providing a topical analgesic that includes a neo-tryptophan-containing neurotensin analog and applying the topical analgesic to the ocular tissue in a dose of about 0.0001 to about 5 mg, alternatively about 0.0001 to about 3... Agent:

20120208767 - Method to detect or treat painful bladder syndrome based on relation to quinone oxidoreductase 1: A method includes obtaining a biological sample from a subject that does not display a symptom of Painful Bladder Syndrome (PBS). The method also includes analyzing the biological sample for a mutated form of NAD(P)H dehydrogenase [quinone], also known as Quinone Oxidoreductase 1, abbreviated NQO1, or a mutation of a... Agent: University Of Maryland, Baltimore

20120208768 - Specific binding sites in collagen for integrins and use thereof: The present invention identified a high affinity binding sequence in collagen type III for the collagen-binding integrin I domains. Provided herein are the methods used to characterize the sequence, the peptides comprising this novel sequence and the use of the peptides in enabling cell adhesion. Also provided herein are methods... Agent: The Texas A&m University System

20120208770 - Carcinoma homing peptide (chp), its analogs, and methods of using: A mini-peptide and its analogs have been found to target gene products to tumors. The peptide, named Carcinoma Homing Peptide (CHP), increased the tumor accumulation of the reporter gene products in five independent tumor models, including one human xenogeneic model. A CHP-IL-12 fusion gene was also developed using CHP and... Agent:

20120208769 - Chemokine-mucin fusions linked to glycosylphosphatidylinositol (gpi)-anchors in tissue regeneration and as tumour immune adjuvants: The present invention relates to chemokine-mucin fusions linked to glycosylphosphatidylinositol (GPI)-anchors and their use as anti-cancer adjuvants and as agents in tissue regeneration and suppression of vascular damage. GPI-linked chemokines are incorporated in the surface membrane of tumour cells and effect a recruitment of cytotoxic immune cells to the tumour... Agent:

20120208771 - Synthetic cholesterylamine-linker derivatives for agent delivery into cells: Synthetic cholesterylamine-linkers can include derivatives of cholesterol, cholesteryl, or sitosteryl coupled through the linker to an agent for delivery into cells. The cholesterylamines are thought to mimic cholesterol in the capacity and mechanism for enhanced entry into cells. The configuration of the cholesterylamine-linker that is thought to provide for enhanced... Agent: University Of Kansas

20120208772 - Cytokine zalpha11 ligand: Antibodies that bind to polypeptides and peptides comprising the sequence of zalpha11 Ligand as shown in SEQ ID NO: 2 are described. The antibodies may bind the full length sequence of 162 amino acid residues or a fragment thereof, including a mature polypeptide of 131 amino acid residues and smaller... Agent: Zymogenetics, Inc.

20120208773 - Pharmaceutical compositions with tetrabenazine: The present invention provides for a pharmaceutical composition that includes tetrabenazine and a release-retarding agent; and a method of treating a hyperkinetic movement disorder (e.g., Huntington's disease, chorea associated with Huntington's disease, hemiballismus, senile chorea, tic disorders, tardive dyskinesia, myoclonus, dystonia and/or Tourette's syndrome). The method includes administering an effective... Agent: Valeant International (barbados) Srl

20120208774 - Method for inhibiting \"melanoma inhibitory activity\" mia: The present invention is directed to peptides, antibodies and antibody fragments inhibiting activity of “Melanoma Inhibitory Activity” (MIA).... Agent:

20120208775 - Sorbitol polyesters having liquid and solid domains: The present invention is directed to a series of sorbitol esters that have two different molecular weight ester chains, one solid and one liquid, which when combined into a single molecule make a polymer that is solid, but has very unique flow properties. These materials find applications as additives to... Agent:

20120208776 - Anti-neoplastic compositions comprising extracts of black cohosh: A method is provided for treating, preventing or ameliorating neoplasia in a subject. This method includes administering to the subject an amount of actein or an amount of an extract of black cohosh that contains a triterpene glycoside, which amount of the actein or black cohosh is effective to treat,... Agent:

20120208777 - Diosmetin compounds, a process for their preparation and pharmaceutical compositions containing them: m

20120208778 - Avermectins and milbemycins for the treatment, prevention or amelioration of flavivirus infections: Avermectin and milbemycin compounds, particularly the substance ivermectin, for preparing an antiviral medicament for the treatment, prevention or amelioration of a Flavivirus infection, such as those caused by YFV (yellow fever virus), DENV (Dengue virus), JEV (Japanese encephalitis virus), TBEV (tick-borne encephalitis virus) or MODV (Modoc virus) are provided. The... Agent: Aix-marseille Universite

20120208779 - Macrolide synthesis process and solid-state forms: Described are methods for making macrolides, and, in particular, a method for making optionally substituted 20,23-dipiperidinyl-5-O-mycaminosyl-tylonolide and derivatives thereof, as well as uses of macrolides to make medicaments, methods of treatment using macrolides, and methods for making intermediates that, inter alia, may be used to make macrolides. Also described are... Agent: Intervet International B.v.

20120208780 - Hybrid nanomaterials consisting of pseudorotaxanes, pseudopolyrotaxanes, rotaxanes, polyrotaxanes, nanoparticles and quantum dots: This invention provides the synthesis of biocompatible and high functional hybrid nanomaterials consisting of pseudorotaxanes, pseudopolyrotaxanes, rotaxanes, polyrotaxanes, nanoparticles and quantum dots (QDs). The molecular self-assembly of hybrid nanomaterials lead to the formation of nano-objects with different shapes such as core-shell, spindle-like or necklaces. Due to their well-defined molecular self-assemblies,... Agent: Lorestan University

20120208781 - Aminoglycoside dosing regimens: The present invention provides new aminoglycoside dosing regimens associated with enhanced microbicidal activity and reduced nephrotoxicity, as well as methods of using these dosing regimens to treat various bacterial infections.... Agent: Achaogen, Inc.

20120208860 - Compositions and methods for inhibiting expression of factor vii gene: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the Factor VII gene.... Agent:

20120208864 - Compounds and methods for modulating expression of gcgr: The present disclosure describes short antisense compounds, including such compounds comprising chemically-modified high-affinity monomers 8-16 monomers in length. Certain such short antisense compound are useful for the reduction of target nucleic acids and/or proteins in cells, tissues, and animals with increased potency and improved therapeutic index. Thus, provided herein are... Agent: Isis Pharmaceuticals, Inc.

20120208865 - Exon skipping therapy for dysferlinopathies: The present invention relates to methods for restoring the function of a mutated dysferlin comprising the step of preventing splicing of one or more exons which encode amino acid sequences that cause said dysferlin dysfunction. Particularly, the splicing of exon 32 is prevented. The present invention also relates to a... Agent:

20120208861 - Ifn type-i production inhibitor and method for screening for same: It has been found that Spi-B, in cooperation with IRF-7, induces type I IFN production. This invention is based on the finding, and provides a type I IFN production inhibitor comprising an antisense nucleic acid or siRNA against Spi-B, or an expression vector capable of expressing the same; a screening... Agent: Riken

20120208863 - Modulation of glut4 gene promoter activity by ahnak: Agents capable of alleviating AHNAK phosphoprotein-mediated repression of GLUT4 gene expression are useful for prevention, treatment, and/or alleviation of insulin resistance associated with obesity, lipotoxicity, hypertension, metabolic syndrome and type 2 diabetes. Preferred agents are double-stranded siRNAs.... Agent: Technion Research And Development Foundation Ltd.

20120208862 - Rip140 regulation of glucose transport: Inhibition of RIP140 increases glucose transport. Compounds that inhibit RIP140 expression or activity are useful for treating disorders associated with aberrant glucose transport (e.g., diabetes), treating obesity, increasing metabolism (e.g., fatty acid metabolism), and increasing brown fat.... Agent:

20120208869 - Endometriosis-related markers and uses thereof: The present invention relates to markers of endometriosis which are differentially expressed in the endometrial cells of females with endometriosis compared to endometriosis-free females. The invention also relates to methods for determining likelihood of endometriosis in female subjects, to methods for grading endometriosis in females suffering from endometriosis and to... Agent:

20120208870 - Hepatitis c virus codon optimized non-structural ns3/4a fusion gene: Aspects of the present invention relate to the discovery of a novel hepatitis C virus (HCV) isolate. Embodiments include HCV peptides, nucleic acids encoding said HCV peptides, antibodies directed to said peptides, compositions containing said nucleic acids and peptides, as well as methods of making and using the aforementioned compositions... Agent: Chrontech Pharma Ab

20120208867 - Hmgb1 binding nucleic acid molecule and applications thereof: A nucleic acid molecule that can bind to HMGB1 protein and applications thereof are provided. A nucleic acid molecule having a dissociation constant for HMGB1 protein of 5×10−7 or less can be used as the nucleic acid molecule that can bind to HMGB1 protein. The HMGB1 binding nucleic acid molecule... Agent:

20120208866 - Intact minicells as vectors for dna transfer and gene therapy invitro and invivo: A composition comprising recombinant, intact minicells that contain a therapeutic nucleic acid molecule is disclosed. Methods for purifying a preparation of such minicells also are disclosed. Additionally, a genetic transformation method is disclosed, which comprises (i) making recombinant, intact minicells available that contain a plasmid comprised of a first nucleic... Agent: Engeneic Molecular Delivery Pty. Ltd.

20120208868 - Purification process of nascent dna: The present invention relates to the use of purified nascent DNA for the implementation of a process allowing the mapping and the numbering of the active DNA replication origins of multi cellular eukaryotic cells, and the characterisation of the sequence of the replication origins.... Agent: Centre National De La Recherche Scientifique

20120208871 - Use of toll-like receptor and agonist for treating cancer: The present invention is directed to methods and agents used for treating cancer or infectious diseases by providing toll-like receptors such as toll-like receptor 5 (TLR-5) in combination with providing a toll-like receptor agonists such as flagellin resulting in a cis and intrans effect that recruits cells involved in both... Agent:

20120208782 - Modulation of growth of bifidobacteria using a combination of oligosaccharides found in human milk: A prebiotic formulation for oral administration to a human comprising 2′-fucosyllactose, 3′-sialyllactose and 6′-sialyllactose, and a method for modulating or stimulating the growth of Bifidobacteria in the gut. The formulation may be an infant formula.... Agent: Wyeth LLC

20120208783 - Medicine, food and drink or feed containing sphingomyelin: It is intended to find novel pharmaceutical use of sphingomyelin and to provide preventive or therapeutic agents for various diseases as well as a food and drink product and feed comprising any of these agents. The present invention provides a pharmaceutical agent which contains sphingomyelin as an active ingredient and... Agent: Snow Brand Milk Products Co., Ltd.

20120208784 - Substituted propane phosphinic acid derivatives:

20120208785 - Prodrugs of 2,4-pyrimidinediamine compounds and their uses: The present disclosure provides prodrugs of biologically active 2,4-pyrimidinediamine compounds, salts and hydrates of the prodrugs, compositions comprising the prodrugs, intermediates and methods for synthesizing the prodrugs and methods of using the prodrugs in a variety of applications.... Agent: Rigel Pharmaceuticals, Inc.

20120208786 - Bisphosphonate compositions and methods for treating heart failure: The present invention provides for methods and compositions for treating and/or preventing cardiac dysfunction by administering to subject a therapeutically effective amount of a bisphosphonate, functional analogue or a pharmaceutically effective salt thereof.... Agent:

20120208787 - Crystalline form of fosamprenavir calcium: The present invention relates to a crystalline form of fosamprenavir calcium. The crystalline form of the present invention is designated as Form II of fosamprenavir calcium. The present invention also relates to a process for the preparation of crystalline Form II of fosamprenavir calcium. The present invention further relates to... Agent: Ranbaxy Laboratories Limited

20120208789 - Hydroswellable, segmented, aliphatic polyurethanes and polyurethane ureas: Hydroswellable, absorbable and non-absorbable, aliphatic, segmented polyurethanes and polyurethane-urea capable of swelling in the biological environment with associated increase in volume of at least 3 percent have more than one type of segments, including those derived from polyethylene glycol and the molecular chains are structurally tailored to allow the use... Agent: Poly-med, Inc.

20120208788 - Tetracycline compounds: The present invention is directed to a compound represented by Structural Formula (1): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula (I) are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula (I) and its therapeutic use.... Agent:

20120208790 - Ion channel modulators and methods of use: In general, the invention relates to compounds useful as ion channel modulators. It has now been found that compounds of this invention, and pharmaceutically acceptable compositions thereof, are useful as inhibitors of voltage-gated sodium channels.... Agent: Vertex Pharmaceuticals Incorporated

20120208791 - Imidazopyridine derivatives as inhibitors of receptor tyrosine kinases: The invention relates to new bicyclic heterocyclic derivative compounds, to pharmaceutical compositions comprising said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.... Agent: Astex Therapeutics Limited

20120208792 - Protein kinase modulators: The invention relates in part to molecules having certain biological activities that include, but are not limited to, inhibiting cell proliferation, modulating protein kinase activity and modulating polymerase activity. Molecules of the invention can modulate Pim kinase activity and/or FMS-like tyrosine kinase (Flt) activity. The invention also relates in part... Agent: Cylene Pharmaceuticals, Inc.

20120208793 - Thieno- and furo-pyrimidine modulators of the histamine h4 receptor: Thieno- and furo-pyrimidine compounds are described, which are useful as H4 receptor modulators. Such compounds may be used in pharmaceutical compositions and methods for the modulation of histamine H4 receptor activity and for the treatment of disease states, disorders, and conditions mediated by H4 receptor activity, such as inflammation.... Agent:

20120208794 - Fused heterocyclic ring derivative and use thereof: i

20120208795 - Compositions and methods for the treatment of addiction and other neuropsychiatric disorders: The present invention is based, in part, on our discovery that certain types of therapeutic agents can be used in combination to treat a variety of neuropsychiatric and related disorders, including addiction (e.g., to a substance or to an activity) as well as to alleviate some of the symptoms experienced... Agent: Board Of Supervisors Of Louisiana State University & Agricultural & Mechanical College

20120208796 - Heterocyclic derivatives: The present invention relates to a heterocyclic derivative of formula (I) wherein the variables are as defined in the specification or to a pharmaceutically acceptable salt or solvate thereof. The present invention further relates to pharmaceutical compositions comprising said heterocyclic derivatives and to their use in therapy, for instance in... Agent:

20120208797 - Pyrimidone derivatives: wherein Z represents nitrogen atom or C—X; X represents hydrogen atom or fluorine atom; R1 is hydrogen atom or a C1-C3 alkyl group; L represents single bond or a C1-C6 alkylene group which may be substituted; Y represents single bond, sulfur atom, oxygen atom, NH, or the like; R2 represents... Agent: Mitsubishi Tanabe Pharma Corporation

20120208799 - Compounds: e

20120208798 - Tetrahydroquinoline derivatives and their pharmaceutical use:

20120208800 - Bromodomain inhibitors for treating autoimmune and inflammatory diseases: The use of compounds in the treatment of autoimmune and inflammatory diseases or conditions, pharmaceutical compositions containing such compounds and to methods for identifying compounds for use in the treatment of such diseases or conditions.... Agent:

20120208801 - Aminodiazepines as toll-like receptor modulators: Provided are compositions and methods useful for modulation signaling through the Toll-like receptor TLR8. The compositions and methods have use in the treatment of autoimmunity, inflammation allergy, asthma, graft rejection, graft versus host disease, infection, sepsis, cancer and immunodeficiency.... Agent: Array Biopharma Inc.

20120208802 - Antimicrobial locking solutions comprising taurinamide derivatives and biologically acceptable salts and acids, with the addition of small concentrations of heparin: o

20120208803 - Pyrrolidine derivatives as nk2 receptor antagonists:

20120208804 - Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 based on the 1,3 -oxazinan- 2 -one structure: This invention relates to substituted 1,3-oxazin-2-one compounds of the Formula (I), (II), (IIA), (IIB), (IIC), (II D), (IIE), (III), (III A), (III B), (IV), (IV A), (IV B), (IV C), (IV D), (V), (V A), (V B), (VI), (VI A), (VI B), (VII), (VII A), (VII B), pharmaceutically acceptable salts... Agent: Vitae Pharmaceuticals, Inc.

20120208806 - Hsp90 inhibitors: The present application provides compounds useful in the inhibition of Hsp90, and hence in the treatment of disease.... Agent: Sloan-kettering Institute For Cancer Research

20120208805 - Triazolium salts as par1 inhibitors, production thereof, and use as medicaments: where X, A−, Q1, Q2, Q3, R2, R3, R4, R5, R6, R7, R8 and R9 are each as defined below. The compounds of formula I have antithrombotic activity and inhibit especially protease-activated receptor 1 (PAR1). The invention further relates to a process for preparing the compound of formula I and... Agent: Sanofi

20120208807 - Tofa analogs useful in treating dermatological disorders or conditions: This invention is directed to analogs of 5-(tetradecyloxy)-2-furancarboxylic acid (TOFA) and their use in the treatment of dermatological disorders or conditions characterized by sebaceous gland hyperactivity, such as acne and oily skin, and other dermatological disorders and conditions. This invention is also directed to pharmaceutical compositions comprising analogs of TOFA... Agent: Valocor Therapeutics, Inc.

20120208808 - Pyrazolopyrimidine derivatives: Compounds of the formula (I), in which X, R1 and R2 have the meanings indicated in claim 1, are PI3K inhibitors and can be employed, inter alia, for the treatment of autoimmune diseases, inflammation, cardiovascular diseases, neurodegenerative diseases and tumours.... Agent: Merck Patent Gesellschaft Mit Beschrankter Haftung

20120208809 - 9h-pyrrolo[2,3-b: 5,4-c'] dipyridine azacarboline derivatives, preparation thereof, and therapeutic use thereof: The invention relates to novel 9H-pyrrolo[2,3-b:5,4-c′]dipyridine azacarbolines of formula (I), where: Z2, Z3, and Z4 are CH, CRa, CRs, or N; R3 is H, Hal; CF3, CHF2; OH, alkoxy; NH2, NH (alkyl), N(alkyl)2; C(O)O alkyl; CONH(alkyl), CON(alkyl)2; C1-C10 alkyl; aryl; heteroaryl; R6 is heteroaryl; Ra is CONH2, CONH alkyl, CONH... Agent: Sanofi

20120208810 - Novel 1,2,3,4-tetrahydro-pyrimido(1,2-a)pyrimidin-6-one derivatives, preparation thereof, and pharmaceutical use thereof: The invention relates to the novel materials of formula (I), where: R1 is an optionally substituted L-aryl or L-heteroaryl, such that L is a single bond, alkyl, CO, or CO-alk, or L-X, with L□ being an alkyl and X being O or S; R2 is H or alkyl; R3 is... Agent: Sanofi

20120208811 - Aminopyrazole derivative: A compound represented by formula (I) or a pharmacologically acceptable salt thereof, which can inhibit a fibroblast growth factor receptor (FGFR) family kinase in cancer tissues. (In the formula, A represents a 5- to 10-membered heteroaryl group, or a C6-10 aryl group; R1 and R2 independently represent H, OH, X,... Agent: Chugai Seiyaku Kabushiki Kaisha

20120208812 - Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators: Disubstituted octahydropyrrolo[3,4-c]pyrrole compounds are described, which are useful as orexin receptor modulators. Such compounds may be useful in pharmaceutical compositions and methods for the treatment of diseased states, disorders, and conditions mediated by orexin activity, such as insomnia.... Agent: Janssen Pharmaceutica N.v.

20120208813 - 3-carbamoyl-2-pyridone derivatives: s

20120208814 - Thetrahydroquinolines derivatives as bromodomain inhibitors:

20120208815 - Pim kinase inhibitors and methods of their use: New compounds, compositions and methods of inhibition of kinase activity associated with tumorigenesis in a human or animal subject are provided. In certain embodiments, the compounds and compositions are effective to inhibit the activity of at least one serine/threonine kinase or receptor tyrosine kinase. The new compounds and compositions may... Agent:

20120208817 - Novel dihydropyrimidin-2(1h)-one compounds as s-nitrosoglutathione reductase inhibitors: The present invention is directed to novel dihydropyrimidin-2(1H)-one compounds useful as S-nitrosoglutathione reductase (GSNOR) inhibitors, pharmaceutical compositions comprising such compounds, and methods of making and using the same.... Agent: N30 Pharmaceuticals, LLC

20120208816 - Organic compounds: e

20120208818 - Compounds useful as antagonists of ccr2: or a pharmaceutically acceptable salt thereof, wherein X, n, Y, and R1 are defined generally and in subsets herein. Compounds of the invention are inhibitors of CCR2 and accordingly are useful for the treatment of a variety of inflammatory, allergic, and autoimmune diseases, disorders, or conditions.... Agent: Millennium Pharmaceuticals, Inc.

20120208819 - Heterocyclic compounds useful as pdk1 inhibitors: The present invention provides compounds useful as inhibitors of PDK1. The present invention also provides compositions thereof, and methods of treating PDK1-mediated diseases.... Agent:

20120208820 - Diazabicyclic central nervous system active agents: e

20120208821 - Alpha adrenergic receptor modulators: Compounds are described herein useful for treating diseases and conditions by modulation of one or more alpha adrenergic receptor. The compounds can include a naphthalene, a quinoline, a benzoimidazole or an isoquinoline as a core structure. Methods of making, using and formulating these compounds are described.... Agent: Allergan, Inc

20120208822 - Pyrimido-pyrrolo-quinoxalinedione inhibitors of cystic fibrosis transmembrane conductance regulator protein and uses therefor: Provided herein are pyrimido-pyrrolo-quinoxalinedione (PPQ) compounds, and compositions comprising these compounds, that inhibit cystic fibrosis transmembrane conductance regulator (CFTR) mediated ion transport and that are useful for treating diseases and disorders associated with aberrantly increased CFTR chloride channel activity. The compounds, and compositions comprising the compounds, described herein are useful... Agent: The Regents Of The University Of California

20120208823 - New compounds: o

20120208824 - Ros kinase in lung cancer: The invention provides the identification of the presence of polypeptides with ROS kinase activity in mammalian lung cancer. In some embodiments, the polypeptide with ROS kinase activity is the result of a fusion between a ROS-encoding polynucleotide and a polynucleotide encoding a second (non-ROS) polypeptide. Three different fusion partners of... Agent: Cell Signaling Technology, Inc.

20120208825 - Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactic acid salts: The present invention relates to non-hydrate crystalline forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one lactic acid salts, solid pharmaceutical formulations containing the same and methods of use. The present invention also relates to crystalline hydrates of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-l-yl)-lH-benzimidazol-2-yl]-lH-quinolin-2-one lactic acid salts, pharmaceutical formulations containing the same and methods of use related thereto. The present invention... Agent:

20120208826 - Heterocyclic amide compounds as protein kinase inhibitors: The present invention relates to heterocyclic amide derivatives of Formula (I): Formula (I) wherein the variables are as defined in the specification. The present invention further relates to compositions comprising said heterocyclic amide derivatives of formula (I) and methods for using said heterocyclic amide derivatives of formula (I) for treating... Agent: Schering Corporation

20120208827 - Benzimidazoles as fatty acid synthase inhibitors: This invention relates to the use of benzimidazole derivatives for the modulation, notably the inhibition of the activity or function of fatty acid synthase (FAS). Suitably, the present invention relates to the use of benzimidazoles in the treatment of cancer.... Agent: Glaxosmithkline LLC

20120208828 - Azole derivatives as wtn pathway inhibitors: The present invention relates to new compounds of formula I, to processes for their preparation, to pharmaceutical formulations containing such compounds and to their use in therapy. Such compounds find particular use in the treatment and/or prevention of conditions or diseases which are affected by over-activation of signaling in the... Agent: Oslo University Hospital Hf

20120208829 - 2-phenoxy pyrimidinone analogues: wherein variables are as described herein. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods... Agent: Neurogen Corporation

20120208830 - Anhydrous crystalline forms of n-[1-(2-ethoxyethyl)-5-(n-ethyl-n-methylamino)-7-(4-methylpyridin-2-yl-amino)-1h-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide: The invention comprises (1) anhydrous crystalline forms of N-[1-(2-ethoxyethyl)-5-(N-ethyl-N-methylamino)-7-(4-methylpyridin-2-yl-amino)-1H-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide, (2) pharmaceutical compositions comprising at least one such form, (3) methods for the treatment of a phosphodiesterase-5-mediated condition using at least one such form, and (4) methods for preparing such forms. The compound N-[1-(2-ethoxyethyl)-5-(N-ethyl-N-methylamino)-7-(4-methylpyridin-2-yl-amino)-1H-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide has the following structure (I).... Agent: Pfizer Inc.

20120208831 - 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions: e

20120208832 - Process for converting a solid (meth)acrylate copolymer into a dispersed form by means of a dispersing agent: The present invention provides a process for converting a solid (meth)acrylate copolymer into a dispersed form by preparing an aqueous dispersion comprising the components (a) a (meth)acrylate copolymer which is composed of free-radical polymerized methyl methacrylate, ethylacrylate and a salt of 2-trimethylammoniumethyl methacrylate, present in solid form as a powder... Agent: Evonik Roehm Gmbh

20120208833 - 4-(substituted anilino)-quinazoline derivatives useful as tyrosine kinase inhibitors: The present invention relates to 4-(substituted anilino)-quinazoline derivatives as tyrosine kinase inhibitors. Specifically, compounds of formula I, or pharmaceutically acceptable salts or solvates thereof are disclosed, in which each substitutent in formula I is defined in the description. Preparation method of the compounds of formula I, pharmaceutical compositions and pharmaceutical... Agent: Qilu Pharmaceutical Co., Ltd.

20120208834 - Process for preparing spray dried formulations of 4-[[6-amino-5-bromo-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethylbenzonitrile: This invention relates to a process for producing a spray-dried powder comprising microcrystalline cellulose in a solid dispersion of the anti-HIV compound etravirine (TMC125) in a water-soluble polymer.... Agent:

20120208835 - Method and dosage regimens for eliminating a chemical substance in blood: A method of reducing the concentration of a chemical or drug substance in the blood plasma comprising titrating an initial peak concentration of the chemical or drug substance in the blood for a predefined dosing period, titrating a lowest concentration level of the chemical or drug substance in the blood... Agent:

20120208836 - Compositions and methods for the treatment of obesity and related disorders: Provided herein are compositions and methods for the treatment of obesity and related disorders, including, but not limited to insulin resistance, diabetes, and hepatic steatosis. For example, in some embodiments, pharmaceutically acceptable compositions and methods are provided employing amlexanox, a derivative thereof, or a pharmaceutically acceptable salt thereof, alone or... Agent: The Regents Of The University Of Michigan

20120208837 - Substituted azaindoles: This invention relates to novel substituted azaindoles and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a compound showing selective inhibitory activity of oncogenic... Agent:

20120208838 - Diuretics: A compound having the structure (I) wherein R is selected from the group consisting of 1) and 2), or a pharmaceutically acceptable salt thereof, and methods of using the compounds for treating hypertension.... Agent:

20120208840 - Condensed ring pyridine compounds as subtype-selective modulators of sphingosine-1-phosphate-2 (s1p2) receptors: The invention provides compounds represented by the formula I, each of which compounds may have sphingosine-1-phosphate receptor agonist and or antagonist biological activity, wherein these compounds selected from the group consisting of wherein A, B, C, D, X, Y, Z and R3 are defined in the specification. Said compounds are... Agent: Allergan, Inc.

20120208839 - New compounds: e

20120208841 - Modulators of cystic fibrosis transmembrane conductance regulator: The present invention relates to modulators of cystic fibrosis transmembrane conductance regulator (“CFTR”), compositions thereof, and methods therewith. The present invention also relates to methods of treating diseases using modulators of CFTR.... Agent: Vertex Pharmaceuticals Incorporated

20120208842 - Novel 1-(1-oxo-1,2,3,4-tetrahydroisoquinolin-7-yl)urea derivatives as n-formyl peptide receptor like-1 (fprl-1) receptor modulators: The present invention relates to novel 1-(1-Oxo-1,2,3,4-tetrahydroisoquinolin-7-yl)urea derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the N-formyl peptide receptor like-1 (FPRL-1) receptor.... Agent: Allergan, Inc

20120208843 - Method of using gpr35 to identify metabolic-stabilizing compounds: The present invention relates to a method for identifying a metabolic stabilizing compound, comprising: a) contacting a candidate compound with GPR35, and b) determining whether GPR35 functionality is increased, wherein an increase in GPR35 functionality is indicative of the candidate compound being a metabolic stabilizing compound. The invention further relates... Agent:

20120208844 - Substituted piperidines that increase p53 activity and the uses thereof: The present invention provides a compound of Formula (1) as described herein or a pharmaceutically acceptable salt, solvate or ester thereof. The compounds are useful as inhibitors of the HDM2 protein. Also disclosed are pharmaceutical compositions comprising the above compounds and methods of treating cancer using the same.... Agent:

20120208845 - Agonists and antagonists of human bitter taste receptor tas2r49 and uses thereof: The present invention relates to agonists and antagonists of the human bitter-taste receptor hTAS2R49. The invention also relates to methods for identifying further molecules that suppress or enhance hTAS2R49-mediated bitter taste transduction or bitter taste response and uses thereof.... Agent:

20120208847 - Diagnostic and therapeutic alkyl piperidine/piperazine compounds and process: Described herein are piperidine and piperazine compounds useful for treating neurodegenerated diseases characterized by a lack of dopamine neuron activity. The compounds are also useful for imaging dopamine neurons.... Agent: The General Hospital Corporation

20120208848 - Gacyclidine formulations: Improved formulations of gacyclidine for direct administration to the inner or middle ear.... Agent: Neurosystec Corporation

20120208846 - Therapeutic methods for type i diabetes: The invention relates to the treatment and prevention of type I diabetes. More specifically, the invention relates to compounds that treat or prevent the body's immune system from destroying β-cells (i.e., insulin-producing cells in the pancreatic islets of Langerhans) by inhibition of JNK2, selective inhibition of JNK2, or inhibition of... Agent: University Of Massachusetts

20120208849 - Methods for controlling pain in canines using a transdermal solution of fentanyl: This invention provides methods of controlling pain in a canine comprising transdermally administering a composition comprising fentanyl, a penetration enhancer, and a volatile liquid, wherein the composition is a solution. The invention also provides a single unit dose of the composition.... Agent: Eli Lilly And Company

20120208850 - Methods, compounds, and compositions for delivering 1,3-propanedisulfonic acid: The invention relates to methods, compounds, and compositions for delivering 1,3-propanedisulfonic acid (1,3PDS) in a subject, preferably a human subject. The invention encompasses compounds that will yield or generate 1,3PDS, either in vitro or in vivo. The invention also relates to sulfonate ester prodrugs of 1,3PDS as well as Gemini... Agent: Bellus Health Inc.

20120208851 - Formulations: Colloidal suspensions comprising a therapeutic agent and squalene. Squalene binds to certain compounds, such as gacyclidine, much more tightly than other drug carriers, such as polylactic glycolic acid. Including squalene in the particulate phase sequesters the therapeutic agent and provides superior stability at room or body temperature.... Agent: Neurosystec Corporation

20120208852 - Heterocyclic-substituted 2-acetamido-5-aryl-1,2,4-triazolones and use thereof: The present application relates to new, heterocyclyl-substituted 2-acetamido-5-aryl-1,2,4-triazolones, to processes for preparing them, to their use alone or in combinations for the treatment and/or prevention of diseases and also to their use for the production of medicaments for the treatment and/or prevention of diseases, more particularly for the treatment and/or... Agent: Bayer Pharma Aktiengesellschaft

20120208853 - Pest control composition: The present invention provides a pest control composition comprising, as active ingredients, an amide compound of the formula (I) [(I) where in R1 and R3 represent, for example, a C1-C6 alkyl group; R2 represent, for example, a Hydrogen atom, a C1-C6 alkyl group; R4 represent, for example, a halogen atom,... Agent:

20120208854 - Therapeutic combination: This invention relates to pharmaceutical combinations of amlodipine or a pharmaceutically acceptable acid addition salt thereof and atorvastatin or a pharmaceutically acceptable salt thereof, kits containing such combinations and methods of using such combinations to treat subjects suffering from angina pectoris, atherosclerosis, combined hypertension and hyperlipidemia and to treat subjects... Agent:

20120208855 - Amino-benzoic acid derivatives for use in the treatment of dihydrogenase-related disorders: Provided herein is method of modulating, and in particular decreasing dihydroorotate dehydrogenase (DHODH) activity, as well as a method of treating a DHODH related disease or disorder.... Agent: Sanofi

20120208856 - Heterocyclic benzoxazole compositions as inhibitors of hepatitis c virus: This invention relates to benzoxazole compounds, compositions and devices for delivering them, processes for manufacturing them, and methods of using them in the treatment of Hepatitis C Virus.... Agent: University Of Maryland, Baltimore County

20120208857 - Pharmaceutical compositions: The present invention relates to pharmaceutical compositions useful for administration for treating, preventing, or reducing the risk of microbial infections.... Agent:

20120208858 - Pharmaceutical cream compositions of oxymetazoline and methods of use: The present invention is directed to: a) a method of treating telangiectasia; b) a method of treating inflammatory lesions; and c) a method of treating two or more symptoms of rosacea selected from erythema, telangiectasia, or inflammatory lesions comprising topical administration of a pharmaceutical composition comprising oxymetazoline and a pharmaceutically... Agent: Allergan, Inc.

20120208859 - Novel mek inhibitors useful in the treatment of diseases: The invention pertains to compound of Formula (I) wherein X, Y, Z, R1, R2, R3, R4, A and A′ are as described hereinabove. Formula (I) and (II) compounds can be used in pharmaceutical compositions, useful for the treatment of diseases.... Agent: Allostem Therapeutics LLC

20120208873 - Tea polyphenols products for ceasing smoking and treating and/or preventing nicotine or nicotine-derived compounds or estrogen induced breast cancer: This invention relates to methods of aiding smoking cessation and/or treating and/or preventing smoking addition or methods of treating and/or preventing nicotine or nicotine-derived compounds or estrogen induced breast cancer, which comprises administering to a subject an effective amount of a tea polyphenol. The invention uses catechins (such as epigallocatechin... Agent: Taipei Medical University

20120208872 - Use of tea polyphenols for treating and/or preventing nicotine or nicotine-derived compounds or estrogen induced breast cancer: This invention relates to methods of treating and/or preventing nicotine or nicotine-derived compounds or estrogen induced breast cancer, which comprises administering to a subject an effective amount of a tea polyphenol. The invention uses catechins (such as epigallocatechin gallate (“EGCG”), epigallocatechin (“EGC”), epicatechin gallate (“ECG”), epicatechin (“EC”), gallocatechin gallate (“GCG”),... Agent: Taipei Medical University

20120208874 - Substituted alkynyl phenoxy compounds as new synergists in pesticidal compositions: A composition comprising an alkynyl phenoxy compound of Formula (I) as a synergist and a pesticidal active ingredient is described, wherein R1 and R2, similar or different, are (C1-C4)alkyl or R1O— and R2O— together represent a group —O—CH2—O—, —O—CH(CH3)—O, —O—CH2—CH2—O—, —O—CH2—CH2—, R3 is (C1-C6)alkyl, (C3-C6)alkenyl or —B—(CH2-CH2—O)z-R6 where B is... Agent: Rothamsted Research Ltd.

20120208875 - Method for inhibiting blood vessel stenosis: Provided is a method for inhibiting blood vessel stenosis in a subject, comprising administrating to the subject an effective amount of an active ingredient selected from a group consisting of a compound of formula (I), a pharmaceutically acceptable salt of the compound, a pharmaceutically acceptable ester of the compound, and... Agent: China Medical University

20120208876 - Amino acid derivatives for the treatment of neuropathic pain: The invention relates to compounds, to compositions comprising the same and uses thereof for the prevention or treatment of pain, e.g neuropathic pain while having neutral or beneficial effect on metabolic parameters.... Agent:

20120208877 - Skin treatment in antiseptic thin film form with silver: A skin treating and antibacterial composition, consisting essentially water, emollient, emulsifier, humectant, thickener, silver or silver citrate, and additional ingredients, and providing a superior hand lotion.... Agent: James C. Caillouette

20120208878 - Medical composition: The object of the invention is to find the actions of the crude drugs contained in Daikenchuto or their components and the synergistic effect of the components with one another or with other pharmacologically active substances, and to provide new drugs or pharmaceutical compositions based on the findings. The invention... Agent: Tsumura & Co.

20120208879 - Methods and pharmaceutical compositions useful for treating psoriasis: Pharmaceutical or cosmetic compositions including cruciferous plant extract or isothiocyanates such as 4-methyl-thio-butyl-isothiocyanate which are useful for treating psoriasis are provided.... Agent: S.u.l.v.e. Ltd.

20120208880 - (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability: The invention relates to solid pharmaceutical compositions comprising (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4′-trifluoromethylphenyl)-amide, as well as a process for the preparation of the same, methods of using such compositions to treat subjects suffering from autoimmune diseases in particular systemic lupus erythematosus or chronic graft-versus-host disease, multiple sclerosis or rheumatoid arthritis.... Agent: Sanofi

20120208881 - Methods for concomitant administration of colchicine and a second active agent: Methods for concomitant administration of colchicine together with one or more second active agents, e.g., verapamil, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits. Methods of notifying health care practitioners and patients regarding appropriate dosing for concomitant administration of colchicine together... Agent:

20120208882 - Organic compounds: The invention describes novel pharmaceutically acceptable salt forms of camostat, processes for lyophilisation, taste-masked formulations, nebulised formulations and the use of each of the fore-going in the treatment of respiratory diseases, particularly cystic fibrosis and chronic obstructive pulmonary disease (COPD).... Agent:

20120208883 - Treatment of oncological diseases: The present invention relates to the use of acetyl L-carnitine for the preparation of a medicament for the prevention and/or treatment of cancer. Methods of preventing and/or treatment of cancer by administering an effective amount of acetyl L-carnitine to subject in need thereof are also disclosed.... Agent: Sigma-tau Industrie Farmaceutiche Riunite S.p.a

20120208884 - Compositions comprising polyunsaturated fatty acid monoglycerides, derivatives thereof and uses thereof: There are provided various compounds and compositions comprising polyunsaturated fatty acid monoglycerides and derivatives thereof. These compounds and compositions can be useful as cancer chemopreventive agents. They can also be useful for enhancing solubility of various active agents and enhancing their bioavailability.... Agent:

20120208885 - L-ornithine phenyl acetate and methods of making thereof: Disclosed herein are forms of L-ornithine phenyl acetate and methods of making the same. A crystalline form may, in some embodiments, be Forms I, II, III and V, or mixtures thereof. The crystalline forms may be formulated for treating subjects with liver disorders, such as hepatic encephalopathy. Accordingly, some embodiments... Agent: Ocera Therapeutics, Inc.

20120208886 - Moisture resistant container systems for rapidly bioavailable dosage forms: Provided are rapidly bioavailable solid oral dosage forms of acute pain medications, and moisture resistant packaging that enables the formulation of such rapidly bioavailable dosage forms.... Agent: Apr Applied Pharma Research, S.a.

20120208887 - Stable, liquid, ready-to-use ketoprofen formulations: Stable, liquid, ready-to-use ketoprofen formulation for parenteral administration are provided. In some embodiments, the formulation comprises ketoprofen solubilized in a solely aqueous solvent comprising a buffering agent, wherein the composition has a pH of about 5.5 to about 6.5.... Agent:

20120208888 - Biocide compositions and related methods: The invention relates to biocide compositions comprising organic acyl polyoxychlorine and methods for producing said biocide compositions. The biocide compositions form reactive oxygen species when contacted by microorganisms, proteinaceous substances, and oxidizable organic based contaminants.... Agent:

20120208889 - Class- and isoform-specific hdac inhibitors and uses thereof: HDAC inhibitors of the general formula (I) and (II) and pharmaceutically acceptable salts thereof, as described herein, are useful as inhibitors of histone deacetylases or other deacetylases, and thus are useful for the treatment of various diseases and disorders associated with acetylase/deacetylase activity as described herein (e.g., cancer). In certain... Agent: President And Fellows Of Harvard College

20120208890 - Stable hydrogel compositions including additives: The present specification generally relates to hydrogel compositions and methods of treating a soft tissue condition using such hydrogel compositions.... Agent: Allergan, Inc.

20120208891 - Methods for concomitant administration of colchicine and a second active agent: Methods for concomitant administration of colchicine together with one or more second active agents, e.g., verapamil, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits. Methods of notifying health care practitioners and patients regarding appropriate dosing for concomitant administration of colchicine together... Agent:

20120208892 - Emesis treatment: A method of treating or preventing emesis through the administration of an effective dosage of a 2-(amino) tetralin compound in which one of the S or R enantiomers of the 2-(amino) tetralin compound is present in the composition in excess of the other enantiomer, and compositions comprising such a 2-(amino)... Agent: Epiomed Therapeutics, Inc.

20120208893 - Nutritional compositions for modulating inflammation including exogenous vitamin k2: Nutritional compositions and methods of making and using the nutritional compositions are provided. In a general embodiment, the present disclosure provides a nutritional composition including exogenous vitamin K2. The nutritional compositions may further include an additional component selected from the group consisting of phosphorus, magnesium, zinc, iron, copper, manganese, calcium,... Agent: Nestec S.a.

20120208894 - Multi-purpose hand disinfectant: A multi-purpose hand disinfectant and in particular, a hand disinfectant which meets the FDA (Food and Drug Administration) requirements for use both as an antiseptic handwash or health-care personnel handwash drug product and as a surgical hand scrub drug product is described herein.... Agent: Bode Chemie Gmbh & Co. Kg

20120208896 - Amino acid derivatives and absorable polymers therefrom: The present invention relates to the discovery of new class of hydrolysable amino acid derivatives and absorbable polyester amides, polyamides, polyepoxides, polyureas and polyurethanes prepared therefrom. The resultant absorbable polymers are useful for drug delivery, tissue engineering, tissue adhesives, adhesion prevention, bone wax formulations, medical device coatings, stents, stent coatings,... Agent: Bezwada Biomedical, LLC.

20120208895 - Composite material with properties of self-healing and release of active ingredients, for biomedical applications: This invention relates to a composite material for biomedical applications, in particular dental applications, which possesses self-healing capacity and is able to incorporate a system for the release of active ingredients at the stage of application and use.... Agent:

20120208897 - Method for preparing acetylated derivatives of an amylaceous material: The present invention relates to a continuous method for preparing acetylated derivatives of an amylaceous material. The invention also relates to a solid composition of at least one acetylated derivative of an amylaceous material obtained by means of said method. The invention finally relates to the use of such a... Agent: Roquette Freres

20120208898 - Viscous liquid cleansing compositions comprising sulfonated fatty acids, esters, or salts thereof and betaines or sultaines: Formulations of personal care compositions and personal care concentrate compositions containing salts of sulfonated fatty acid esters and/or salts of sulfonated fatty acids, and an alkyl betaine or sultaine are described. Personal care compositions of the present technology include liquid hand soaps, bath and shower washes, shampoos, 2-in-1 or 3-in-1... Agent:

20120208900 - Methods of predicting the need for surgery in crohn's disease: The present invention relates to methods of predicting susceptibility to a severe form of Crohn's disease in an individual by determining the presence or absence of one or more risk variants. In one embodiment, the risk variants comprise a combination of genetic risk variants and clinical risk factors. In another... Agent: Cedars-sinai Medical Center

20120208899 - Tool for assessment of symptoms of irritable bowel syndrome: Methods of treating and/or diagnosing irritable bowel syndrome (IBS) are provided, wherein treatment or diagnosis is undertaken on the basis of the patient's recordation of events associated with IBS in an event log and/or symptom diary.... Agent: Astellas US LLC

  
08/09/2012 > 165 patent applications in 124 patent subcategories. inventions list

20120202732 - Modified aav capsid polypeptides: The present invention is concerned with the provision of a polynucleotide encoding an AAV capsid polypeptide comprising an inserted peptide and a vector comprising said polynucleotide. Moreover, contemplated is a host cell comprising said polynucleotide or vector, a method for the manufacture of said capsid polypeptide as well as said... Agent: Deutsches Krebsforschungszentrum

20120202733 - Inhibition of trem receptor signaling with peptide variants: Peptides are provided consisting of L- and/or D-amino acids and combinations thereof, which affect myeloid cells by action on the triggering receptors expressed on myeloid cells (TREMs), including TREM-1 and TREM-2. The peptides act on the TREM/DAP-12 signaling complex. Also provided are lipid and sugar conjugated peptides comprising L- or... Agent: Signablok, Inc.

20120202734 - Antibiotic, its nucleotide sequence, methods of construction and uses thereof: The present invention belongs to field of biology and medicine, and especially relates to a novel antibiotic, its nucleotide sequence, methods of construction and uses thereof. A novel antibiotic, wherein the end of any peptide of the allosteric colicin is connected linearly to the end of peptide of the Staphylococcus... Agent: Protein Design Lab, Ltd.

20120202735 - Antimicrobial cationic peptides and formulations thereof: Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an... Agent: Carrus Capital Corporation

20120202736 - Spray-dried collectin compositions and process for preparing the same: The present invention relates to a spray-dried composition comprising as an active ingredient at least one member protein of the collectin family or its functional equivalent for treating and preventing microbial infectious diseases. The present invention also relates to a method for producing the same composition. The composition produced by... Agent: Dobeel Corporation

20120202737 - New bacitracin antibiotics: The invention concerns new Bacitracin compounds containing methylene-isoleucine.... Agent: Xellia Pharmaceuticals Aps

20120202738 - Therapy for enteric infections: There is disclosed herein a composition for treating gastrointestinal or neurological disorders, constipation, functional constipation, irritable bowel syndrome, diverticulitis, travelers diarrhoea, chronic idiopathic nausea, IBD-associated constipation and diarrhoea, pseudo-obstruction, diabetic gastroparesis, cyclic vomiting, reflux oesophagitis, autism enteropathy, flatulence, halitosis, chronic fatigue, bloating, proctalgia fugax, Parkinsons disease, MS, Alzheimers Disease, Motor... Agent:

20120202739 - Gdf3 antibodies and related methods: In certain aspects, the present invention provides compositions and methods for regulating body weight, in particular, for treating obesity and obesity-associate disorders. The present invention also provides methods of screening compounds that modulate activity of GDF3. The compositions and methods provided herein are also useful in treating diseases associated with... Agent: Acceleron Pharma, Inc.

20120202740 - Scgb3a2 as a growth factor and anti-apoptotic agent: The present disclosure is generally related to methods of using the secretory protein SCGB3A2 for promoting lung development and treating lung disease. Some embodiments are, for example, methods for treating and inhibiting the development of neonatal respiratory distress. Other embodiments are methods of promoting lung development in damaged or diseased... Agent: The United States Of America, As Represented By The Secretary, Department Of Health And Human

20120202741 - Delivery of bmp-7 and methods of use thereof: The present invention generally relates to delivery of BMP-7 or functional variants or functional fragments thereof and/or a BMP-7 agonist and methods of use thereof. In some embodiments, methods and devices are provided for delivery of BMP-7 or functional variants or functional fragments thereof and/or a BMP-7 agonist to a... Agent: Agency For Science, Technology And Research

20120202742 - Methods and devices for the sustained release of multiple drugs: The invention relates to an drug delivery device and a method for delivering multiple drugs over a prolonged period of time. The drug delivery device has two or more unitary segments comprising a drug-permeable polymeric substance, wherein at least one of the segments further comprises a pharmaceutically active agent. The... Agent: The General Hospital Corporation D/b/a Massachusetts General Hospital

20120202743 - Sustained release formulations comprising gnrh analogues: The present invention relates to pharmaceutical compositions for the controlled and sustained release of active substance comprising a biodegradable polymer or copolymer. Furthermore, the invention relates to pharmaceutical compositions for the controlled and sustained release of at least one active substance such as peptides or hormones and analogues thereof and... Agent: Ipsen Pharma S.a.s.

20120202744 - Dual antagonism of endothelin type a and bradykinin b1 receptors for treating pain and preventing cartilage degradation: The present invention relates to the field of anatomy, and more particularly to the control of pain and to the prevention and treatment of osteoarthritic cartilage degradation. Described herein are methods for treating pain which comprise administering to a subject in need a combination of (i) an antagonist of the... Agent:

20120202745 - Adult cerebellum-derived neural stem cells and compositions and methods for producing oligodendrocytes: This disclosure describes a novel population of cerebellum-derived neural stem cells that can be isolated from the adult brain, expanded, and differentiated into neurons, astrocytes and oligodendrocytes. This disclosure also describes compositions and methods for producing oligodendrocytes. Oligodendrocytes can be produced in vitro (e.g., in culture) or in vivo (e.g.,... Agent: Regents Of The University Of Michigan

20120202746 - Daptomycin for multiple sclerosis: Compounds and compositions, and methods of use thereof, for treatment and/or prevention of multiple sclerosis, including symptoms associated with multiple sclerosis, and/or treatment and/or prevention of other disease/disorder affecting the nervous system (e.g. central, peripheral) or muscle including symptoms thereof, comprising administering to a subject in need thereof daptomycin and/or... Agent:

20120202747 - Pharmaceutical composition, food or drink, and methods related thereto: A pharmaceutical composition including, as an active ingredient, one of the following proteins (I) and (II): (I) an apoptosis inhibitor of macrophage; and (II) a protein which consists of an amino acid sequence having deletion, substitution, or addition of one or more amino acids in an amino acid sequence of... Agent: Toru Miyazaki

20120202748 - Recombinant mussel adhesive protein fp-131: The present invention relates to a bio-adhesive derived from mussel. In particular, it relates to a recombinant protein fp(foot protein)-131 that is a hybrid of fp-3 variant A and fp-1. According to the present invention, the recombinant protein with adhesive activity can be economically produced in large scale to be... Agent: Postech Academy-industry Foundation

20120202749 - Secreted frizzled related protein, sfrp, fragments and methods of use thereof: The invention stems from the discovery that sFRP and fragments thereof can bind to members of the Wnt family of proteins and cause an increase in Wnt biological activity. Furthermore, fragments of sFRP that do not contain the CRD domain are shown to bind to Wnt proteins and modulate Wnt... Agent: The Govt. Of The U.s.a. As Represented By The Secretary Of The Dept. Of Health & Human Services

20120202750 - Inhibitors of iap: e

20120202751 - Methods of monitoring endoplasmic reticulum (er) stress response: Transgenic mammals, cells derived from the animals, and methods of using these to monitor the endoplasmic reticulum (ER) stress response are provided. In some embodiments, the methods allow for monitoring the ER stress response in real time. Some of the methods allow non-invasive in vivo visualization of ER stress response.... Agent: The Board Of Trustees Of The Leland Stanford Junior University

20120202752 - Antisense oligonucleotides: Embodiments of the present invention are directed generally to antisense compounds and compositions for the treatment of muscular dystrophy, and in particular, Duchenne muscular dystrophy (DMD). In one embodiment, the invention is directed to antisense oligonucleotide molecules, pharmaceutical compositions and formulations comprising antisense oligonucleotide molecules, and methods of treating muscular... Agent: The Charlotte-mecklenburg Hospital Authority D/b/a Carolinas Medical Center

20120202753 - Inhibiting inflammation with milk oligosaccharides: A method of inhibiting inflammation in a subject comprising the administration of milk oligosaccharides or glycoconjugates containing milk oligosaccharides is disclosed.... Agent: (cchmc)

20120202754 - Enhanced substrates for the protease activity of serotype a botulinum neurotoxin: Substrates of botulinum toxin serotype A (BoNT A), kits comprising the substrates, and methods of using the substrates are disclosed. BoNT A cleaves SNAP-25 and the substrates that are based upon a portion of SNAP-25. Various amino acid modifications to the sequence of the peptide based on SNAP-25 are performed.... Agent:

20120202755 - Foliamangiferosides, preparation method and use thereof: b

20120202756 - Use of prodrugs to avoid gi mediated adverse events: The present invention relates to prodrugs of a wide variety of drugs and pharmaceutical compositions containing such prodrugs. Methods for minimizing locally mediated (from within the gut lumen) adverse gastrointestinal events associated with the underivatised drug and increasing the sustainment of plasma drug levels with the aforementioned prodrugs are also... Agent:

20120202757 - Antihypertensive composition containing a ginsenoside-enriched fraction: The present invention related to an antihypertensive composition containing a fraction enriched with ginsenosides of ginseng. The composition according to the present invention increases the production of nitric oxide through the activation of nitric oxide synthase, and thus exhibits superior antihypertensive effects through the vasodilatory activity. Consequently, the composition of... Agent:

20120202758 - Core 2glcnac-t inhibitors: e

20120202759 - Isoflavone compositions for reducing accumulation of body fat in male mammals, and methods for their use: Edible compositions useful for weight management in male animals are disclosed. The compositions comprise one or more isoflavones or isoflavone metabolites and are particularly useful for reducing or preventing the accumulation of body fat. Also disclosed are methods useful for weight management in an animal utilizing compositions comprising one or... Agent:

20120202761 - Compositions and methods of improving the tolerability of daunorubicin when given as orotate salt: This invention is in the field of anthracycline family of drugs. More particularly, it concerns converting daunorubicin hydrochloride to an orotate salt and providing methods of improving the tolerability of daunorubicin in animals by reducing the adverse effects and toxicity in noncancerous tissues. Daunorubicin orotate provides a safer treatment for... Agent: Savvipharm Inc

20120202760 - Methods and compositions for enhancing sensitivity of cytotoxic drugs with timely combinatorial therapy with carboxyamidotriazole orotate: This invention relates to enhancing sensitivity of cytotoxic drugs by targeting their interfering mechanisms induced in the tumor microenvironment which lead to drug resistance, using combinatorial therapy with carboxyamidotriazole orotate. Specific doses of cytotoxic drugs are titrated with carboxyamidotriazole orotate to improve the sensitivity and anticancer activity of cytotoxic drugs.... Agent:

20120202762 - Methods of use of glycomimetics with replacements for hexoses and n-acetyl hexosamines: Methods are provided for using a compound to treat, for example, endothelial dysfunction including vascular abnormalities. More specifically, methods are described for using an oligosaccharide compound or glycomimetic compound wherein a cyclohexane derivative is incorporated in either.... Agent: Glycomimetics, Inc.

20120202763 - Methods for treating cancer and non-neoplastic conditions: Compounds that selectively inhibit pathological production of human vascular endothelial growth factor (VEGF) and compositions comprising such Compounds are described. Compounds that inhibit viral replication or the production of viral RNA or DNA or viral protein and compositions comprising such Compounds are described. Also described are methods of reducing VEGF... Agent: Ptc Therapeutics, Inc

20120202874 - Antisense oligonucleotide modulation of stat3 expression: Compounds, compositions and methods are provided for inhibiting the expression of human STAT3. The compositions comprise antisense oligonucleotides targeted to nucleic acids encoding STAT3. Methods of using these oligonucleotides for inhibition of STAT3 expression and for promotion of apoptosis are provided. Methods for treatment of diseases, particularly inflammatory diseases and... Agent: Isis Pharmaceuticals, Inc.

20120202871 - Cationic lipids and methods for the delivery of therapeutic agents: The present invention provides compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel cationic lipids and nucleic acid-lipid particles that provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells in vivo. The compositions of the present... Agent: Protiva Biotherapeutics, Inc.

20120202875 - Method of treatment: The present invention relates to methods for treatment or prevention of autoimmune and inflammatory diseases and conditions by inhibiting or modifying histone demethylation. In a further aspect the invention relates to a method for identifying agents useful in said methods of treatment. The invention particularly describes the role of certain... Agent:

20120202872 - Methods and compositions for the diagnosis and prognosis of cervical intraepithelial neoplasia and cervical cancer: The invention provides methods and compositions for the diagnosis and prognosis of cervical intraepithelial neoplasia and cervical cancer. The methods comprise the step of determining the expression levels or genetic status of specific miRNAs.... Agent:

20120202873 - Rnai probes targeting cancer-related proteins: RNAi sequences that are useful as therapeutics in the treatment of cancers of various types, including prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma, breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer, anaplastic large cell lymphoma and melanoma; and Alzheimer's disease. These sequences target clusterin, IGFBP-5, IGFBP-2,... Agent: The University Of British Columbia

20120202870 - Treatment of inflammatory diseases using mir-124: Methods of treating, reducing the risk of developing, or delaying the onset of an inflammatory disease are disclosed. The methods involved providing a subject with or at risk of developing an inflammatory disease and administering to the subject an effective amount of a first therapeutic composition comprising miR-124. Further provided... Agent: The Brigham And Women's Hospital, Inc.

20120202764 - Low molecular weight pharmacological activity modulators: Claimed are a compound of the general formula (I) and pharmaceutically acceptable salts thereof, where M signifies metal atoms selected independently from the group comprising Pd, Fe, Mn, Co, Ni, Cu, Zn and Mo; R1 and R2, independently of each other, signify hydrogen, amino, hydroxy, oxy, carboxy, cyano, C1-12alkyl, C2-12alkenyl,... Agent: "ivy Pharm" Jsc.

20120202765 - Effective treatment of esophogeal adenocarcinoma using triciribine and related compounds: The inventors have determined, contrary to the prior art and experience, how to successfully use triciribine to treat esophogeal adenocarcinoma by one or a combination of (i) administering triciribine only to patients which according to a diagnostic test described below, exhibit enhanced sensitivity to the drug; (ii) use of a... Agent: University Of South Florida

20120202766 - N4-acylcytosine nucleosides for treatment of viral infections: The present invention is directed to a method and composition of treating or preventing viral infections, in particular, human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infections, in human patients or other animal hosts, comprising the administration of N.sup.4-acyl-2′,3′-dideoxy-5-fluorocytidine or N.sup.4-acyl-2′,3′-didehyd-ro-2′,3′-dideoxy-5-fluorocytidine, and pharmaceutically acceptable salts, prodrugs, and other derivatives... Agent: Pharmasset, Inc.

20120202767 - Hyaluronic acid based mucoadhesive therapeutic composition for the prevention and treatment of epithelial and mucosal lesions of the human body: A sucralfate and hyaluronic acid based mucoadhesive composition of very low viscosity and its physiologically acceptable salts for the treatment and prevention of epithelial and mucosal lesions of the human body.... Agent: Biofarmitalia S.p.a.

20120202770 - Animal feeds and veterinary compositions: The present invention relates to an animal feed composition comprising protein from the family Fabaceae and protein from the family Asteraceae and to such formulations which also comprise glucan and/or mannan; such feeds finding utility in stabilising or increasing weight in a target animal, particularly fish, as well as in... Agent: Biorigin Scandinavia As

20120202769 - Fgf receptor-activating n-sulfate oligosaccharides, preparation thereof, and therapeutic use thereof: The invention relates to FGF receptor-activating N-sulfate oligosaccharides having Formula (I), wherein R1, R4, R6, and R8 are —OSO3− or hydroxyl groups, R2 is an —O-alkyl group or a monosaccharide having Formula (II), R3 is a disaccharide having Formula (III), R5 is a disaccharide having Formula (IV), R7 is a... Agent: Sanofi

20120202768 - Microalgal polysaccharide compositions: Provided herein are microalgal polysaccharide compositions and. Also provided are methods of using polysaccharides for applications such as topical personal care products, cosmetics, and wrinkle reduction compositions. The invention also provides novel microalgal compositions useful for improving the health and appearance of skin. The invention also includes insoluble polysaccharide particles... Agent: Solazyme, Inc.

20120202771 - Therapeutic agent for influenza virus infection diseases: Provided is a therapeutic agent for an influenza virus infectious disease, which utilizes an active ingredient derived from a natural product and has an excellent effect. The therapeutic agent for an influenza virus infectious disease includes, as an active ingredient, a β-glucan-containing composition obtained from a culture of a microorganism... Agent: Aureo Co., Ltd.

20120202772 - Cyclodextrin-based polymers for therapeutic delivery: Methods and compositions relating to CDP-proteasome inhibitor conjugates are described herein.... Agent:

20120202773 - Pharmaceutical composition for treatment of diseases associated with decrease in bone mass comprising ep4 agonist as active ingredient: A pharmaceutical composition for topical administration for prevention and/or treatment of diseases associated with decrease in bone mass comprising an EP4 agonist as an active ingredient. An EP4 agonist, in which includes a compound possessing prostaglandin skeleton as a representative, possesses promoting action on bone formation, so it is useful... Agent: Ono Pharmaceutical Co., Ltd.

20120202774 - Acyloxy- and phosphoryloxy-butadiene-fe(co)3 complexes as enzyme-triggered co-releasing molecules: The present invention provides acyloxy- and phosphoryloxy-butadiene-Fe(CO)3 complexes which can deliver carbon monoxide to a physiological target, wherein release of carbon monoxide can be enzymatically-triggered. The present invention also provides for methods of manufacturing the enzymatically-triggered carbon monoxide releasing molecules and methods for their use.... Agent: Universitaet Zu Koeln

20120202775 - Substituted indole and azaindole oxoacetyl piperazinamide derivatives: e

20120202776 - Phosphorus derivatives as kinase inhibitors: The invention features compounds of the general formula (I) in which the variable groups are as defined herein, and to their preparation and use.... Agent: Ariad Pharmaceuticals, Inc.

20120202777 - C-linked hydroxamic acid derivatives useful as antibacterial agents: e

20120202778 - Use of at least one omega-3 fatty acid and of at least one polyphenol for the endogenous synthesis of eicosapentanoic acid and docosahexanoic acid: The present invention relates to the use of at least one fatty acid of the omega-3 group, selected from among α-linolenic acid and stearidonic acid, and of at least one polyphenol as an agent for increasing the endogenous synthesis of eicosapentanoic acid and docosahexanoic acid, for preparing a food, health,... Agent:

20120202779 - Management of breakthrough bleeding in extended hormonal contraceptive regimens: The present invention relates to a flexible extended use regimen for a hormonal contraceptive useful to manage bleeding problems associated with fixed extended use of hormonal contraceptives and to a pharmaceutical package containing the respective hormonal contraceptive.... Agent: Bayer Pharma Ag

20120202780 - Carrier composition: A carrier composition of the present invention comprises a phosphate compound of an electron transfer agent and a relatively high concentration of a polar protic solvent. A biologically active compound may be formulated with a carrier composition of the present invention to provide a formulation.... Agent:

20120202781 - Indane derivatives: The present invention relates to anindane derivative according to formula I wherein the variables are defined as in the specification, or to a pharmaceutically acceptable salt or solvate thereof. The present invention also relates to a pharmaceutical composition comprising one or more of said indane derivatives and to their use... Agent:

20120202782 - Compounds and compositions as itpkb inhibitors: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or dysregulated B cell activities, particularly diseases or disorders that involve aberrant activation of inositol 1,4,5-trisphosphate 3-kinase B (ITPKb).... Agent: Irm LLC

20120202783 - Fused heterocyclic compounds as orexin receptor modulators: Disubstituted 3,8-diaza-bicyclo[4.2.0]octane and 3,6-diazabicyclo[3.2.0]heptane compounds are described, which are useful as orexin receptor modulators. Such compounds may be useful in pharmaceutical compositions and methods for the treatment of diseased states, disorders, and conditions mediated by orexin activity, such as insomnia.... Agent:

20120202785 - Heterocyclic compounds and methods of use: Formula I compounds, including stereoisomers, geometric isomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting the delta isoform of PI3K, and for treating disorders mediated by lipid kinases such as inflammation, immunological disorders, and cancer. Methods of using compounds of Formula I for in vitro, in situ,... Agent:

20120202784 - Isoindolinone inhibitors of phosphatidylinositol 3-kinase: The present invention relates to compounds useful as inhibitors of PI3K, particularly of PI3Kγ. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.... Agent: Vertex Pharmaceuticals Incorporated

20120202787 - Novel heteroaryl imidazoles and heteroaryl triazoles as gamma-secretase modulators: e

20120202786 - Therapeutic isoxazole compounds: wherein A1, A2, A3, R1, X, Y, and B have any of the values described herein, as well as salts of such compounds, compositions comprising such compounds, and therapeutic methods that comprise the administration of such compounds. The compounds are inhibitors of monoamine oxidase B (MAO-B) enzyme function and are... Agent: Dart Neuroscience (cayman) Ltd.

20120202788 - Azabenzothiazole compounds, compositions and methods of use: Provided are compounds of Formula I, stereoisomers, tautomers, solvates, prodrugs and pharmaceutically acceptable salts thereof, wherein A, X, R1, R2, R4 and R5 are defined herein, a pharmaceutical composition that includes a compound of Formula I and a pharmaceutically acceptable carrier, adjuvant or vehicle, methods of using the compound or... Agent:

20120202789 - Compositions and methods for the treatment of cancer: The present invention relates to the use of specific compounds related to the indolocarbazole K252a, for the preparation of pharmaceutical compositions for the treatment of various forms of cancer.... Agent: Tautatis, Inc.

20120202790 - [6,6] and [6,7]-bicyclic gpr119 g protein-coupled receptor agonists: e

20120202791 - Tricyclic and tetracyclic systems with activity on the central nervous and vascular systems: The present invention relates to chemistry and pharmacy and, in particular, to the production of novel molecular entities, tricyclic and tetracyclic derivatives of benzodiazepine, pyridodiazepine and pyrimidodiazepine type fused with 1,4-dihydropyridine derivatives, having an effect on the central-nervous and vascular systems. Derivatives containing a dihydropyridine ring are used, by means... Agent:

20120202792 - Antimicrobial compounds and methods of making and using the same: The present invention relates generally to the field of antimicrobial compounds and to methods of making and using them. These compounds are useful for treating, preventing, and/or reducing the risk of microbial infections in humans and animals.... Agent: Rib-x Pharmaceuticals, Inc.

20120202794 - Compounds: Disclosed herein are compounds useful for treating a viral infection, such as HCV.... Agent: Pharmasset, Inc.

20120202793 - Rho kinase inhibitors: The present invention relates to inhibitors of ROCK1 and ROCK2, which may be selective for ROCK2, and methods of modulating the pharmacokinetic and/or pharmacodynamic properties of such compounds. Also provided are methods of inhibiting ROCK1 and/or ROCK2. Also provided are treatments combining inhibitors of ROCK1 and/or ROCK2 with statins.... Agent:

20120202795 - Substituted pyridones as inhibitors of poly(adp-ribose) polymerase (parp): wherein R, R1, R2, R3 and R4 are as defined herein. This invention also relates to methods of making these compounds. The compounds of this invention are inhibitors of poly(adenosine 5′-diphosphate ribose) polymerase (PARP) and are therefore useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety... Agent: Aventis Pharmaceuticals Inc.

20120202798 - Compositions controlling ph range of release and/or release rate: e

20120202799 - Condensed azepine derivatives as bromodomain inhibitors:

20120202796 - Method for combating adverse effects arising from antipsychotic treatment: This invention relates to a method for combating adverse effects arising from antipsychotic treatment. The invention furthermore relates to novel pharmaceutical compositions comprising a therapeutically effective combination of a compound of formula I and an antipsychotic drug.... Agent: Neurosearch A/s

20120202797 - Substituted [(5h-pyrrolo[2,1-c][1,4]benzodiazepin-11-yl)piperazin-1-yl]-2,2-dimethylpropanoic acid compounds as dual activity h1 inverse agonists/5-ht2a antagonists: i

20120202800 - Dual small molecule inhibitors of cancer and angiogenesis: The present invention provides analogs and derivatives of thalidomide which inhibit cancer and angiogenesis. The present invention further provides compounds which disrupt microtubule polymerization. The present further provides methods of treating cancers comprising mutant p53.... Agent: University Of Virginia Patent Foundation

20120202801 - Methods for treating breast cancer: Methods for treating breast cancer involving the administration of a compound that selectively inhibits pathological production of human vascular endothelial growth factor (VEGF) are described. The compound can be administered as a single agent therapy or in combination with one or more additional therapies to a human in need of... Agent:

20120202802 - Spirocyclic compounds as modulators of chemokine receptor activity: The present application describes modulators of chemokine receptor activity of formula (I) or stereoisomers or pharmaceutically acceptable salts thereof. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and transplant rejection using modulators of formula... Agent: Bristol-myers Squibb Company

20120202804 - Fused aminodihydro-oxazine derivatives: A compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof or a solvate thereof, wherein Ring A is a C6-14 aryl group or the like, L is —NReCO— or the like (wherein Re is a hydrogen atom or the like), Ring B is a C6-14 aryl... Agent: Eisai R&d Management Co., Ltd.

20120202803 - N-[3-(5-amino-3,3a,7,7a-tetrahydro-1h-2,4-dioxa-6-aza-inden-7-yl)-phenyl]-amides as bace1 and/or bace2 inhibitors: c

20120202805 - Pi3k (delta) selective inhibitors: Novel PI3K, especially PI3K delta isoform, selective inhibitors are disclosed. The compounds are useful in treating disorders related to abnormal PI3K or PI3Kδ activities such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine disorders and neurological disorders.... Agent:

20120202806 - Novel pyrimidine- and triazine-hepcidine antagonists: The present invention relates to new hepcidin antagonists, pharmaceutical compositions containing them and the use thereof as a drug, in particular for the treatment of iron metabolism disorders such as, in particular, iron deficiency diseases and anaemia, in particular anaemia associated with chronic inflammatory disease (ACD: anaemia of chronic disease... Agent: Vifor (international) Ag

20120202807 - Azabicycloalkane derivatives, preparation thereof and use thereof in therapy: e

20120202808 - Novel thiophenediamine derivative having urea structure: R4 and R5 represent halogen, lower alkyl, hydroxyl, or lower alkoxy; R6 represents halogen, lower alkyl, aryl, heterocyclic, hydroxy, lower alkoxy, mercapto, lower alkylthio, lower alkylcarbonyl, amino, nitro or cyano; R7 represents lower alkyl, hydroxyl or lower alkoxy; Ra and Rb represent hydrogen or lower alkyl; ring A represents a... Agent: Santen Pharmaceutical Co., Ltd.

20120202809 - Novel n-pyrimidin-4-yl-3-amino-pyrrolo[3,4-c]pyrazole derivatives as pkc kinase inhibitors: wherein A, B, R1, R2, R3, R4, R5, R6, R7, R8, R9 and R10 are as defined above. The invention further relates to pharmaceutical compositions comprising the compounds and pharmaceutically acceptable salts and to methods of treating diabetes mellitus and its complications, cancer, ischemia, inflammation, central nervous system disorders, cardiovascular... Agent: Pfizer Inc.

20120202810 - Substituted 4-aminocyclohexane derivatives: The invention relates to compounds that have an affinity to the μ-opioid receptor and the ORL 1-receptor, methods for their production, medications containing these compounds and the use of these compounds for the treatment of pain and other conditions.... Agent: Grunenthal Gmbh

20120202811 - Novel compounds: wherein R1 is 2-indanyl, R2 is 1-methylpropyl, R3 is a group selected from 2,6-dimethyl-3-pyridyl or 4,6-dimethyl-3-pyridyl, R4 represents methyl and R5 represents hydrogen or methyl or, R4 and R5 together with the nitrogen atom to which they are attached represent morpholino and pharmaceutically acceptable derivatives thereof are described, as are... Agent: Glaxo Group Limited

20120202814 - Compounds with ddx3 inhibitory activity and uses thereof: The present invention relates to the medical use of the compound of formula 1, 2, 3 or 4:... Agent: Consiglio Nazionale Delle Ricerche

20120202812 - Heteroaryls and uses thereof: e

20120202815 - Heterobicycle-substituted azolyl benzene fungicides: Also disclosed are compositions containing the compounds of Formula 1 and methods for controlling plant disease caused by a fungal pathogen comprising applying an effective amount of a compound or a composition of the invention.... Agent: E.i.du Pont De Nemours And Company

20120202813 - Triazole compounds that modulate hsp90 activity: The present invention relates to substituted triazole compounds and compositions comprising substituted triazole compounds. The invention further relates to methods of inhibiting the activity of Hsp90 in a subject in need thereof and methods for preventing or treating hyperproliferative disorders, such as cancer, in a subject in need thereof comprising... Agent: Synta Pharmaceuticals Corp.

20120202816 - Novel compounds: The present invention discloses a novel thyroid like compounds of formula (I), wherein R1 R2, R3, R4 and Z are as defined in the specification, method for its preparation, composition containing such compounds and use of such compounds and composition as medicament. Further, compounds of formula (I) has significantly low... Agent: Torrent Pharmaceuticals, Ltd.

20120202817 - Compounds having 4-pyridylalkylthio group as a substituent: wherein A is an aromatic five-membered heterocycle which optionally is fused with a cycloalkane ring; B is an alkylene; R1 and R2 are hydrogen, hydroxyl, alkoxy, aryloxy, alkyl, cycloalkyl, aryl, heterocycle, amino, alkylamino, arylamino or acyl, or R1 and R2 join together to form a heterocycle; X and Y are... Agent: Santen Pharmaceutical Co., Ltd.

20120202818 - Ureidophenyl substituted triazine derivatives and their therapeutical applications: The present invention provides Uredophenyl substituted triazine derivatives and provides methods of using these compounds to modulate protein kinases and methods of using these compounds to treat protein kinase mediated diseases and conditions.... Agent: California Capital Equity, LLC

20120202819 - Combination therapy using a beta 3 adrenergic receptor agonists and an antimuscarinic agent: Described herein is an improved method of treating overactive bladder, wherein the method comprises administering to a patient in need thereof a beta 3 adrenergic receptor agonist, an antimuscarinic agent, and an optional selective M2 antagonist. Such combination therapy provides improved efficacy and/or reduced side effects.... Agent: Merck Sharp & Dohme Corporation

20120202820 - Pharmaceutical composition having the active substances metformin and sitagliptin or vildagliptin: The present invention relates to a pharmaceutical composition that comprises the active substance metformin in combination with one of the active substances sitagliptin or vildagliptin. The present invention further relates to a method of production of said pharmaceutical composition.... Agent: Ratiopharm Gmbh

20120202821 - Conformationally constrained, fully synthetic macrocyclic compounds: Conformationally restricted, spatially defined 12-30 membered macrocyclic ring systems of type (I) are constituted by three distinct building blocks: an aromatic template a, a conformation modulator b and a spacer moiety c as detailed in the description and the claims. Macrocycles of type (I) are readily manufactured by parallel synthesis... Agent: Polyphor Ag

20120202822 - Combination: The present invention relates to a method of treating cancer in a mammal and to pharmaceutical combinations useful in such treatment. In particular, the method relates to a novel combination comprising the MEK inhibitor: N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)6,8-dimethy; -2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide, or a pharmaceutically acceptable salt or solvate thereof, and the PI3 kinase inhibitor: 2,4-difluoro-N-{2-(methyloxy)-5-[4-(4-pyridazinyl)-6-quinolinyl]-3-pyridinyl}benzenesulfonamide,... Agent:

20120202823 - Multi-api loading prodrugs: The present invention accomplishes this by having multiple molecules of parent drugs attached to carrier moieties and by extending the period during which the parent drug is released and absorbed after administration to the patient and providing a longer duration of action per dose than the parent drug itself. Prodrug... Agent: Alkermes, Inc.

20120202824 - Pyrazines as delta opioid receptor modulators: e

20120202825 - Soluble salts of thieno [2,3-d] pyrimidine derivatives: The present invention is directed to novel salts of thieno[2,3-d]pyrimidine derivatives, including 4-(2-fluorophenyl)-6-methyl-2-(piperazin-1-yl)thieno[2,3-d]pyrimidine salts. The present invention is also directed to compositions including such polymorphs and methods for using such salts, e.g., in the treatment of gastrointestinal and/or genitourinary disorders.... Agent:

20120202826 - Tetrahydropyrrolopyrimidinediones and their use in therapy: e

20120202827 - Sulfoxide derivatives for the treatment of tumors: Sulfoxide derivatives of the formula Ia to Im as described, and pharmaceutically usable salts, solvates, enantiomers, tautomers and stereoisomers thereof, including mixtures thereof in all ratios, for the treatment of tumours.... Agent: Merck Patent Gesellschaft Mit Beschrankter Hafung

20120202828 - Fused aminodihydropyrimidone derivatives: A compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof or a solvate thereof, wherein Ring A is a C6-14 aryl group or the like, L is —NReCO— or the like (wherein Re is a hydrogen atom or the like), Ring B is a C6-14 aryl... Agent: Eisai R&d Management Co., Ltd.

20120202829 - 6-cycloalkyl-pyrazolopyrimidinones for the treatment of cns disorders: The new compounds are for use as the active entity of medicaments or for the manufacture of medicaments respectively, in particular medicaments for the treatment of conditions concerning deficits in perception, concentration, learning or memory. Such conditions may for example be associated with Alzheimer's disease, schizophrenia and other diseases. The... Agent: Boehringer Ingelheim International Gmbh

20120202830 - Substituted xanthine derivatives: This invention relates to novel compounds that are substituted xanthine derivatives and pharmaceutically acceptable salts thereof. For example, this invention relates to novel substituted xanthine derivatives that are derivatives of pentoxifylline. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use... Agent: Concert Pharmaceuticals, Inc.

20120202832 - Kinase inhibitors, prodrug forms thereof and their use in therapy: Also provided are reductive prodrugs, comprising a kinase inhibitor as defined above and a reductive trigger linked directly or indirectly to a nitrogen of the kinase inhibitor. Further provided are pharmaceutical compositions, comprising the kinase inhibitors or the prodrugs, and the use of such compositions in therapy, in particular for... Agent: Auckland Uniservices Limited

20120202831 - Pharmaceutical formulation: s

20120202833 - Tricyclic pyrazolopyrimidine derivatives: A pyrazolopyrimidine compound represented by formula (1) that inhibits the function of HSP90 as a chaperone protein and that has antitumor activity, a medicament comprising a compound represented by formula (1), a pharmaceutical composition comprising a compound represented by formula (1), and a method for treating cancer using a compound... Agent: Daiichi Sankyo Company, Limited

20120202835 - Combination: The present invention relates to a method of treating cancer in a human and to pharmaceutical combinations useful in such treatment. In particular, the method relates to a cancer treatment method that includes administering N-{3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide or a pharmaceutically acceptable salt thereof, and N-{(1S)-2-amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxamide, or a pharmaceutically acceptable salt thereof, to... Agent: Glaxosmithkline LLC

20120202834 - Glucagon receptor modulators: or a pharmaceutically acceptable salt thereof wherein R1, R2, R3, A1, A2, A3, A4, L, B1, B2, B3 and B4 are as defined herein. The compounds of Formula I have been found to act as glucagon antagonists or inverse agonists. Consequently, the compounds of Formula I and the pharmaceutical compositions... Agent: Pfizer Inc.

20120202836 - Method of treating proliferative disorders and other pathological conditions mediated by bcr-abl, c-kit, ddr1, ddr2 or pdgf-r kinase activity: The present invention relates to a regimen for the administration of a pyrimidylaminobenzamide of formula I as defined herein for the treatment of proliferative disorders, particularly solid and liquid tumors, and other pathological conditions mediated by the Bcr-AbI oncoprotein, the cell transmembrane tyrosine kinase receptor c-Kit, DDR1 (discoidin domain receptor... Agent:

20120202837 - Spirocyclic piperidine derivatives useful as renin inhibitors: Renin inhibitors which are spirocyclic piperidine derivatives, of formula (I) and pharmaceutical compositions thereof useful in the treatment of cardiovascular diseases and renal insufficiency, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of the stereoisomer thereof, wherein: n, for each instance in which... Agent:

20120202838 - Drug formulations: In one embodiment, the present invention relates to abuse-deterrent drug formulations comprise a plurality of discrete domains uniformly dispersed in a pharmaceutically acceptable matrix, wherein said domains have high fracture toughness and comprise at least one polymer and at least one abuse-relevant drug. In another embodiment, the present invention relates... Agent: Abbott Gmbh & Co. Kg

20120202839 - Methods and compositions for deterring abuse of orally administered pharmaceutical products: This invention relates to an abuse deterrent formulation of an oral dosage form of a therapeutically effective amount of any active drug substance that can be subject to abuse combined with a gel forming polymer, a nasal mucosal irritating surfactant and a flushing agent. Such a dosage form is intended... Agent: Acura Pharmaceuticals, Inc.

20120202840 - Use of flubendazole and vinca alkaloids for treatment of hematological diseases: Provided are methods for treating a hematological malignancy comprising administering an effective amount of flubendazole alone or in combination with a vinca alkaloid. Also provided are compositions and kits comprising an effective amount of flubendazole and/or a vinca alkaloid for use in the methods of the disclosure.... Agent: University Health Network

20120202842 - 2-heteroarylcarboxylic acid amides: The invention relates to novel 2-heteroarylcarboxamides, processes for their preparation, and their use for producing medicaments for the treatment and/or prophylaxis of diseases and for improving perception, concentration, learning and/or memory.... Agent: Bayer Schering Pharma Ag

20120202841 - Topical compositions comprising ascomycins: The present invention relates to a composition for topical administration comprising an ascomycin and a carrier vehicle comprising means to retain water in the outer skin layer and means to hinder water evaporating from the skin.... Agent: Meda Pharma Sarl

20120202843 - H3k27me3 and cancer: Methods of diagnosing and monitoring cancers and precancerous lesions associated with human papillomavirus (HPV), by detecting abnormal levels of lysine (K)-specific demethylase 6A (KDM6A), KDM6B, or trimethylated Histone H3 Lys27 (H3K27me3).... Agent: The Brigham And Women's Hospital, Inc.

20120202844 - Crystal forms of kinase inhibitors: Citrate salts of N-(4-{4-amino-7-[1-(2-hydroxyethyl)-1H-pyrazol-4-yl]thieno[3,2-c]pyridin-3-yl}phenyl)-N′-(3-fluorophenyl)urea and crystalline forms thereof are suitable pharmaceutical ingredients for pharmaceutical compositions useful in the treatment of disease, for example, cancer.... Agent: Abbott Laboratories

20120202845 - Diuretics: A compound having the structure formula (I) or a pharmaceutically acceptable salt thereof, and methods of using the compounds for treating hypertension.... Agent:

20120202846 - Molecular target of neurotoxicity: The present invention relates to the fields of biology, genetics and medicine. In particular it concerns new methods for the detection, characterisation and/or treatment (or management) of neurodegenerative diseases, particularly amyotrophic lateral sclerosis. The invention equally concerns methods for identifying or screening compounds active in these diseases. The invention further... Agent: Exonhit Therapeutics Sa

20120202847 - Novel tetrahydroisoquinoline compounds: The present invention relates to a compound or a pharmacologically acceptable salt thereof having an excellent DGAT inhibitory effect and feeding suppressant effect. The present invention provides trans-6-[3-(2,4-difluoro-phenyl)-ureido]-3,4-dihydro-1H-isoquinoline-2-carboxylic acid 4-carboxymethyl-cyclohexyl ester, trans-6-[3-(2-chloro-phenyl)-ureido]-3,4-dihydro-1H-isoquinoline-2-carboxylic acid 4-carboxymethyl-cyclohexyl ester, trans-6-[3-(2,3-difluoro-phenyl)-ureido]-3,4-dihydro-1H-isoquinoline-2-carboxylic acid 4-carboxymethyl-cyclohexyl ester, trans-6-[3-(2,5-difluoro-phenyl)-ureido]-3,4-dihydro-1H-isoquinoline-2-carboxylic acid 4-carboxymethyl-cyclohexyl ester, trans-6-[3-(2,6-difluoro-phenyl)-ureido]-3,4-dihydro-1H-isoquinoline-2-carboxylic acid 4-carboxymethyl-cyclohexyl ester, or the like,... Agent:

20120202848 - Therapy of autoimmune colitis using a tip60 inhibitor: This invention is in the fields of immunology and autoimmunity. More particularly it concerns methods of treating patients with compounds which are useful agents for inhibiting the functions of TIP60 in the treatment of an individual suffering, for example, from ulcerative colitis and other irritable bowel diseases.... Agent: The Trustees Of The University Of Pennsylvania

20120202849 - Pharmaceutical compositions for the treatment/prophylaxis of non-alcoholic fatty liver disease: Disclosed herein is a novel synergistic pharmaceutical composition comprising hydroxychloroquine with insulin sensitizing agents and lipid lowering agents such as statins along with pharmaceutical excipients/carriers useful in treating Non-Alcoholic Fatty Liver Disease.... Agent:

20120202850 - Method for treating thrombosis and inhibiting platelet aggregation with 21-(s)-argatroban: A method for inhibiting coagulation including administering to a patient in need thereof a pharmaceutical composition containing 21-(S)-Argatroban and/or a pharmaceutically acceptable salt thereof. Compared with 21-(R)-Argatroban, 21-(S)-Argatroban significantly prolongs coagulation time of whole blood (CT), recalcification time (RT), kaolin partial thromboplastin time (APTT), pro-time prothrombin time (PT), thrombin time... Agent: Tianjin Weijie Technology Co., Ltd.

20120202851 - Pim kinase inhibitors and methods of their use: The present invention relates to new compounds of Formulas I and II, their tautomers, stereoisomers and polymorphs, and pharmaceutically acceptable salts, esters, metabolites or prodrugs thereof, compositions of the new compounds together with pharmaceutically acceptable carriers, and uses of the new compounds, either alone or in combination with at least... Agent:

20120202852 - Heterocycle amide t-type calcium channel antagonists: The present invention is directed to heterocycle amide compounds which are antagonists of T-type calcium channels, and which are useful in the treatment or prevention of disorders and diseases in which T-type calcium channels are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use... Agent:

20120202853 - Substituted pyrazoles as estrogen receptor ligands: The invention provides a compound of formula (I) wherein G is a pyrazole ring as defined in the specification and R4, R5, R6 and R7 are as defined in the specification; or a pharmaceutically acceptable ester, amide, solvate or salt thereof, including a salt of such an ester or amide,... Agent: Karo Bio Ab

20120202854 - 4-substituted phenoxyphenylacetic acid derivatives: e

20120202855 - Methods for treating hyperlipidemia with intermediate release nicotinic acid compositions having unique biopharmaceutical characteristics: Methods for treating hyperlipidemia with intermediate release nicotinic acid formulations having unique biopharmaceutical characteristics, without causing drug-induced hepatotoxicity to a level which would require discontinuation of the therapy, are disclosed. According to the methods of the present invention, the intermediate nicotinic acid formulations are administered as a single dose once-a-day... Agent:

20120202856 - Substituted benzimdazole derivatives useful as trpm8 receptor modulators: The present invention is directed to benzimidazole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by TRP M8, including for example, inflammatory pain, inflammatory hyperalgesia, inflammatory hypersensitivity condition, neuropathic pain, neuropathic cold allodynia, inflammatory somatic hyperalgesia, inflammatory visceral hyperalgesia, cardiovascular disease aggravated... Agent:

20120202859 - Macrocyclic inhibitors of hepatitis c virus: e

20120202857 - Novel salts and polymorphs of desazadesferrithiocin polyether analogues as metal chelation agents: Disclosed herein are new salts and polymorphs of desazadesferrithiocin polyether (DADFT-PE) analogues, as well as pharmaceutical compositions comprising them and their application as metal chelation agents for the treatment of disease. Methods of chelation of iron and other metals in a human or animal subject are also provided for the... Agent: Ferrokin Biosciences, Inc.

20120202858 - Solid pharmaceutical dosage form: A solid pharmaceutical dosage form providing improved oral bioavailability is disclosed for inhibitors of HIV protease. In particular, the dosage form comprises a solid dispersion of at least one HIV protease inhibitor and at least one pharmaceutically acceptable water-soluble polymer and at least one pharmaceutically acceptable surfactant, said pharmaceutically acceptable... Agent: Abbott Laboratories

20120202860 - Analgesic compounds, compositions and uses thereof: The invention relates to compounds, compositions, and methods for diminishing pain in a subject in need thereof comprising administering the compounds and compositions herein described.... Agent: Galleon Pharmaceuticals, Inc.

20120202861 - Novel estrogen receptor ligands: The invention provides a compound of formula (I) or a pharmaceutically acceptable ester, amide, solvate or salt thereof, including a salt of such an ester or amide, and a solvate of such an ester, amide or salt. The invention also provides the use of such compounds in the treatment or... Agent: Karo Bio Ab

20120202862 - Substituted carbamoylmethylamino acetic acid derivatives as novel nep inhibitors: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R6, A1, A2, X1, s and m are defined herein. The invention also relates to a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents... Agent: Novartis Ag

20120202863 - Compositions and methods for treatment of glaucoma: The invention provides α-2 adrenergic receptor agonist compositions and methods for treating glaucoma and other intraocular conditions. The preferred α-2 agonist used in the inventive compositions and methods is dexmedetomidine at near alkaline pH and extremely low concentrations.... Agent:

20120202864 - Compositions and methods for treatment of glaucoma: The invention provides α-2 adrenergic receptor agonist compositions and methods for treating glaucoma and other intraocular conditions. The preferred α-2 agonist used in the inventive compositions and methods is dexmedetomidine at acidic pH and extremely low concentrations.... Agent: Alpha Synergy Development Inc.

20120202865 - Substituted-aryl-(imidazole)-methyl)-phenyl compounds as subtype selective modulators of alpha 2b and/or alpha 2c adrenergic receptors: e

20120202866 - Buccal, polar and non-polar spray containing ondansetron: Buccal aerosol sprays or capsules using polar and non-polar solvents have now been developed which provide ondansetron for rapid absorption through the oral mucosa, resulting in fast onset of effect. The buccal polar compositions of the invention comprise formulation I: aqueous polar solvent, ondansetron, and optional flavoring agent; formulation II:... Agent:

20120202867 - Novel microbiocides: Compounds of formula (I), in which the substituents are as defined in claim 1, are suitable for use as microbiocides.... Agent: Syngenta Crop Protection LLC

20120202868 - Method for treatment of bronchial asthma: wherein R1=H or OCH3; R2═CH3 or CHO; R3═H or OCH3; R4═H or OCH3 Herbal route for the isolation of compound of general formula 1 from the bark of plant Murraya Koenigii and chemical route for the preparation of such compounds from basic compounds such as vanillin is also reported.... Agent: Council Of Scientific & Industrial Research

20120202869 - Antidepressant oral pharmaceutical compositions: The invention provides a pharmaceutical composition of duloxetine or its pharmaceutically equivalent derivatives like salts, isomers, complexes, polymorphs, hydrates or esters thereof and at least one buffering agent. The duloxetine or its pharmaceutically equivalent derivative is present from about 2 mg to approximately 200 mg; and the buffering agent is... Agent: Wockhardt Ltd.

20120202876 - Methods of treating diseases with proanthocyanidin oligomers such as crofelemer: Disclosed herein are methods of treating diseases including gastrointestinal disorders, such as secretory diarrheas, with the proanthocyanidin oligomer, crofelemer. Also disclosed is the anti-secretory effect of crofelemer on Calcium-activated chloride channels (CaCC) and Cystic fibrosis transmembrane conductance regulator (CFTR).... Agent: Regents Of The University Of California

20120202877 - Anti-influenza agents: The present invention relates to compounds that selectively inhibit influenza A virus group (1) sialidases and are therefore potential anti-influenza agents.... Agent:

20120202878 - Method for treating psoriasis: A method for treating psoriasis including the steps of applying an isothiocyanate functional surfactant to an area affected by psoriasis, wherein the isothiocyanate functional surfactant comprises at least one isothiocyanate functional group associated with an aliphatic and/or aromatic carbon atom of the isothiocyanate functional surfactant.... Agent:

20120202879 - Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy: Disclosed are formulations of gamma-hydroxybutyrate in an aqueous medium that are resistant to microbial growth. Also disclosed are formulations of gammahydroxybutyrate that are also resistant to the conversion into GBL. Disclosed are methods to treat sleep disorders, including narcolepsy, with these stable formulations of GHB. The present invention also provides... Agent: Jazz Pharmaceuticals, Inc.

20120202880 - Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy: Disclosed are formulations of gamma-hydroxybutyrate in an aqueous medium that are resistant to microbial growth. Also disclosed are formulations of gammahydroxybutyrate that are also resistant to the conversion into GBL. Disclosed are methods to treat sleep disorders, including narcolepsy, with these stable formulations of GHB. The present invention also provides... Agent: Jazz Pharmaceuticals, Inc.

20120202881 - Novel niddm regimen: The present invention relates to the use of a short-acting oral hypoglycemic agent and to a novel regimen in the treatment of type 2 diabetes in which the endogenous secretion of insulin is stimulated in connection with meals by administering in connection with the meals a short-acting oral hypoglycaemic agent.... Agent: Novo Nordisk A/s

20120202882 - Permeation enhancers for topical formulations: A composition to be used as a permeation enhancer is provided. The composition may be added to topical cosmetics or pharmaceutical formulations that are topically applied. The composition comprises about 0.05-5% w/w of one or more phospholipids, 1-20% w/w of one or more oils having essential fatty acids, behenic acid,... Agent: Professional Compounding Centers Of America, Ltd.

20120202883 - Effects of idh1 and idh2 mutations on the cellular metabolome: Point mutations of the NADP+-dependent isocitrate dehydrogenases (IDH1 and IDH2) occur early in the pathogenesis of gliomas. When mutated, IDH1 and IDH2 gain the ability to produce the metabolite (R)-2-hydroxyglutarate (2HG), but the downstream effects of mutant IDH1 and IDH2 proteins or of 2HG on cellular metabolism are unknown. Here,... Agent: Duke University

20120202884 - Inhibitors of cxcr1/2 as adjuvants in the transplant of pancreatic islets: The invention relates to CXCR1 and/or CXCR2 inhibitors for the preparation of a medicament for use as an adjuvant in the transplant of pancreatic islets in Type 1 diabetes patients. In particular, the compounds that can be used according to the invention have the following formula (I) in which R... Agent: Dompe' S.p.a.

20120202885 - Methods, assays and compositions for treating retinol-related diseases: Described herein are methods and compositions for treating certain retinol-related diseases and conditions by modulation of transthyretin (TTR) and retinol binding protein (RBP) availability in the subject. For example, the methods and compositions provide for therapeutic agents for the treatment and/or prevention of age-related macular degeneration and/or dystrophies, metabolic disorders,... Agent: Revision Therapeutics, Inc.

20120202886 - Method of enhancing hair growth: wherein the dashed bonds represent a single or double bond which can be in the cis or trans configuration, A, B, Z, X, R1 and R2 are as defined in the specification. Such compositions are used in treating the skin or scalp of a human or non-human animal. Bimatoprost is... Agent: Allergan, Inc.

20120202887 - Facially amphiphilic polyaryl and polyarylalkynyl polymers and oligomers and uses thereof: The present invention discloses methods of use of facially amphiphilic polyaryl and polyarylalkynyl polymers and oligomers, including, but not limited to, pharmaceutical uses of the polymers and oligomers as antimicrobial agents and as antidotes for hemorrhagic complications associated with heparin therapy. The present invention also discloses novel facially amphiphilic polyaryl... Agent: The Trustees Of The University Of Pennsylvania

20120202888 - Biomarkers of prostate cancer and predicting mortality: Measurement of circulating C-peptide levels is useful for the prognostic evaluation of subjects, in particular for the prediction of adverse clinical outcomes, e.g., mortality, and the detection of fatal prostate cancer.... Agent: The Brigham And Women's Hospital, Inc.

20120202889 - Production method for astaxanthin-containing composition: The present invention relates to a method for reducing the relative ratio of 3-hydroxy-3′,4′-didehydro- β, Ψ-caroten-4-one (HDCO) to astaxanthin in a composition containing astaxanthin and HDCO by contacting the composition with an acidic medium having a pH of 3 or less and/or a basic medium having a pH of 9... Agent: Kaneka Corporation

20120202890 - Polymer-carbohydrate-lipid conjugates: The invention comprises compounds, methods of making, and methods of using. The compounds may have a backbone and three appended functional groups: one lipid, one hydrophilic polymer, and one carbohydrate. Specific functional groups may be selected for specific applications in formulating pharmaceuticals, cosmetics, nutriceuticals, and the like. A variety of... Agent:

20120202891 - Cannabinoid-containing compositions and methods for their use: This invention relates to cannabinoid-containing compositions, particularly cannabinoid-containing gel formulations and methods for the treatment of traumatic injury, e.g., strains, sprains and contusions, and disease conditions, e.g., arthritis, particularly osteoarthritis. The methods involve topically applying a cannabinoid or a cannabinoid-containing composition to a subject's skin near, or distant from, the... Agent: University Of Kentucky Research Foundation

20120202892 - Cannabinoid-containing compositions and methods for their use: This invention relates to cannabinoid-containing compositions, particularly cannabinoid-containing gel formulations and methods for the treatment of traumatic injury, e.g., strains, sprains and contusions, and disease conditions, e.g., arthritis, particularly osteoarthritis. The methods involve topically applying a cannabinoid or a cannabinoid-containing composition to a subject's skin near, or distant from, the... Agent: University Of Kentucky Research Foundation

20120202893 - Method of manufacturing a purified product of alkyl-modified polydimethylsiloxane, a cosmetic raw material, and cosmetics: To provide a method for manufacturing a purified product of an alkyl-modified polydimethylsiloxane that is practically odorless and compatible with other cosmetic raw materials. The manufacturing method comprises the steps of: [A] synthesizing an alkyl-modified polydimethylsiloxane by subjecting a hydrosilyl-containing polydimethylsiloxane and an C2-C30 α-olefin to a hydrosilation reaction, and... Agent:

20120202894 - Rapidly soluble solid pharmaceutical preparations containing amphiphilic copolymers based on polyethers in combination with hydrophilic polymers: Dosage forms comprising formulations of sparingly water-soluble active ingredients in a polymer matrix composed of amphiphilic polyether copolymers and of at least one hydrophilic polymer, in which the sparingly water-soluble active ingredient is present in amorphous form in the polymer matrix.... Agent: Basf Se

20120202895 - Paste composition and cosmetic containing it: The present invention has an object to provide a paste composition having a high thickening effect to an oil material such as a silicone oil and giving a silky and light feeling without poor spreading properties and without such feelings as an oily, a sticky, and an oil-film feeling and... Agent: Shin-etsu Chemical Co., Ltd.

20120202896 - Composition including a copolyamide and a cross-linked polyolefin: The invention relates to a composition including: 45 to 95 wt % of a semi-aromatic copolyamide containing at least two separate units having the following general formulation: A/X.T, where A is selected from among a unit obtained from an amino acid, a unit obtained from a lactam, and a twit... Agent: Arkema France

  
08/02/2012 > 154 patent applications in 120 patent subcategories. inventions list

20120196789 - Peptide based peroxidase inhibitors and methods of using same: The present invention provides peptide-based peroxidase inhibitors having the formula AA1-AA2-AA3, wherein AA1 is a positively charged, negatively charged or neutral amino acid, AA2 is a redox active amino acid, and AA3 is an amino acid possessing a reducing potential such that AA3 is capable of undergoing a redox reaction... Agent:

20120196790 - Cyclic depsipeptides: The present application relates to cyclic depsipeptides, or derivatives thereof, having the structure of formula (I), and uses thereof, e.g. as inhibitors of kallikrein 7 and human neutrophil elastase.... Agent: Novartis Ag

20120196791 - Combination therapies using antibacterial aminoglycoside compounds: Methods for treating a bacterial infection in a mammal in need thereof, and compositions related thereto, are disclosed, the methods comprising administering to the mammal an effective amount of an antibacterial aminoglycoside compound and a second antibacterial agent.... Agent: Achaogen, Inc.

20120196793 - Biomarkers for iap inhibitor compounds: A method to predict which patients will respond to a IAP inhibiting compound comprising administering an IAP inhibitor compound to a patient/and measuring IL1B, Lymphotoxin alpha (LTa), TWEAK, LIGHT, Fas, TNF alpha or TRAIL levels.... Agent:

20120196792 - Macrocyclic hepatitis c serine protease inhibitors: The present invention relates to novel macrocyclic compounds and methods of treating a hepatitis C infection in a subject in need of such therapy with said macrocyclic compounds. The present invention further relates to pharmaceutical compositions comprising the compounds of the present invention, or pharmaceutically acceptable salts, esters, or prodrugs... Agent: Abbott Laboratories

20120196794 - Combinations of hepatitis c virus inhibitors: The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit Hepatitis C virus (HCV), compositions comprising such compounds, and methods for treating hepatitis C using such combinations.... Agent: Bristol-myers Squibb Company

20120196796 - Amylin family peptides and methods for making and using them: The present invention relates to novel compounds having a function of a peptide in the amylin family, related nucleic acids, expression constructs, host cells, and processes production of the compounds. The compounds of the invention include one or more amino acid sequence modifications. In addition, methods and compositions are disclosed... Agent: Amylin Pharmaceuticals, Inc.

20120196797 - Methods and compositions for the treatment of gastrointestinal disorders: Compositions and related methods for treating IBS and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), duodenogastric reflux, Crohn's disease, ulcerative colitis, inflammatory bowel disease, functional heartburn, dyspepsia (including functional dyspepsia or nonulcer dyspepsia), gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudoobstruction), and... Agent: Ironwood Pharmaceuticals, Inc.

20120196795 - Novel exendin variant and conjugate thereof: The invention provides a novel Exendin variant and the Exendin variant conjugate conjugating polymer thereon, the pharmaceutical composition comprising them and use of them for treating diseases such as reducing blood glucose, treating diabetes, especially Type II diabetes. The invention also provides the use of Exendin conjugate for lowering body... Agent: Pegbio Co., Ltd.

20120196799 - Amylin family peptides and methods for making and using them: Methods for treating obesity are disclosed which comprise administration of a therapeutically effective amount of an amylin or an amylin agonist alone or in conjunction with another obesity relief agent. Additionally, methods for reducing insulin-induced weight gain are disclosed which comprise administration of a therapeutically effective amount of an amylin... Agent: Amylin Pharmaceuticals, Inc.

20120196798 - Glp-1 analogues and their pharmaceutical salts and uses: t

20120196800 - Stable non-aqueous liquid pharmaceutical compositions comprising an insulin: The invention describes a non-aqueous liquid pharmaceutical composition comprising at least one lipid and at least one insulin. Also described is a method of producing a pharmaceutical composition comprising a lipid and a method of purifying a lipid, a cosolvent, a surfactant or a pharmaceutical composition comprising a lipid.... Agent: Novo Nordisk A/s

20120196801 - Wound-healing, anti-ambustial, regenerating, and anti-viral pharmaceutical formula for local administration: The main active ingredients of the formula are papaverin, bendazol, and insulin. The drug may be produced in soft, liquid medicinal form or as an aerosol.... Agent:

20120196802 - Modified exendins and uses thereof: The present invention discloses a modified exendin or pharmaceutically acceptable salts thereof, wherein the modified exendin comprises an amino acid sequence having at least 90% sequence identity to SEQ ID No. 17 and the amino acid sequence has a higher stability than the non-modified exendin of SEQ ID No. 4.... Agent: Wuxi Grandchamp Pharmaceutical Technology Co., Ltd.

20120196803 - Fusion proteins for delivery of gdnf and bdnf to the central nervous system: The present invention relates to a compound that includes a peptide vector, such as angiopep-2 which acts as a carrier across the blood-brain barrier, linked to glial-derived neurotrophic factor (GDNF), brain-derived neurotrophic factor (BDNF), or a related molecule, such as an analog or a fragment thereof. The compounds of the... Agent: Angiochem Inc.

20120196804 - Glucagon analogs exhibiting physiological solubility and stability: Modified glucagon peptides are disclosed having improved solubility and stability, wherein the native glucagon peptide has been modified by pegylation, or the addition of a carboxy terminal peptide selected from the group consisting of SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, or both.... Agent: Indiana University Research And Technology Corporation

20120196805 - Compositions and methods to control angiogenesis with cupredoxins: The present invention relates to compositions comprising cupredoxins, and their use to inhibit angiogenesis in mammalian cells, tissues, and animals, and particularly the angiogenesis that accompanies tumor development and particularly in humans. Specifically, the present invention relates to compositions comprising the cupredoxin(s), and or peptides that are variants, derivatives or... Agent:

20120196806 - Anticoagulant and composition for preventing thrombus containing poly-gamma-glutamic acid: The present invention relates to an anticoagulant and a composition for preventing thrombus formation, which contain poly-gamma-glutamic acid (PGA) as an active ingredient. The inventive PGA is a water-soluble, anionic, biodegradable and edible amino acid polymer material, which has an anticoagulant effect of preventing thrombi from being accumulated in blood... Agent: Bioleaders Corporation

20120196807 - Kidney-targeting drug delivery agent comprising recombinant gelatin: An object of the present invention is to provide a kidney-targeting drug delivery agent which is composed of bioabsorbable materials, transiently accumulates in a kidney and particularly kidney functional units such as tubular epithelial cells for a short period of time, and does not remain in the kidney for a... Agent: Fujifilm Corporation

20120196808 - Peptidic vasopressin receptor agonists: The present application relates to novel compounds, pharmaceutical compositions comprising the same, use of said compounds for the manufacture of a medicament for treatment of inter alia shock conditions as well as to a method for treatment of said conditions, wherein said compounds are administered. The compounds are represented by... Agent: Ferring B.v.

20120196809 - Use of icam-1 for prevention or treatment of neurological diseases: The present invention relates to a pharmaceutical composition for the prevention or treatment of neurological disorders, comprising an ICAM-1 (intercellular adhesion molecule-1) protein, or a fragment or a variant thereof as an active ingredient, which can increase the expression of neprilysin to remove amyloid-beta (Aβ), a cause of dementia, and... Agent: Medipost Co., Ltd.

20120196810 - Anionic polymer, polyion complex and ternary polymer composite using anionic polymer, and pharmaceutical composition: where : A represents a residue having one or more aminoethyl bonds; B represents an in vivo cleavable bond; and X represents a small RNA. A polyion complex according to an embodiment of the invention includes the anionic polymer as described above and a cationic polymer. A ternary polymer composite... Agent: The University Of Tokyo

20120196811 - Veterinary pharmaceutical composition and method (alternatives) for the prophylaxis and treatment of diseases of the gastrointestinal tract and intoxications of diverse etiology in animals: A veterinary pharmaceutical composition for treating diseases of the gastrointestinal tract and intoxications of diverse etiology in animals comprises, as the active component, hydrolyzed lignin and a prebiotic from the following group: lactulose, fructooligo-saccharides, galacto-saccharides and inulin, and is in a form suitable for use in the composition of a... Agent:

20120196812 - Pharmaceutical composition, methods for treating and uses thereof: The invention relates to the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia using a SGLT-2 inhibitor. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions.... Agent: Boehringer Ingelheim International Gmbh

20120196814 - (r)-1-(4-(4-fluoro-2-methyl-1h-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-ol metabolites: The present invention is directed to metabolites of (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-ol, the compound of formula (I), pharmaceutical compositions thereof, and to methods of using the metabolites and the pharmaceutical compositions in the treatment of cancer.... Agent: Bristol-myers Squibb Company

20120196813 - Glycoside derivative and uses thereof: e

20120196816 - Method for enhancing nutrient absorption with astragalosides: The present application relates to a method for enhancing absorption of a nutrient in a subject in need thereof with an effective amount of an isolated astragaloside compound.... Agent: Nuliv Holding Inc.

20120196817 - Method for enhancing nutrient absorption with astragalosides: The present application relates to a method for enhancing absorption of a nutrient in a subject in need thereof with an effective amount of an isolated astragaloside compound.... Agent: Nuliv Holding Inc.

20120196815 - Withanolide isolated from physalis longifolia and analogs and methods of use thereof: The present invention features novel withanolides, as well as analogs and salts thereof, for use in the treatment of proliferative disease, cardiovascular disease, neurodegenerative disease and inflammatory disease.... Agent: Kansas University Center For Technology Commercialization

20120196818 - Method for preparing polyphenol extracts from spinach leaves: A method for preparing a concentrated spinach extract in a liquid or dry form and having a polyphenol titer greater than or equal to 50% is described. The method includes a step of purifying a raw spinach extract in a liquid form using a liquid-liquid extraction technique with a food... Agent: Burgundy

20120196819 - Animal treatments: Compositions and methods for the treatment and control of various conditions in an animal which comprises administering to said animal an effective amount of a immediate release composition of about 0.5% to 50% wt/wt of active ingredient together with excipients to a total of about 100%, wherein said compositon dissolves... Agent: Newmarket Pharmaceuticals LLC

20120196820 - Insescticidal composition and processes related thereto: m

20120196821 - Method and formulation for the control of parasites: An aqueous micellar formulation for localised topical application to an animal for the concurrent control of internal and external parasites in and on the animal, the formulation comprising a water-miscible co-solvent, a fatty alcohol alkoxylate, a macrocyclic lactone and water. Also described is a method for the concurrent control of... Agent:

20120196822 - Diyne compositions: A novel class of diyne compounds and diyne salts provided herein are effective and potent Ole1 protein inhibitors, useful for treating fungal pathogens. Compounds, fungicides and methods are provided as novel, potent and broad spectrum anti-fungal agents for treatment against a wide variety of fungal pathogens in humans and animals,... Agent: Evolva Ag

20120196823 - Pharmaceutical compositions of cytidine analogs and methods of use thereof: The present disclosure provides pharmaceutical compositions comprising cytidine analogs for parenteral administration. Also provided are methods of preparing the compositions and methods of treating diseases and disorders using the compositions provided herein.... Agent: Celgene Corporation

20120196824 - Therapeutic agent for cerebral infarction: e

20120196920 - Antisense oligonucleotides against acetylcholinesterase for treating inflammatory diseases: The present invention relates to novel uses of antisense oligolucleotides targeted to the coding region of acetylcholinesterase (AChE) for treating inflammatory disorders other than inflammatory disorders of the central nervous system or the peripheral nervous system innervating voluntary muscles. More particularly, the present invention relates to uses of antisense oligodexoynucleotides... Agent: Amarin Pharma, Inc.

20120196919 - Ex-vivo treatment of immunological disorders with pkc-theta inhibitors: Disclosed is a method for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC-theta, including immunological disorders and atherosclerosis. Specifically, the invention relates to a method of treating an immunological disorder or atherosclerosis in a patient comprising treating blood from the patient,... Agent: Boehringer Ingelheim International Gmbh

20120196918 - Preventing islet inflammation and dysfunction and maintaining proper glucose levels by controlling eif5a and its hypusination: Pancreatic islet dysfunction, in both type 1 and type 2 diabetes results, in part, from cytokine-mediated inflammation leading to iNOS generation and the death of pancreatic islets. The production of pro-inflammatory cytokines involved in the generation of iNOS is facilitated by the availability of the hypusine-containing translational factor eIF5A, necessary... Agent:

20120196924 - Methods and products for expression of micro rnas: The invention relates to microRNAs, methods of producing microRNAs and methods for using microRNAs.... Agent: Whitehead Institute For Biomedical Research

20120196921 - Modulation of sglt-2 expression: Compounds, compositions and methods are provided for modulating the expression of SGLT2. The compositions comprise oligonucleotides, targeted to nucleic acid encoding SGLT2. Methods of using these compounds for modulation of SGLT2 expression and for diagnosis and treatment of diseases and conditions associated with expression of SGLT2 are provided.... Agent: Isis Pharmaceuticals, Inc.

20120196923 - Polymers for delivering a substance into a cell: Disclosed herein are polymers that can be made cationic and used to deliver a substance into a cell. Also disclosed are pharmaceutical compositions comprising the polymers and methods of using the polymers.... Agent:

20120196925 - Therapeutic and diagnostic molecules: The present invention relates to methods for modulating angiogenesis, comprising administering to a subject, or cells or tissue derived therefrom: (i) one or more miRNA, or precursors or variants thereof, wherein at least one of said miRNA comprises a seed region comprising the sequence UCACAGU (SEQ ID NO:37) to inhibit... Agent: University Of Sydney

20120196922 - Znf206: a novel regulator of embryonic stem cell self-renewal and pluripotency: We have identified ZNF206, a novel repressor of human embryonic stem cell (hESC) differentiation. Repressing extra-embryonic endoderm development preserves the pluripotent state of human embryonic stem cells, and, conversely down-regulating expression of ZNF206 in hESCs causes them to upregulate the expression of genes associated with the extra-embryonic endodermal lineage, down-regulate... Agent: Sanford-burnham Medical Research Institute

20120196825 - Compositions and methods for modulating the immune system: The present invention provides methods and compositions for the prophylaxis of blood cell disorders such as neutropenia, thrombocytopenia, lymphocytopenia, and anaemia. The invention provides methods wherein compositions comprising at least one cytokinin compound are administered either therapeutically or prophylactically. The invention further has utility in methods of DNA repair.... Agent:

20120196826 - Methods for transdifferentiation of body tissues: The invention relates to methods for transdifferentiation of body tissues which can be used to generate specific cell types needed for regenerating organs or body parts, following cellular degeneration, injury or amputation. The present invention also describes the use of tissue transdifferentiation for treating cancer and autoimmune disease.... Agent:

20120196827 - Methylation markers for early detection and prognosis of colon cancers: Using a combination of analytic methods epigenetic silencing of markers in cancer have been determined. The cancers are generally those of the gastrointestinal tract including but not limited to esophageal, head and neck, gastric, pancreas, liver, and colon. The genes can be used for the early detection of cancer or... Agent: Oncomethylome Sciences S.a.

20120196828 - Sensitization of cancer cells to treatment: The present application provides methods for the treatment of cancer, comprising administering substantially non-anticoagulant 2-O, 3-O desulfated heparin to patients suffering from cancer that is, or can become resistant to, cancer treatment, such as chemotherapy, targeted cancer therapy, or radiation therapy. The compositions can be administered to sensitize, or to... Agent: Paringenix, Inc.

20120196829 - Method of using beta-hydroxy-beta-methylbutyrate for the prevention and treatment of disease conditions: The present invention relates to methods for the prevention and treatment of chronic inflammatory diseases, cancer, and involuntary weight loss. In the practice of the present invention patients are enterally administered HMB alone or alternatively in combination with eicosapentaenoic (20:5 ω-3), FOS, carnitine and mixtures thereof. HMB may be added... Agent: Abbott Laboratories

20120196830 - Kits and improved compositions for treating lower urinary tract disorders: Superior buffered formulations and their kits for treating lower urinary tract symptoms and disorders are provided in the invention. In particular superior buffered formulations have demonstrated improvement for treating lower urinary tract symptoms of patients experiencing severe pain and/or urgency of the bladder and associated areas of the lower urinary... Agent:

20120196831 - Composition for treating and preventing obesity including high water-soluble 2-hydroxypropyl-betacyclodextrin as effective component: There is provided a composition for preventing and treating obesity including high water-soluble β-cyclodextrin derivatives as an effective component. Specifically, the composition including the high water-soluble β-cyclodextrin derivatives, especially, 2-hydroxypropyl-β-cyclodextrin (HP-β-CD, HPBCD) has effects on suppressing an increase in body weight induced by a high fat diet, suppressing appetite through... Agent: Song Ho Biomed Co., Ltd

20120196832 - Substituted polyalkoxysiloxane compositions and methods of use: Linear polydialkoxysiloxanes with 2-8 polymeric units have been reacted with alcohols by a transetherification reaction to provide hydrophilic and water soluble silicone products. The glycerol substituted siloxanes in particular are effective in topically treating skin lesions such as radiation burns. Compositions including the substituted polydialkoxysiloxane products inhibit biofilm formation when... Agent: One Unlimited, Inc.

20120196833 - Phosphorus containing quinazoline compounds and methods of use: Disclosed are novel quinazoline derivatives containing phosphorus substitutions and methods for the treatment of hyperproliferative diseases (e.g. cancer) using the compounds. These compounds are type I receptor protein kinase inhibitors useful in treating disorders related to abnormal protein kinase activities such as cancer and inflammation in mammals. Also disclosed are... Agent: Newgen Therapeutics, Inc.

20120196834 - Highly stable compositions of orally active nucleotide analogues or orally active nucleotide analogue prodrugs: Disclosed are highly stable compositions having outstanding storage stability and/or demonstrating exceptional resistance to aqueous solution degradation, the composition including an orally active nucleotide analogue or an orally active nucleotide analogue prodrug, which is orally bioavailable, such as adefovir dipivoxil and tenofovir disoproxil. For example, when a composition of the... Agent: Sigmapharm Laboratories, LLC

20120196835 - Enzyme inhibiting compounds and methods: The invention provides compounds, compositions, and methods for studying the Rohmer pathway and for treating bacterial infections or parasitic infections. The parasitic infection can be a protozoan infection, such as malaria. The compounds and compositions can also be used as antibiotics, for example, to kill bacteria or parasites, or to... Agent:

20120196836 - Synergistic antimicrobial composition: A synergistic antimicrobial composition having two components. The first component is a hydroxymethyl-substituted phosphorus compound. The second component is one of the following biocides: hexahydro-1,3,5-tris(2-hydroxyethyl)-s-triazine, 2,6-dimethyl-1,3-dioxan-4-yl acetate or ortho-phenylphenol or its alkali metal or ammonium salts.... Agent:

20120196837 - Method of treating frailty: Disclosed is a method of treatment or prevention of frailty in an elderly patient, particularly having an age of 60 or older. The method provides the concomitant parenteral administration of a combination of an anabolic steroid and a vitamin D compound. A preferred combination comprises nandrolone decanoate and cholecalciferol (vitamin... Agent:

20120196840 - Compositions and methods for treating, reducing, ameliorating, or preventing infections: Compositions for treating, reducing, ameliorating, or preventing infections comprise a fluoroquinolone having Formulae I-VIII and an additional anti-infective agent. Methods for treating, reducing, ameliorating, or preventing such infection use such compositions. Such compositions and methods can be effective against mixed types of pathogens including certain antibiotic-resistant microbial pathogens found in... Agent:

20120196839 - Compounds as lysophosphatidic acid receptor antagonists: Described herein are compounds that are antagonists of lysophosphatidic receptor(s). Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists, alone and in combination with other compounds, for treating LPA-dependent or LPA-mediated conditions or diseases.... Agent: Amira Pharmaceuticals Inc.

20120196838 - Compounds for inflammation and immune-related uses: s

20120196841 - Ceramide production enhancer and moisturizer:

20120196842 - Certain chemical entities, compositions, and methods: Chemical entities that are novel compounds, pharmaceutical compositions and methods of treatment of cancer are described.... Agent:

20120196843 - Compositions containing topical-active agents and pentyleneglycol: Disclosed are cosmetic and dermatological compositions containing hydrocortisone or a derivative thereof, a glycol and a thickening or gelling agent, and methods of making and using them.... Agent: L'oreal

20120196845 - Quinolinone-pyrazolone m1 receptor positive allosteric modulators: The present invention is directed to quinolinone-pyrazolone compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical... Agent:

20120196844 - Compounds and compositions as modulators of gpr119 activity: The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of GPR119.... Agent: Irm LLC

20120196847 - 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors: and pharmaceutically acceptable salts thereof, wherein X1, X2, X3, X4, X5, X6, X7, R1, and Q1 are defined herein, inhibit the IGF-1R enzyme and are useful for the treatment and/or prevention of hyperproliferative diseases such as cancer, inflammation, psoriasis, allergy/asthma, disease and conditions of the immune system, disease and conditions... Agent: Osi Pharmaceuticals, LLC

20120196846 - Anti-rsv compounds: The present invention relates to anti-RSV compounds of Formula (I) and methods for use of the compounds in the treatment and prevention of RSV infection.... Agent: Gilead Sciences, Inc.

20120196848 - Thienooxazepine derivative: e

20120196849 - Compounds and compositions as hedgehog pathway modulators: The invention provides a method for modulating the activity of the hedgehog signaling pathway. In particular, the invention provides a method for inhibiting aberrant growth states resulting from phenotypes such as Ptc loss-of-function, hedgehog gain-of-function, smoothened gain-of-function or Gli gain-of-function, comprising contacting a cell with a sufficient amount of a... Agent: Irm LLC

20120196850 - Association of a sinus node if current inhibitor and an angiotensin converting enzyme inhibitor, and pharmaceutical compositions containing it: e

20120196851 - Wnt pathway antagonists: The present invention relates to known and novel compounds of formula (I) as herein described and pharmaceutical compositions thereof. The compounds of formula (I) have inhibitory effect on the Wnt pathway and are therefore useful in the preparation of a medicament, in particular for the treatment of cancer.... Agent: Siena Biotech S.p.a.

20120196852 - Inhibitors of methionine aminopeptidases and methods of treating disorders: The invention is directed towards novel naphthoquinone and naphthothiazole compounds, and methods of treating disorders related to MetAP, including tuberculosis and bacterial infection, using various naphthoquinone, hydroxyquinonline, and naphthothiazole compounds.... Agent: The Johns Hopkins University

20120196853 - Novel quinoline-hepcidine antagonists: The present invention relates to novel hepcidin antagonists of the general formula (I), pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for treatment of disorders in iron metabolism, such as, in particular, iron deficiency diseases and anaemias, in particular anaemias in connection with chronic inflammatory diseases... Agent: Vifor (international) Ag

20120196854 - Pharmaceutical composition comprising aromatic heterocyclic compound: [wherein Q1 represents CR2 (wherein R2 represents a hydrogen atom or the like) or the like; Q2 represents CR3 (wherein R3 represents a hydrogen atom or the like) or the like; Q3 represents a nitrogen atom or the like; R1 represents —C(═O)OR16 (wherein R16 represents a hydrogen atom or the... Agent: Kyowa Hakko Kirin Co., Ltd.

20120196855 - Oxygen linked pyrimidine derivatives: The present invention relates to pyrimidine compounds that are useful as anti-proliferative agents. More particularly, the present invention relates to oxygen linked and substituted pyrimidine compounds, methods for their preparation, pharmaceutical compositions containing these compounds and uses of these compounds in the treatment of proliferative disorders. These compounds may be... Agent: S*bio Pte Ltd.

20120196856 - Aryl aminopyridine pde10 inhibitors: The present invention is directed to aryl aminopyridine compounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or... Agent:

20120196858 - Method of promoting apoptosis and inhibiting metastasis: The invention provides a method of promoting apoptosis in tumor cells, which can result in inhibiting tumor growth, or inhibiting tumor metastasis, or promoting tumor apoptosis, or any combination thereof, by administration of an effective amount of a focal adhesion kinase (FAK) inhibitor. The inhibitor is a small molecule organic... Agent: Poniard Pharmaceuticals ,inc.

20120196857 - Modulators of muscarinic receptors: The present invention relates to modulators of muscarinic receptors. The present invention also provides compositions comprising such modulators, and methods therewith for treating muscarinic receptor mediated diseases.... Agent: Vertex Pharmaceuticals Incorporated

20120196859 - Heterocyclic analogs of propargyl-linked inhibitors of dihydrofolate reductase: The compositions and methods described herein disclose the design, synthesis and testing of compounds that act as inhibitors of DHFR. The basic scaffold of these inhibitors includes a 2,4-diaminopyrimidine ring with a propargyl linker to another substituted aryl, bicyclo or heteroaryl ring. These DHFR inhibitors are potent and selective for... Agent:

20120196860 - Triazine derivatives and their therapeutical applications: The invention provides Triazine derivatives and further provides methods of using these compounds to modulate protein kinases and for treating diseases and conditions mediated by protein kinases.... Agent: California Capital Equity, LLC

20120196861 - Il17 and ifn-gamma inhibition for the treatment of autoimmune inflammation: The present invention relates to compounds of the general formula (I), and the pharmaceutically acceptable salt or solvate thereof, as anti-inflammatory and immunomodulatory agents.... Agent: 4sc Discovery Gmbh

20120196862 - Il17 and ifn-gamma inhibition for the treatment of autoimmune inflammation: The present invention relates to compounds of the general formula (I), and the pharmaceutically acceptable salt or solvate thereof, as anti-inflammatory and immunomodulatory agents.... Agent: 4sc Discovery Gmbh

20120196863 - 1,4 oxazines as bace1 and/or bace2 inhibitors: e

20120196864 - Prophylactic or therapeutic agent for cancer:

20120196865 - Acyl guanidine derivatives modulating the hedgehog protein signaling pathway: The present invention relates to acyl guanidine derivatives modulating the hedgehog protein signaling pathway to be used as drugs, in particular for treating diseases involving a tissue dysfunction associated with a deregulation of the hedgehog protein signaling pathway, as well as to pharmaceutical compositions containing same. The present invention also... Agent: Centre National De La Recherche Scientifique

20120196866 - 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses: The present invention concerns 2-oxo-1-pyrrolidine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals.... Agent: Ucb Pharma, S.a.

20120196867 - Composition comprising a pde4 inhibitor and a pde5 inhibitor: The claimed subject matter relates to pharmaceutical compositions comprising a PDE4 inhibitor and a PDE5 inhibitor and the treatment of a disease in which phosphodiesterase 4 (PDE4) and/or phosphodiesterase 5 (PDE5) is detrimental.... Agent: Nycomed Gmbh

20120196868 - Therapeutic compositions and methods: The present invention relates in general to therapeutic compositions and methods of use. In preferred embodiments, the invention relates to the field of eye health. In some embodiments, the invention relates to the prevention and treatment of macular degeneration by administering compounds disclosed herein. In some embodiments, the invention relates... Agent: The Texas A&m University System

20120196869 - Pyrrolopyrazine-spirocyclic piperidine amides as modulators of ion channels: The invention relates to pyrrolopyrazine-spirocyclic piperidine amide compounds useful as inhibitors of ion channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.... Agent:

20120196870 - Combination therapy and cancer: The disclosure relates to methods of treating tuberous sclerosis in a subject, comprising administering a composition comprising an mTOR inhibitor and a tyrosine kinase inhibitor to a subject that is diagnosed with, suspected of, or exhibiting symptoms of cancer. In some embodiments, the cancer is tuberous sclerosis. In some embodiments,... Agent: Emory University

20120196872 - New 5-alkynyl-pyridines: wherein R1, R2, R3, Ra, Rb, Rc, X, Y and Z are defined as mentioned hereinafter, the individual diastereomers, the individual enantiomers and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, medicaments containing these compounds, the use thereof and processes for the... Agent: Boehringer Ingelheim International Gmbh

20120196871 - Process for the synthesis of 2-aminothiazole compounds as kinase inhibitors: which are useful as certain tyrosine kinase inhibitors and more particularly as c-kit and bcr-abl inhibitors. The groups R1 and R2, identical or different, represent each a hydrogen, halogen atom, an alkyl, an alkoxy, a trifluoromethyl, an amino, an alkylamino, a dialkylamino, a solubilising group; m is 0-5 and n... Agent: Ab Science

20120196873 - Stabilization of amorphous drugs using sponge-like carrier matrices: The present invention relates to drug formulations for the stabilization of amorphous forms of drugs. In particular the present invention relates to pharmaceutical compositions comprising sponge-like carrier matrices, particularly polyelectrolyte complexes or porous particles. The invention also relates to methods for the production of such pharmaceutical compositions.... Agent: Capsulution Nanoscience Ag

20120196874 - Stilbene analogs and methods of treating cancer: Stilbene analogs and pharmaceutical compositions that are useful for the treatment of various cancers, including without limitation, colorectal cancer (CRC) and breast cancer are disclosed. The halogenated stilbene analogs include nitrogen heteroaryl groups and/or amino groups on the stilbene ring.... Agent:

20120196875 - Pharmaceutical compositions for treatment of respiratory and inflammatory diseases: The present invention relates to pharmaceutical composition comprising a CRTH2 antagonist and at least one PDE4 inhibitor, medicaments containing said pharmaceutical compositions, and the use of said pharmaceutical compositions for treating respiratory and inflammatory diseases and conditions.... Agent: Boehringer Ingelheim International Gmbh

20120196876 - (9e)-15-(2-pyrrolidin-1-yl-ethoxy)-7,12,25-trioxa-19,21,24-triaza-tetracyclo[18.3.1.1(2.5).1(14,18)]hexacosa-1(24),2,4,9,14,16,18(26),20,22-nonaene citrate salt: The present invention relates to certain salts of a 9E-15-(2-pyrrolidin-1-yl-ethoxy)-7,12,25-trioxa-19,21,24-triaza-tetracyclo[18.3.1.1(2,5). 1(14,18)]hexacosa-1(24),2,4,9, 14,16,18(26),20,22-nonaene (Compound I) which have been found to have improved properties. In particular the present invention relates to the citrate salt of this compound. The invention also relates to pharmaceutical compositions containing the citrate salt and methods of use... Agent: S*bio Pte Ltd.

20120196877 - Compositions of 5-ht3 antagonists and dopamine d2 antagonists for treatment of dopamine-associated chronic conditions: The present invention provides novel compositions comprising a combination of a 5-HT3 receptor antagonist and a selective dopamine D2 receptor antagonist for the treatment of obsessive, impulsive and compulsive behavioral activities and other dopamine pathway-associated disorders or conditions. Preferably, the pharmaceutical compositions of the present invention comprise amounts of the... Agent:

20120196878 - Methods of optimizing drug therapeutic efficacy for treatment of immune-mediated gastrointestinal disorders: The present invention provides a method of optimizing therapeutic efficacy and reducing toxicity associated with 6-mercaptopurine drug treatment of an immune-mediated gastrointestinal disorder such as inflammatory bowel disease. The method of the invention includes the step of determining the level of one or more 6-mercaptopurine metabolites in the patient having... Agent: H&#xf4 Pital-sainte-justine

20120196879 - Pharmaceutical combination of mek inhibitor and b-raf inhibitors: A novel combination comprising the MEK inhibitor N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)6,8-dimethyl;-2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide, or a pharmaceutically acceptable salt or solvate thereof, with a B-Raf inhibitor, particularly N-{3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophen-}-2,6-difluorobenzenesulfonamide or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same and methods of using such combinations and compositions in the treatment of conditions in which the inhibition... Agent:

20120196880 - Pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators: n

20120196882 - Compounds that treat malaria and prevent malaria transmission: The invention provides methods and compounds for the treatment and prevention of malaria infection and transmission in a mammal by administering compounds of the invention to a mammal having or suspected of having a malaria infection. The invention also provides pharmaceutical compositions that can kill or arrest the growth of... Agent:

20120196881 - Treatment of pulmonary hypertension with carbonic anhydrase inhibitors: This disclosure relates generally to methods and pharmaceutical compositions useful in treating pulmonary hypertension. In one embodiment, for example, the disclosure provides a method for treating pulmonary hypertension comprising administering a therapeutically effective dose of a carbonic anhydrase inhibitor to a patient in need of treatment. The disclosure finds utility... Agent: Vivus, Inc.

20120196883 - Selective calcium channel antagonists: The present invention relates to compositions and methods for the treatment and/or prevention of neurodegenerative disorders, e.g., Parkinson's disease (PD). In particular, the present invention provides compositions comprising selective antagonists of calcium ion channels (e.g., cav1.3-type ion channels), and methods of use thereof to treat or prevent neurodegenerative disorders.... Agent:

20120196884 - Urea substituted sulphonamide derivatives: The present invention relates to sulphonamide derivatives, whith a urea moiety. The invention also relates to the use of the derivatives as inhibitors of collagen receptor integrins, especially α2β1 integrin inhibitors e.g. in connection with diseases and medical conditions that involve the action of cells and platelets expressing collagen receptors,... Agent: Biotie Therapies Corporation

20120196886 - Combination: The present invention relates to a method of treating cancer in a human and to pharmaceutical combinations useful in such treatment. In particular, the method relates to a cancer treatment method that includes administering N-{3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide or a pharmaceutically acceptable salt thereof, and N-{(1S)-2-amino-1-[(3,4-difluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-furancarboxamide, or a pharmaceutically acceptable salt thereof, to... Agent: Glaxosmithkline LLC

20120196885 - New histone deacetylase inhibitors based simultaneously on trisubstituted 1h-pyrroles and aromatic and heteroaromatic spacers: e

20120196887 - Methods and compositions for improved rifamycin therapies: Compositions comprising one or more rifamycin antibiotics and one or more bile acids, and methods of using the compositions for the treatment of infection.... Agent:

20120196888 - Process for preparing oxymorphone, naltrexone, and buprenorphine: Methods are provided which include converting oripavine to other opiates, including converting oripavine to naltrexone, buprenorphine, 14-hydroxymorphinone and/or converting 14-hydroxymorphinone to oxymorphone. Purification and salt formation are optionally included.... Agent: Penick Corporation

20120196889 - Catecholamine derivatives and prodrugs thereof: The present invention relates to novel catecholamine derivatives of Formula I, to processes for their preparation, pharmaceutical compositions containing them and to their use in therapy.... Agent: H. Lundbeck A/s

20120196890 - 4-substituted azaadamantane derivatives and methods of use thereof: The invention relates to compounds that are 4-substituted azaadamantane derivatives, compositions comprising such compounds, and methods of using such compounds and compositions.... Agent:

20120196891 - Heterocyclic compound and its use for control of an arthropod pest: e

20120196893 - Composition, method, system and kit for optical electrophysiology: The present invention provides a method of optical electrophysiological probing, including: providing a fluorescing chemical probe; contacting a thick portion of tissue with the fluorescing chemical probe to create a thick portion of treated tissue; applying a first range of wavelengths of electromagnetic radiation to the treated portion of tissue;... Agent: The Research Foundation Of State University Of New York

20120196892 - Novel caspase-2 inhibitors: Novel compounds of formula (I) and slats thereof and pharmaceutical compositions which contain such a compound or salt are useful for inhibiting pro-apoptotic caspase-2 and for preventing and/or treating diseases and injuries where caspase-2 activity is implicated, in particular neonatal brain ischemia.... Agent: Chiesi Farmaceutici S.p.a.

20120196894 - Novel trpa1 antagonists: The present invention relates to compositions and methods that modulate at least one TRP family member. Specifically, the present invention relates to novel TRPA1 antagonists and their use in the treatment of pain such as chronic inflammatory and neuropathic pain. Compounds that can modulate one or more TRPA1 functions are... Agent:

20120196895 - Novel forms of eperisone: The invention relates to novel crystalline forms of (2RS)-1-(4-ethylphenyl)-2-methyl-3-piperidin-1-yl-propan-1-one. The preparation and characterization of the novel crystalline forms according to various embodiments of the invention is described. The invention also relates to pharmaceutical compositions containing the novel crystalline forms, which are useful to treat and/or prevent various conditions such as... Agent: Bionevia Pharmaceuticals, Inc.

20120196897 - New compounds: e

20120196896 - Treatment for oxidative stress and/or hypertension: One aspect of the invention relates to compounds, compositions and methods for treating oxidative stress and/or hypertension. In certain embodiments, the invention relates to a mixture of tempol and an angiotensin receptor blocker (ARB) and the use of said mixture to treat oxidative stress and/or hypertension. In certain embodiments, the... Agent: Georgetown University

20120196898 - Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation: The present invention provides methods of improving cognitive and motor deficits associated with central nervous system (CNS) disorder or condition in an animal. The methods comprise a general administration of phosphodiesterase 4 inhibitors and optionally training the animal under conditions sufficient to produce an improvement in performance.... Agent:

20120196899 - Methods and products for treating inflammation: Pharmaceutical compositions comprising an isolated form of a compound of Formula IB (e.g., R-(+)-anatabine) or a salt thereof can be used to treat disorders comprising an inflammatory component, including chronic, low-level inflammation. Compounds of Formula I also can be provided, for example, in other vehicles such as beverage products and... Agent: Rock Creek Pharmaceuticals, Inc.

20120196900 - Pyridine non-classical cannabinoid compounds and related methods of use: a

20120196901 - Tertiary amide orexin receptor antagonists: The present invention is directed to tertiary amide compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the... Agent: Merck Sharp & Dohme Corp.

20120196903 - 2-aminooxazolines as taar1 ligands: or to a pharmaceutically suitable acid addition salt thereof. The invention also relates to pharmaceutical compositions containing such compounds and methods for the treatment of diseases related to the biological function of the trace amine associated receptors, which diseases include depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related... Agent:

20120196904 - Nitrocatechol derivatives as comt inhibitors: New compounds of formula I are described. The compounds have potentially valuable pharmaceutical properties in the treatment of some central and peripheral nervous system disorders.... Agent:

20120196902 - Sulfoximines as kinase inhibitors: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.... Agent:

20120196905 - Synthetic compounds and methods to decrease nicotine self-administration: Methods and small molecule compounds for smoking and CNS disease harm reduction are provided. One example of a class of compounds that may be used is represented by the compound having the structure IA or IB in the form of free base or a pharmaceutically acceptable salt, hydrate or solvate... Agent: Human Biomolecular Research Institute

20120196906 - Substituted imidazole derivatives, compositions, and methods of use as ptpase inhibitors: The present invention provides imidazole derivatives of Formula (I-IV), methods of their preparation, pharmaceutical compositions comprising the compounds of Formula (I-IV), and their use in treating human or animal disorders. The compounds of the invention inhibit protein tyrosine phosphatase 1B and thus can be useful for the management, treatment, control,... Agent: Transtech Pharma, Inc.

20120196907 - Diazonamide analogs: Novel diazonamide analogs having anti-mitotic activity, useful for the treatment of cancer and other proliferative disorders are provided.... Agent:

20120196908 - Benzyl aralkyl ether compounds, method for preparing same, intermediate compounds, use of said compounds, method for treatment and/or prevention, pharmaceutical composition and medicament containing same: This invention also refers to their salts, solvates, prodrugs, esters, enantiomers and/or pharmaceutically acceptable diastereoisomers, or mixtures thereof, processes for the preparation of these compounds, intermediate compounds, pharmaceutical compositions comprising such compounds and/or derivatives, including those compounds and/or derivatives, as well as the uses and methods of these compounds and/or... Agent: Biolab Sanus Farmaceutica Ltda.

20120196909 - Deferacirox dispersible tablets: The invention pertains to dispersible tablets comprising as active ingredient 4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid or pharmaceutically acceptable salt thereof in an amount of from 5 to 40% in weight by weight of the total tablet.... Agent: Novartis Ag

20120196910 - Use of azabicyclo hexane derivatives: e

20120196911 - Unsubstituted and substituted 4-benzyl-1,3-dihydro-imidazole-2-thiones acting as specific or selective alpha2 adrenergic agonists and methods for using the same: where the variables have the meaning defined in the specification are used to activate alpha2 adrenergic receptors. The compounds of Formula 1 are incorporated in pharmaceutical compositions and are used as medicaments in mammals, including humans, for treatment of diseases and or alleviations of conditions which are responsive to treatment... Agent: Allergan, Inc.

20120196912 - Parasiticidal formulation: The present invention provides a parasiticidal formulation comprising: Fipronil, or a veterinarily acceptable derivative thereof; at least one C1-C6 alcohol co-solvent, wherein the total amount of C1-C6 alcohol is up to 8% by weight of the formulation; at least one organic solvent which is not the C1-C6 alcohol co-solvent; and... Agent: Fidopharm, Inc.

20120196913 - Ketorolac tromethamine compositions for treating or preventing ocular pain: The present invention provides an aqueous ophthalmic solution comprising an effective amount of ketorolac which comprises carboxymethyl cellulose in an aqueous solution wherein said concentration of carboxymethyl cellulose is selected to provide an increased absorption of ketorolac in the eye of a patient that is at least 130% greater than... Agent: Allergan, Inc.

20120196914 - Ketorolac tromethamine compositions for treating or preventing ocular pain: The present invention provides an aqueous ophthalmic solution comprising an effective amount of ketorolac which comprises carboxymethyl cellulose in an aqueous solution wherein said concentration of carboxymethyl cellulose is selected to provide an increased absorption of ketorolac in the eye of a patient that is at least 130% greater than... Agent: Allergan, Inc.

20120196915 - Antitumor 1,2-diphenylpyrrole compounds and their preparation process: The present invention relates to a new series of 1,2-diphenylpyrroles of formula (I) or their pharmaceutically acceptable salts, or their pharmaceutically acceptable solvates, having antitumor activity, wherein R1 and R2 are individually selected from the group consisting of halogen, optionally substituted O(C1-C4)alkyl and optionally substituted (C1-C4)alkyl; and R3 is selected... Agent: Argon Pharma, S.l.

20120196917 - Antidepressant oral liquid compositions: The invention provides for the first time an oral liquid composition of duloxetine or its pharmaceutically equivalent derivatives like salts, isomers, complexes, polymorphs, hydrates or esters thereof. The duloxetine or its pharmaceutically equivalent derivative is present from about 2 mg to approximately 200 mg; and a buffering agent was used... Agent: Wockhardt Ltd.

20120196916 - Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds: Disclosed are beta and gamma-amino isoquinoline amide compounds and substituted benzamide compounds. In particular, the invention provides compounds that affect the function of kinases in a cell and that are useful as therapeutic agents or with therapeutic agents. The compounds of the invention are useful in the treatment of a... Agent:

20120196926 - Benzopyran compounds as melanogenesis modifiers and uses thereof: wherein R3, R4, R5, R6, R7 and R8 are described herein. Also provided are plant extracts containing a compound of formula I, and the use of such a plant extract to modulate (e.g., inhibit) melanogenesis and pigmentation. The compound or plant extract may be prepared as pharmaceutical and cosmetic compositions,... Agent:

20120196927 - Prophylactic and/or therapeutic agent for metabolic syndrome: A method for screening a substance for treating visceral adiposity syndrome comprises: (1) extracting a total RNA fraction from skeletal muscle collected from non-human mammals of a group to which a predetermined amount of the test substance has been administered and from non-human mammals of a group to which the... Agent: Erina Co., Inc.

20120196928 - Red yeast rice extract high in monacolin k content: Compositions comprising Red Yeast Rice extracts which comprise greater than 5 wt. % monacolin K are useful for lowering cholesterol and/or triglyceride levels in a subject.... Agent:

20120196929 - Use of rosmarinic acid and the derivaties thereof to treat ciguatera: The present invention relates to rosmarinic acid and to the derivatives thereof, expressed by the compounds of general formula (I), for the use thereof to prevent and/or treat disorders caused by ciguatoxin poisoning and for preparing a pharmaceutical composition for preventing and/or treating disorders caused by ciguatoxin poisoning.... Agent: Institut De Recherche Pour Le Developpement

20120196930 - Topical formulation for diabetic foot ulcers: This invention relates to a new topical gel formulation of the drug Esmolol hydrochloride for treatment of chronic wounds such as diabetic wounds, burn wounds, venous ulcers and pressure ulcers.... Agent: Vlife Sciences Technologies Pvt. Ltd.

20120196931 - Treatment for multiple sclerosis: Provided are certain methods of screening, identifying, and evaluating neuroprotective compounds useful for treatment of neurological diseases, such as, e.g., multiple sclerosis (MS). The compounds described upregulate the cellular cytoprotective pathway regulated by Nrf2. Also provided are certain methods of utilizing such compounds in therapy for neurological disease, particularly, for... Agent: Biogen Idec Ma Inc.

20120196932 - Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism: Methods and compositions for treating or preventing, the occurrence of senile dementia of the Alzheimer's type, or other conditions arising from reduced neuronal metabolism and leading to lessened cognitive function are described. In a preferred embodiment the administration of triglycerides or fatty acids with chain lengths between 5 and 12,... Agent: Accera, Inc.

20120196933 - Mexiletine prodrugs: The present invention concerns prodrugs of mexiletine (and mexiletine's active metabolite) pharmaceutical compositions containing such prodrugs. Methods for treating myotonic conditions, while reducing the inherent adverse GI side effects associated with mexiletine, increasing the bioavailability of mexiletine, and improving the pharmacokinetic reproducibility of mexiletine with the aforementioned prodrugs are also... Agent:

20120196934 - Compositions comprising a fatty acid oil mixture comprising epa and dha in free acid form and a surfactant, and methods and uses thereof: Preconcentrates comprising a fatty acid oil mixture and at least one surfactant, and methods and uses thereof are disclosed. The preconcentrates are capable of forming a self-nanoemulsifying drug delivery system (SNEDDS), a self-microemulsifying drug delivery system (SMEDDS), or self-emulsifying drug delivery systems (SEDDS) in an aqueous solution.... Agent: Pronova Biopharma Norge As

20120196935 - Methods for detecting autodigestion: Materials and methods for detecting the early onset of shock and multi-organ failure by production of tissue breakdown products in biological samples (e.g., expired air).... Agent: The Regents Of The University Of California

20120196936 - Composition comprising s-allyl-l-cysteine as active ingredient for preventing or treating gastrointestinal disorders: A composition including S-allyl-L-cysteine as an active ingredient and having an anti-Helicobacter pylori activity or a gastric mucosa protective effect, a composition for preventing, relieving, or treating gastrointestinal disorders, and a method of using the compositions.... Agent: Pharmaking Co., Ltd.

20120196937 - Treatment of ophthalmic disorders using urea: Methods for treating disorders of the eye and/or disorders of a nerve in a human or veterinary patient by delivering to the patient a therapeutically effective amount of a compound selected from the group of; urea, urea derivatives, thiourea, thiourea derivatives, guanidine, guanidine derivatives and compounds having General Formula I... Agent: Kato Pharmaceuticals, Inc.

20120196938 - Beta 2 adrenergic receptor agonists such as terbutaline for use in the treatment of nocturnal hypoglycemia: The invention is concerned with methods, regimens and dosage forms employing a beta 2 adrenergic receptor agonist such as terbutaline sulphate, for treating nocturnal hypoglycaemia in human subjects whilst reducing incidence of hyperglycaemia in said subjects upon wakening.... Agent: Jagotec Ag

20120196939 - Therapeutic compounds: A (−)-stereoisomer of formula (I): (formula I), wherein X is H or F; or a pharmaceutically acceptable salt or pro drug thereof, is useful as an anesthetic.... Agent:

20120196940 - Pharmaceutical formulations: The present invention is directed to novel pharmaceutically acceptable polymeric compositions suitable for melt extrusion and injection molding of single or multi-component pharmaceutical dosage forms comprising a plurality of drug substance containing sub-units, being capsule compartments and/or solid sub-units comprising a solid matrix of a polymer which contains a drug... Agent: Capsugel Belgium Bvba.

20120196941 - Absorption enhancers for drug administration: A composition including a surfactant and at least one alkyl glycoside and/or saccharide alkyl ester and a drug. The surfactant composition(s) when admixed with a drug is non-toxic and non-irritating, while stabilizing and increasing the bioavailability of the drug. The invention also provides compositions that enhance absorption of drugs via... Agent:

20120196942 - Novel liquid crystal composition: A liquid crystal composition contains liquid crystals containing one kind of or two or more kinds of silicone surfactants, a phenyl-modified silicone oil and water. The liquid crystal composition of the present invention contains 5 to 95% by weight in total of one kind of or two or more kinds... Agent:

Previous industry: Perfume compositions
Next industry: Colloid systems and wetting agents; subcombinations thereof; processes of


######

RSS FEED for 20140807: xml
Integrate FreshPatents.com into your RSS reader/aggregator or website to track weekly updates.
For more info, read this article.

######

Thank you for viewing Drug, bio-affecting and body treating compositions patents on the FreshPatents.com website. These are patent applications which have been filed in the United States. There are a variety ways to browse Drug, bio-affecting and body treating compositions patent applications on our website including browsing by date, agent, inventor, and industry. If you are interested in receiving occasional emails regarding Drug, bio-affecting and body treating compositions patents we recommend signing up for free keyword monitoring by email.



Results in 5.09235 seconds

PATENT INFO